var title_f34_1_34832="TTTS6";
var content_f34_1_34832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TTTS6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross section of the fetal chest and heart of the recipient fetus at&nbsp;approximately 25&nbsp;weeks of gestation. Arrows point to the thickened myocardial walls of the fetal heart. The interventricular septum is also thickened.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34832=[""].join("\n");
var outline_f34_1_34832=null;
var title_f34_1_34833="Normal mitral valve M mode";
var content_f34_1_34833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/77762/mmodenor_conv.mp4?title=Normal+mitral+valve+M+mode\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal M-mode echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The echocardiogram was obtained from the left ventricular chamber at the level of the mitral valve, as shown by the cursor in the 2-D image. Shown are the left ventricle, interventricular septum, the left ventricle and the motion of the anterior and posterior leaflets of the mitral which are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34833=[""].join("\n");
var outline_f34_1_34833=null;
var title_f34_1_34834="Minocycline pigmentation";
var content_f34_1_34834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Minocycline pigmentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blue-black pigmentary changes secondary to minocycline therapy are present on the lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34834=[""].join("\n");
var outline_f34_1_34834=null;
var title_f34_1_34835="Mepivacaine and levonordefrin: Patient drug information";
var content_f34_1_34835=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mepivacaine and levonordefrin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/33/25109?source=see_link\">",
"     see \"Mepivacaine and levonordefrin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg; 2% with Neo-Cobefrin&reg;;",
"     </li>",
"     <li>",
"      Scandonest&reg; 2% L",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg; 2% with Neo-Cobefrin&reg;;",
"     </li>",
"     <li>",
"      Scandonest 2%&reg;  with Levonordefrin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mepivacaine, levonordefrin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11560 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34835=[""].join("\n");
var outline_f34_1_34835=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193034\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193035\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025687\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025686\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025691\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025692\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025694\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025689\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025695\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025696\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/33/25109?source=related_link\">",
"      Mepivacaine and levonordefrin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34836="Doxylamine and pyridoxine: Drug information";
var content_f34_1_34836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxylamine and pyridoxine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/17/42259?source=see_link\">",
"    see \"Doxylamine and pyridoxine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diclectin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nausea and vomiting associated with pregnancy: Oral: Two delayed release tablets (a total of doxylamine 20 mg and pyridoxine 20 mg) at bedtime. In severe cases or in cases with nausea/vomiting during the day, dosage may be increased by 1 tablet in the morning and/or afternoon.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, delayed release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diclectin&reg;: Doxylamine 10 mg and pyridoxine 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diclegis&reg;: FDA approved April 2013; availability anticipated in May 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pregnancy-associated nausea and vomiting",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Doxylamine may be confused with doxycycline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Disorientation, dizziness, drowsiness, headache, paradoxical CNS stimulation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric pain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxylamine, pyridoxine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: Pyridoxine may diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Pyridoxine may increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Pyridoxine may increase the metabolism of Fosphenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Pyridoxine may diminish the therapeutic effect of Levodopa.  Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Pyridoxine may increase the metabolism of Phenytoin. This is most apparent in high pyridoxine doses (e.g., 80 mg to 200 mg daily)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F163438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of doxylamine in combination with pyridoxine during pregnancy has not been shown to increase the baseline risk of major malformations. Doxylamine succinate/pyridoxine hydrochloride is approved for use in pregnant women to manage nausea and vomiting in pregnancy (Canadian labeling; combination product not available in U.S). Doxylamine and pyridoxine are individually recommended for the treatment of nausea and vomiting of pregnancy in the United States. Also refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F163432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxylamine succinate is expected to be found in breast milk; pyridoxine is excreted in breast milk. According to the manufacturer, women using Diclectin&reg; should not breast-feed. Also refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Diclectin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxylamine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity. Pyridoxine is a vitamin which may have modest antiemetic effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to individual agents",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9392 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34836=[""].join("\n");
var outline_f34_1_34836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163442\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163458\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163445\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163446\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163447\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076220\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233708\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163426\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163462\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163456\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163430\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163417\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299236\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163420\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163438\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163431\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163450\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163432\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163433\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163416\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163429\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/17/42259?source=related_link\">",
"      Doxylamine and pyridoxine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34837="Thymic squamous cell carcinoma";
var content_f34_1_34837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Poorly differentiated squamous cell carcinoma of the thymus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADpAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCtd6TeWcmgH7DJc+XM9rcl4zJEilvlZsd+e/AxVHUNUhivFvJ/ON7anypLd28vDMSF2jnd+OMYrpdP8TzW3hx7m1Q3SygANIpVmU54K+3SqWvyarcwWcTaZpl5cwFJtl6OXjAJBQ8ZYc4Ht0Ne1CUr/vEuq3+/87fcfStNXaI7/TrzWI7CK4huJXe5W3mON/2dQpbcwPTpjtVVLg3E98LCG6u5bJUO1TtVCc4JbHPuKt+GdSurC1udS0SyCS3kxaP+0JSGlAPzcZ+8QfbitiXVtupqo8n7POBN8mChHOcY64x+VDnOLcbXS/p/5bjjfY5PSWivBavFayTLcXJS9dpmQQMoxlV/iBz/ADrQl02e1RvDwspzFK23z4ZQ7xEtn5uOB1yDjj3FZ+rT2F3DZ6jprahc2qXQUi1AAzuOA44ytdBNcSJp2qNpd7c2OtTRqwdSGOQ3Kvkep9+MetbTcrq3430d/wBPQG7LQz4pHOq3Fo15bRW9kiW01nKcl+OJF4+YZGT6Zwc8VUksGN3M66RZJb2M6yq4c7pFHAIAODgnt7ZHFdHrNxp9+2iJq4363Pb+SzW6bRNIMBwxHtyPWsXSbcaLeWt3ql15IgEsUaouUdGOSW/D19qVObcbpWfb/Lv6/wCQLXct/wBnyXl1DpbSRob503LL82QTl1UHqOQPbNaumsLTxF/acWnwW92qunyyiN0AyACoPzLkYxjoOtTeFbXSdDubvxPqmqWs1pC0lwNyEyx78AY/QDFcq8H25TdTS291JqN1L5t048qSOIEFVX2wwPPGDUL943Hpts9+v4JDcrvl8iY2U+7UbmO9uLSduX84YSPByx46A5wG98DNXtRiW1gvftd+suntboElSPB3kDLbweckg4PTOKTw3cte6bIs1tbBlgkhih87fHOgGVHmAjb8yjkdMZqa1nvLvRI7XxCmn6e0jGGC0RQE2gfd3Ekn16nnnvWjk1LXp6fh9xcZa6bFXTdL8ixmGv3sV5ZSENCSQYoQoGFJ6HAOetWrLTbSO9jtbDVSskbPLPBw32hCMnnPAA4zj0Iou9Nh0TTYILsE2IjUxRPiRSNwPmEd2J3c+h+lNs5LDU0uriytkfU7ePyVIiEXnJkjaxxypwc5weB2pczknJPT8B6GbrM82p6Rc3pt7rSo0RUa4b52JUgIRt4IIyD78DrWjf6fZ6hdQ6ld2t7du9jvAtE3xRkENkwsCQemQOme9IjfadLmltbu58yxSSK4tNPwwmz/AMsiG4I4GSM98c4qbS7NGvNLvZPtImt0OIy+xLcMORtHUgYWrcuVaaWuCTY2BLy81aOD7BdO0sYmNxJ8q4Yep/i9RnP0IIpZtUvJrTTNQt7O802+juz5qR3AdL2BRjoFwd2MemPWtzXba6aYLoOvy2MBhJHlwK7GckHJLYABHB5/OucnvbSdbye0cWt9bFEdIsqpYNwoQZG0kMSRjA9jUU37RJ2/P019fnsJ+98RJp1xd2dzeRQ6HNookLXEt7dP50anbukMalflXaAML9Pp0F5a2mqQaS0uqMupx7JjNpzYS4HQZzz2IxjjmqSR3U+ia20sttDq1vDDHZ3csO9WVz846HLEEg8dveq1r4i03SbqG0l0dJ/7Ptwv2uyhG6CRz8wGOAeCcYAycVMlKTvBart6efquvyElbQtapo1re63PbzWCXNuzBklE/mwhtnG8L90AnHBBOOhqla6drf8Aao1ab7A0u9Gu7O8hE0UaQnIeAjO3cvTIDAg1o2uoIl0YvsAlsgFlEssaxMSR6KQQ3bH9K0LgrqVu15aB1kKblREKkkcFVHuOT/u8ZzSc5x0e23f/AIbz9EU4qWjOegs7JrnVYL6DUZ9OvJU1OO8kmKGFtxCu2eM5YocEZKZwM1Wa3v1sJZpNba2vFdjPLqVsDDc7yCAu3OCTgDGSMcVb8QPHqnhzD6lHY2qk213Fdo3lTlgGXCjkuuOo5GPbkkvoNC0u6sNWsbGeG3eC08zTA1xIyFc5ljYjYcBSCuOc1snJ69b/AJaddPu8jN2i7E1xb3M2jRSaIIEvbOcyxqmCDvOWVckKzDHHfHHc1T1G8tLjSh/an2n+19Ltft84tbN4UMby7VGzOMjIJA4xxnqK6O40VEvpTZXEun3ksccfmQKGiC/Kys0ZwVJC8gngk9eazRqVn4m1W6sXvLHT57S526VdpqTQvcl/+WW0gZBBHHTJwKzjUvqtlr5q/wCjv+oVJWszNnu4xrWnC0XVbLRdPnC3d1fwtHDcFGC+UcZODkbR1Hpxmqd5JFplpr1lLpkkOjtef6B5Nz9q8tJAQZgeSy8Zx74ya1Liz1Tw9dXK61qs8FhPp8aahNfqJIzcLJ8ojQn+6FG70zitO78P2ljprz+HtNhuJnmWeKCKUrHhgAdvPC99vTnj2r2kItXd0+vT79Ff9O3UjFt3ZlNawLDpGj3pmu4LRzsVJmEcrkdJAeGU/ewOgye9W7bVLmHW7a50+xs7axiVLW+eKMIVdFcldpbcMKI9u0Hdk7jxwXRuLd7O11a7g0/TtQSSOT5F85nAILIPvLglSCDnAOfSk8NaXrFqWsbm1tprGK4JaWZiWaLbzIAP4jgYHoSamTXK3Jp/r38r36ehTSfQxtcvLeUWobT/ALZo11N5vnFCACGwxQDqy988c9e1ddHZWd7rVvqsMd1peIXtpraSVXW7BX5Qufut0ycdgaxZ7nQdR15IoLi9tNQNm8EDeSzWzqrlmUhTkM2eoOCOvNTXV4tmlxbGFr23v4V8ow5ilZlP7slscMScE9cdaU05JJJp/o/w2/pD+L5HQaxa2hLafMI51tJNyrn5kcpg85zyHI9CCcjiqukWr2yXNzeFI7ZULsqgkjH+c/jUfhaSbUWk1rxbYS2GoXSR2QeNWVi6hipZT0BGMnHWtE2trd6p5q3yzx2CywzrAyvDKr5Uqx6hlIOcfyNcrbheDfr6+XzBTstdyexuInMkRSVCMB0cgHac4wRxjIIPcHrUM5zcuijucE9QPSo7ZINLSMzmV57hjGkSuDwMs2OgJY8n1q9JEsztKhDIQPmxyaydlK/Q0g+5kTBReT3M6q8ohEYZ+jNwBn2AOaq+H7+71BLvKeRGiskMjoQN+MLhD16gnmmeJTdW+p2FxaDfZ72SaMhmQk4xkdzgY5roIIYpnTMEbRHBwy8KevA9ea1k0oJvr+Fglfc4w+DNTtdcsL+71hbwSjy7p3i5fIxjH1IPNa2ntuMSxs9vGrGNdyblUjsB6c8Vq6mupTaisdtcxKkiN9nhQqrkqMMWViGOCOq5GMGr9qILjQlvtKvYry2X93PFOnlsrdG46qd3OMY9DSnXk4pz1/TfysRGqo+6ZGuWytHZTxLL9lkQly7cbweQcdM+g9OKraDcvdzRyNGnki18wSGUZiiyyjd6Etu+XtUlvNNqWstpyadeafpwbMc1ywZJSSdxCg8Y/l6Hina9aXWgWlxb2cUJlyrlkUncCw+Yjq2M5xyeKSasqb3ZT106hq0UDQ+WGMah8HzPu7SCCp4OOCRnFVb/AE+6EVs2nakmnzROZHQQCVHXH3SWPAGeuMGobCG7vdI8y+gCy+YwUbSu9RjDkds5PHpWtHGY0aS4jY27LtIiTcB7HvjrTfuaX2BwTRQuEllNtc6fLvWJ9kvbnvkfj096KzrGK+iuJMzWwtwWLsJGLy8AKNjDg559O1FTWw0KjXMr2NIxbMbRUh0/TmtRO3mtJIreZyUOev0/lS67p9/q66db3MKmS0uN/nbvnwOV+owe36Zqlp9vYw6zPFbGUzyL9o8mUhsFuSpJHPbp1q/pvn2SyNOwbHAXqTjPPp0611S92XMt/wDM5Y+8lcrXUuk6nrUUMzOhhlYW8EhwQCPm4B5HXGaTSojZySrfXMLxh5BaIBjgg8E/3u2OlX9O/svUb2589Ik1SOLzrJzlsA9cE/nioodIklsIbmTZd3tlKySMZseVERuJIB5Oc9emafMkuV3Xr+gvMq6KJIbtbRIJhbXRldUaHZg9Mqe65/8ArmrkuqqEjubKLT5Jo4/s2oiSfZIJcfu1UHhgSMEDPI9qZoU89nDdXsEkmr280y7HEhyAfU/wgYqTxLpFlLaS2ekJYQXErJcTIw3+RNjI5H8WPyBNEmnUtL+u9/63BpsoBL7UbSwSKGwg1OCfNxG0mTECcbQTwmR1P61pahFqrS6hEbi2uLeZgYIWG5YBnkhx34/yaqzaRbWzPq6tOk7ho5YoUHlzSKAfmB45/pWhd7ILW6vdQhuLSzv7FUaOV8CJTgDGBnORnp37U+a7Tj/Tvt/Xpcb03Mw6LcHXbW6sSv2YW5tponGUjwMcDuDxkcnrVu10q4lm003mkNexyrJE8tuoS2iBJBBGMEkelXXt7c6jpEhuEjjijeGBPtOFkwMuSOpPPU1XiuNN1DV54ruO40S8I+x6XdG4fyJ2bklD0V8HAPAO6l7STXy/zXe/rb5ik1FXMd7Wz/4RnVbCNI7m4tUMaxQsYzGm4Flz2OMHuMZrS0u907WLdVsljmFquNpyxjULjAz1ORjIpLmKWLQ9UW2uEl1G2ZbZpbiLGWDYk3cckqMZ+vWtHQorRLWR/JtYlh+68KKgfjpx17/hWk5+635/5GsFrcqtJ9i0i9vPsrz5lNs0zOMR7wNwB/hK/wBTVhtBF7E+hxXF2v2BRdm7QhReZAbA2/wDp3Py0yxawinvG1K3t4tOvF+1K0ZKF5AeGOMjuQR39KcJIJbXVNTmvzd6bZKi28ejz/vYMgB+TgYIPft6VDck7r+nol+v/D2Ik9dS6kFq832OeyjlsLkOdiEowmyCScEccc+tJ4omurKyhhivtP8AsjyghHQK0cAHzDP8R4GO+KrvDo97rMr2Ec01y1sFy7PHIkcgGQF+6GAIz71muX0rRZtOn06Z0gcx263ilZBKx4LkYyhwOh5yo60RjeSf4Pz6/kNvqWbHVRPeW01tCLjRWgSA2Mlsd0YLEGY/30PORnPbtVi503SJrG98MaVdpaS2kjSspiZ2iU9Rk8mM7hyDxkYq7r+pOtxoSS2kk9xJClpL9nUwwQSBDvO3qq7se+M1kXuvyrpN5pV7dW7Xdq8cRvbix/cSODuCqyjeUX1Pp0HFOKnO0oq3/D77a/g3f1Ju7ao39L0lrfQILfQ1SGdYthW7nMi5J5IOBnIzgY4xVHU9MvdOjuodNghW3urtJh/ZqqkrcH5mGQSN2Dkk8g9abPqq3urXMT3mq6WIlfyUI2W92uOH3EYUZJODzjHelu9D0q/17R57rTdR1K7uoPIOoxTsEjUDiRsAgjPuBj1NTHmi7z66/ru2vz/Ebd1dGjdWw1i2uZreae2luJxLIxj342k/Jk474bjuADxV/cIr2KFrVoppAdkSZwB2GR3689OvrVKwXxg0kEFwkEKFJfPZVGUCkbGI3Ha3XpkEDsaoaITNrlxqF3c6kksilFW8k8qJmOdrqgA+Tjp6dSaztdPVNLtr/Wxop9kb6i51GO9gjszcRjZ5kF3GGUYPIOeM+hHpWNr+hXL6i1vpUUlm+ps0k91AMmDYN5bknO4AgKO57Ui3mqwaXPBrsVr/AGguWglt7gxxT+3GCv1yO2eQa0Le8is7Lz2muhEkauwB89Y2PVVf73XuT6etCUqbvH+v69PIH7xznhyxigbVLzTL1765kMQPmSfvFU/Md/JAJYk8DAq9caVY6vbyXr6c0piimV7J4VjeWYodvP3Vk6YlGe2aux6tZ3Ua315pt9p00QMJadPLfGeq9Q475yK0Li6ltpWj1ERv5R3oTtVQuM5GTjp2q51J3v1/pf1sKytbY5aGDX/D2nJbxKNV8PRfZHuLC9239xD5nMkciLzHsGTkYBwpGea6S+uo9WuNUl0bUoodDkxBaXEJVlWVQNy5xuXscEHpxxWdY2Nnc6nfanohl0rV9gZRZyJtuxyokMbHGAOvYZyQDms03NtJ4c1GHXbKyudI3K0MtnGiRvP90jMJDA7v4yOOlNx55cz306a626bN6aO+1znhFwZavknfw+ZNWsbuPUdB1JZx9pRWa9gXqYwTkpls556Dn0gstKKeH9Tm0jUNa0WC8uIrj7XdAEgBi3ljocZPU9RjPpSXSWd14g0yYXSDTRbRRJbyNua3+TACyYBYZwSD94HP0fNqTXUF5c+LppjY3bLp0sdtIzxusbEpKiZJibP3iT69Oar3rK3Wz/HZLrs3/wADUq0uquX0W8tZptmo20+lXvMdjbbf3jlTgbQuQc4O7I6Yx0rEsZppdZhk1Fba2tyiLbR3U/zWshO1lUngtkHIJP3h0xVwCbUPKi0v+0tMtYWELoYR55BULGynpzu6ZzxVH7Vp95rU+jXekx38kTCKWfUJH82R0UjzIlwBuLE7j0YYJGc04q19On9dl/XYtu2xua2NZj0O5t7SWBLqaT5bhyGRVB6AnOWHTnpkinxLdWvhxrPTVt02RPHHKIBEkM2AfMKgYPLZ9x78VjWmvaPd6eum6db6zE0gkbzpYCsVuwABLOTnJ5GeoO01Q0DTY9IvdOk8PXN/rVpfWjziQEfuQMMzGMnMh7hRjIOe9RyWTUtHvtvb8huonudvpLyz6NFHqKfaLq1jXz2WPKtIRknI4HTOOgJxVKw8QaTqjbbS537/AJuFKlVBI5H8I4J9cdqqeHL2y1bV9M1u1urmzu57SSxFs5AicI7OZQM8nIPP0p7alpNyluLfULaNr6RgsVuoAZlY53DgjkfcIGT61i6dpNNP/Le/5FRkyTURqgGoPp1vFd3JZYo03HY693ZQfmYcEEcj3rWtdQ8sW8SxMiTKQXZ1YCUZBX2yQf6VyK+HtU0+XT5bcPqStdxx3EUcvJQk5kzx68tz9MV2FzpVnBPJLlkZpC2C/wApIG0Njtgf40qvJZK9/wCvUd1exlpHNdaxpN/rOi2o1uwxDDc207ZWJt21tpwGwSR0OC3bt1FwkEV3LGWJuGTfuRcvtB5JwOOe9UAl/HqWnG2ntxpUcbpOkiky+YR8hRugA4z/AJwzXlubq6VYoFkgjt2REDFQ8jYI3kYOA6g4z/OuaT55Lov67/l5mSTi7JFjUMCwhjhYMVfzEbcOc5+YfXNQ6lZ3OoWVxbLqRtdRuId8bRkebhTnC7u3Y/zqDUxezacLiAW0CW2TJubAZidzqvUnHb8asT3NoHhvURXu/LDoxXIcY+XB7D/9fNFmkmt/vNGm42QulS3Usclpczi5hWJR5jxGN1bjO4f3jzwOBgVuaZ9ntpgcggqQMZPIGc/zrGt9UM2hLdap5cDBA00Hmb1hPcbhzjn8aXSYtKjt57fTnEQtXPmxgnhjyevI+h6VjUi3e6+7Yxa0syt400e38UGCTT7ubTtSiJEdwiHAHUhh0PrnNFakkCqsn2a4SaBupikVgfXBFFVDFSoxUFKy9E/zRpB+7ZPQ8omMtlqLGaCF/NiaOOcBQYjj5SvfIPP04qGw+2W6WSC/huooUb7UjqQ0wzwR3H1rRg1CFysEckMyZCHH3429/Y9Pwplv4fs/7StL2dpormNcPHH/AMtIx0Udhz1PNek5JL3kQu6MfXLb7NqWnyabY39w4madmEnIzj5cYPA61PqK6bNe6bDbxyyG4uFmuGU7ZLWQAYB7EHuPrWnqtyZENhbXBsrlpVRpnA2Nzyoz1zUnmRXSeILOe5so4LrbawMtsFZW7c9wRwD09+1UptJN/r1e/wCN/kJpdB0NpDo+ufZCklqMvGYGJCEnkk4z0B4rMTT30KG7OjWkPnXKs0UlzKf3oBwSRngYrebz5tEuYxcL58duI4pnf5nkAATPqxAxgZzWLNp2paijyXrw3ttJEtvKq/uzDxgluO4z07jtSpyvrJ+vn/XmzRWudJY2E2p+HXIVZp/MEypHISgKoC2B05xjPtUE/hqa+v11rWpLj7KI1iCSH5SpXIbGTkAn0HIrT+GTW9zqcsFlMrWdnE0W0A8HO3v9K43ztL0HU7/Umu5lOqk2ohKlwHBznk4Cn0rGnzupKEXqvLv08tFczn8Vl/VyxaWWmQXkelCN7i906FrhpZeXhUjJfI4YYxxzjirOv2Yh8NWuojUobq3aVLjd5QkCIpA4HZu3bp1rIn8VqtvDPAkjXsiM8ds0WzKZK/NnGExk4PbmphZwXL2d9ps4TTZrdknnifcluFOWTt93jP8AeyCK6uWSalJ2/G/f08v1KbsrJmqsl7f6FqsV3DbWMt3MlxA8bFt8OMgbT0yGqLR9P8wNZm/S+8pw0rqnllGBzgYJ7cH1q3qst8k1vqWlzJqf2yJFXGCHUnG7I5AA7cfpT4I7hdflgsrSK2t5WzMyIQJWxgNn1x6flWSdou2nX9PUqCHa2fsmkxxW5tlhSXzLozR74xEM/u8epOBjrWbZ37PbabeeGtGjt4J7hheRMrfKNxXcM8EFcZ9OBUlpbTXHiITvPahUl8lJvMIW4hzu2bOgPTBPPX61Pehr+GbVNOuJYbiGzk02aOJvkjOCd577QRjOOTzVJKKUXr+WvcUm73LeuytDdXEOnWcdqZrVpXvohwrAcbjjJHYZ6ZHWs42F3reiRxQ6zK99MgRmiJYSFfvRgHB5DA57EClubie6igFhq0MDwrFLMJWz+7VcE5x0yT17V1Wgy2Ml9FHZXdvanOIbeYIFnbBJaNgckHnjqKmUnRgmlqv610/4ASS3ZjX91PbzNLqrw3GnPEmZ4iTdxTKoU7gvyhRj5s9c8ZqPRY7y9lsX1swLCkrldOlkA3QnkMwHXJ5z6VzelaNrlhqs+iPpfm33kvdLZTjeshBJjZZgQF9Pc9eTXWabZ6/LrMT6pYwWFmlo815cMw3wS7fuqMnPA56gc9KuahBWUlt+HS3r5fIUZK12ype6pqeva/dWssi6roU4AljVdkVtjOAvQg/KvqDkHIFXIEV7t7bRdUhij06MLcWke5miyCU4wcqTnPJ6c9aqWutafoMfneH9NkuDeymUyvHulYgcltvCp2Ax3rYgsB/aL6hFeXVqb8+btjhjyrdlZsc9wDz+FTL3Va1lbT163Rag4pJIq3MWs6ektz9oW4vXj3mG6tiLSMg5LM+4bflBxjGSOQaqXmk2+o6XBJBe22kCacNeQXLyXNvKSMOkYI3IR/d9/pnSspIVfU768t5rdrlhA66m48idc9Y0PA64z7VJNHbx6QL6K3jPkT7o4oQGJlAwScdQFHHQ8YqeaUX599P+G/yJauY5vtStra1tLLw+2oWEdvHGI2XaXm8zEjIozhMdOAcnPtU1rrEqObCGw0yHWhIS2mW12ZXhiBxlmUY3YzkduM1etbi+1XUbWytbSWKHV7SSN7233KI2Hc5IKnA55B54Oax55NGtdB1VL2TVdNdwmmy38kKCScg4YoRk7zs5Y8885NWkpPlcdfK/V2119fP0E24y0ZvakFvrm3sob63gR5fn82UGRlU5PlqT1xn881kwyL9lt4/EPlRXF5cPHELSX7QCo4Rn6jJHcZ6HpioNV0/ULTVbO+g0nTJkhmjbTziSWVoiMAtk538jJIzuGSOlQz2kFvqN5EtppumM4muLW7adiZXGMgj064UDAOe9OEVZJPT+vP077FuTevQ2tItLBfMSCES/ZpNm6RQGjYjnH4dR09q09J0iw0+1W0021jhsyzBo0JZGBPIKt2/TpWRoklzrWmO9prkUUwkRlaS2I3KuRJGw6feIIJ6/Q1qG6hcy2jTRC6KlzCvJC5GOemeR+dY1VJtxv67lpqRSbV9Ki+0aVeWUioHLiOaLajsvIYMCdpGAc+h79KiuluDYXEVjbz2TSOGDWqiQOgPBXJ5zgAjIx9M1SiWHWprhLS+hZrVispccDBOOGGCM55HHB5rR0m6MaSI6mUfLvaP5fl7N5ZADDPUg5q3FQ1W/VMm3UguLl9Uh+x3kl5aYUJJKEQSF0I53ZwM5HGMHpRdJpy674YjlntjeWQNsovi3nXMP94ScAsOce9dGvhSI3ttqFteRSrI5ZkdAQGweB6c1k6rYJ9pEt/BmaPEtuZFG1GJ2nYT0Ptjtmso1YSdov9NXoT7s9tznr2ztraK50ZtKe8uL6Vp7iVJT5Em774Vs7gVUZ7Z7dqYttpdtelLu3jh/s0iCK5WVo2TK4wOzfL06n5vU1u3tzqQgWKxtSk8BVnR3DApkgkMPXB496peG4ftF273EP2W2kfzpUfB8x2yc8/Tj2rdS91yf56/1boWkjBigtrq4hCzeXBbFYtOuN4jnbB3yIVIAIy3bH8PqRU2oT6bpGuW6Po4nmupQ1vMigLHJk8kAdzycdK3Vi0W7s72/09Lp2s2kgs5k2ss8w+YhB/EgYfexjI74qhpb6/arpdtqEcDXUxHmRAAPFF6yHIBcjd90E9Peq9pzf5N2/rz8/UlNdDefW7y11TQ7W2015Ly+J+0Sxx5jtkUc7vTqKs3olm1KSGdd0YO5T0xzxk/r+dYfhbXo7m3s7m+WW2ZrnYv2hfLlaPdjzDHn7ik4z2wc1uWUl3eanqtrrSWklrHJm1kgnyZ0zwSB26c/zrjqQ9nLbb/Pp6BdJ3JLCC+fU2mO5oFBIGQBwDhV9vX6VXvteawsru9u4t8cMTSqqj77DhVHvuIBz6+1Go319aXULW5kc72MiKcKEAHAGP1FXriITwsWiPzMruMc464J+tZtK6c1oxpa6mJpMWoXOjxw6wI0vJHe5MUP/LN2XG0546f15rpfhtFp48NRPpiExFn3HHzDB6c8/wD66w9RSaeaCwihu1OoRyxm7hA226qPvEnoTnA9Sah0iO08P2Z0vTzPIPMIa3eTbLPlcEg45B9F56fWnWj7WDitG9fLqKt70eVF/wASWbXml6/H4WmsxfAK0SzjAB3Zkj54BI4GeOR9RNpmjx2Wju9/bILm6iBu8kAynA+TdxkckZP61k6K9tZ6p8k96ZrhjEVuNuFZBkKWHJYjoT1CjFW4LhNcsb62vzNEh/cuGDI4UgZxkfrUyjOK5U9NHfr2/QjlfVl+xsLPT9Plg0WNljklB3F8iMYxgNjJHJ5OTg9cAUVVm1mz0mey0x/Lt1mT/Rt5J3jdtVQfUn+nTNFTae9t+rGlZHB2cMVuiTXCQwzNL5csbDDO2M7kPf3q9a66n9pPYssv7pQRIPmjwegBq9dWcSeIbb7fp0Vzbzg27zT7sQoSCduOAT6nnisf7NCmpzWNvppsNIwDayyOZHdwTuJb0PpXXeNTfsJPWxoeItG0++b7ROnIkEm5ZMYPTv8AWqWmyus1+8s0Nzp8C7gE2s6Ki/eAP8YGenqalW501LqPTL++23F6xjSNIsg4IwScELnH1rGvNLTT9RhktbEkxSsoKMVCqRhmbjk4yfTjmrpptckn6f0waXQbPEupR2L2y+bo16hu4Xlby5vMRsABR0wRz69RVzTpb1/FNy1tezrpht1iOCGiZmPzcd+/uO9a2nGwmuLU/ZBdwBSiOXZXKk5LbhwfmyMDn3qve6Bp1vJFHo7PZWpmMgXzPlJ/iDMx+VRjk1XtE/ckvw/rX5Al3NX4f3F7pyamn9nJb3D3Dqm35i/ow9ea5DUobttS06HxE4inuWeFbSJP3ULtwrs3Y8gnj9K7PxCLCy09LppDcKkQkIiOdpJGcex561z2lRfZrWCXF1qkOoXBZxIxDW6sOO2AwyOc4I4qaMtZVUt/8u7B2vdGYunu+n6uYNHttYOn3MUUTXkpXz4ycNIuCOTwB7H8K39OlWzsrXTBpUVja30kz/ZShk8wqp3KWPHQbeeta0Gm+GtC06P+3JZH8xvKEMakmPJwzkDkDnkmsbxda2FlB4f0/wAGXb3V9pU5uI0kyy7GI6sexJpqqqsuWztrrrbb1tvbp1JcraGlpX9naNaz31gGheZhE1vEOFXGNoxwq81WuPEI0fTLvUWlsFvvPVLdrtXaOLceWYR5JIHQHH1qvue48Q3V9aySrbzAIbU/difcdxGegGDnPrV+bT/s93dX+lSC316RwgTYJFjjHqhGMk7Tnk88d6XLC/v7u3/DPy89SprSw3xJp73l3KttpunvPFIsh84mKJG4yUG4Yzljjk9KpRmx166triy1EebYM32hLdNkcg34+YdMnjtzjNUbnS1NjYxfZNQu2ubvdJPvOyI5ycOQRgknj2NWb+4mtdWEcA03SYrd2k8p0AN7Fzu+YDpkZPOenIxitIxslGL1X/Dee/y7j2RBqDWz3EVs+l29vcanvgNxA2TGinhjjkkEk44HHXNat/pGg2WpaBAjmefSLRXe5tlEcU5GG3SKOhyM/wA654WukaOdLkaxuLuA75PtYUlVk6vz3GcgA9811+gyrIVuLm1uvOe3Fx88ZSKJXOfKLfxMcgkL0HU06r5UpK9tf8vPpp/wbAldq5r+KoB4gtdA121MqO0Elv5cjmNHR2BJ24zkFcg//WqlHcXdjFJZ289vLe3UbW9pBPGywXD997AbUO0Ej1xg++pp2izWvhzULizupdVmkuJJkj+4URjkwr1Ixz9au6NAl/p2oJdG5htzCNsxcpJC2CcDgYIOMg5545FcCqRhDlWsYv8AX+vUyTjGDS6EOlyXVhA8fmZkR/3MkYGIx/EFz1U+9Pa2FlcASxL5yYYHIJH49vwqPTUkOnwx3k6XVwI1MkiJ5eWI+9t7Z9OlSwxkRgOd5I5yec9Ofepe7OlWRW1fS7W71TTr25gRxZMTGjfdZD95T7d6l16KPU9NP9jRQWJfDxSCNJA6hcAYIxjoQfapLu6s4AkWpzxQW7EJI8hwq7sgDPqc8VQTSZYtHtLe0E3kW+VLSOM7cthgR26EY7VUX8Lk9tu3f+vUhpXIdftS1tp1zb+JL2xgsdt1eiGMJllHIY5wMkdOeuOcis2O6guZ7qWDUrW6h1GUXJtVMbiOSQD94Qxymccg4A68Vu6VZJPa39vetDcQXRCzwg7wQRzuA6Z/Cmw6TpdldSyRabZRiVRFMW2o0iLgAbic9vTB75rVTUbxerXp6itbY5PVbzU7zTE1GEyy2LBoJp7GQNNb8n54ZFxlSOGP+1wcHImubXTY7tNCvLS61DUoLZGhukb7O8Q4xkjPJzkg9yepzXYtpWmJaJBa2Ntb2EZLxRRrtRAw+YHHUH19KhfRoLewaLR7a2tE8opAQxxET0Geu3P5Zq1iY6JK34emq1+7f8xK+5ycsc2l6Rp9npen3ElttlikkiH7+NACwZwQN8gyRnp8o+lV9Ps5bDwpFdWS3DXjWgK3N4o82Ruo3g/eKjjbnGNvNaV1d6e9vpV3rWm+TrNg8nkrJK+UlAG4Aj5ZV43AnpkHvVPR7qysE04654jeV7p2EMDqWK9D8x7YP5nOAMGt05cu3X1vv2vf8gTt6FKR4NllNZJp8N3c2nmKWDAm7Y4dlwcbMjgHv39ek8PThPMVpo59RSNDMyuCUwMLxnKjk4Ptn0rM8SwXtraLJc3WlX1xDcNMby0gH7q2bB4DEYxxkgkgc8mobvzppZ/EGkmx0yOeYm9nXJ/dBRhMsMByVAIwMnFEkqkV5/1bv/wRxl5HQzalFpUsTpCUQyqwDH5N3YkntxXTprMOpw3KLHEwJExKqZAw6Z2kZOMc1wdyqa5obWt6wt2uYfPe6T51jwTxkfxADk5znt0qYXFjpz/2lp91MunQRFFA3ZByMsSeSCe3r6da5J4eMl/eHKCk0zrILRYtOEiEieRRvcKApQjpj+g5z1rB1nUbbw9okr3toJIwiOyIA7uG4yFJ5APBHajw7r1/9u+1xTR3enTlXjABGecEg49BjHrW14o0/StZt1vY7pLO9t1OJY+HVDzwccEMARjHcdCazs6dRRqbP+v+AQ5Si7W0fU4GA6dqPizUNShsdT0eWKP7FAwnCxRHbw6RhQM4APBwCR3zUVnaS2uuQaU+pXonvIJ5IGuF837TJGD95yeB1698Z978Nw1zpd2LhZpNStC0TyTAGK6QEYmUgHCnPzZOVPUmo5dSifRtX+2XdtYx3syKZLa4JnjymJIt3RXyAPlHua7ry2j6d/Tf7wWkfd3M3T4lv9F06e90trfxJpkkqyG5yXeCTc21TxzycDkjJx1rptP1SFLeC9upnb5PImBIP2dhkKigckZ4yPSqb6Bc6VDpdjHeBI4B5ht3lM74x3J5zggZpl7oRmUf2RqjWd2k0ckuIgzsqE5Q5PXkcj+7zUTlTqddH69/n6lxjaKaOxZ4owHaNGmX544iufnzxn0HfPtXKi/vor2WS8upktEYmWNYzkKDkucdSeAAR368GoNQu9Qv9bvoLpotOW3mhW2uHfbHMgTMmOPlI2kZzjPvV+HULCfxwlraTmVpbUvsPzIyp1I6jnPU9cE1hCnyK7V9L/qGnU2odchj2Ex7beQKwlVsqTxhT055H0qhd6La3Gol9kjSh96g4+RvUA9/pweKt+JYbeeyMdxGESQNnyxs25HXIHp7HFZkDwPLYWmlQ30VtHCryTTSl9oHTdnOT2/pWUFZc0NPyCKLltaWkouI1uI3lQhpFkbfIxGME46MMAgcVFP9qNz5U6nYp/1pOd4/PI/+tU1lpVjA11PbAeZMd0jg5zznH69Kry3wilhjLhZJCduSAeBnn39v8aa95+7qUi6ttCJrZ7u3juLeM+dF50YYRSdiM9COMMOaKdHdu0cSgghyrFh6DoKKxnG/xEyjfVogmty8f7xQ4I5APeqMtuDayCONQVHKYxwK042KxqzcEjPTgDPr/Ss7VpEt4VbLKZ/kGcndnOP60qbbdjODvocdpNvDbeIYVS4YWUSuERzukZicbs44APH4YqW7v5fDdzdXcHl6lp9wskM9v5gIZnQ4Pqozxn61A1td3eoFp7T+y47afJeMs/2hQMgk9Rn8fen2tpCvnTvpS3t2ZyIrS4mxCnQhj0zg44zgda9RpN3lrpt/wfxvcUtUT6KLuPw/p9nDd2mnwNbtDLEqbtkrZYOkpOQexBPP61kSyTWWnTWl1YX93paCNUuUbdJNlvnwcngEDFbtxZ+IF0qU6hq0MOpNOuyezCMEiIyUC46Dpk+/arJ1O5Et41hqZt512ncpDEsR1x07dKUZWu1Z6369+9hqOlyrK4sr+HSrSG5aGXCb3UeWQcMMsemPX61nsbfVIb2z1GaURWl0siyxAqjsD2IxuX2xn+daVnf6nC9laah5l5dLHKzXhOBE78jdngnGRzj25qOwvLl7GOWO6sr3EbA5IDMykhRtwCe3zYH8qavFX/H9duoX7ia5Hb6rrVy9zFLbaXYqoRgSBORg785yWyM8Y6VTvdOnljEuizpY2r2+JjMgZjwcc44UcEc5HNaS6Ne3UFzMGM13JCFjsC+EEmAeucDpnGe5Gauva65badpltdWluEuvluUliRlAHDcZx6+p6UKooWUZLTv6fj6lJJ6FLR7dP7EaCZ2csFSWZj8sp9c9sk/yqa/vPtOo366dbXreUwhKykGN8A5Zccqcrx2x1ParFyhSZbe1KIrYAXbhQy9OB06dBWDq9rI17emfxFbx31qols4mjdlLO2BuAGRgdue/aiFpSbf6+XY0raWZtO1pf3d/osM0/nQQLJJ5DbVKkAlfrk5/kTWOt1aaZBe6ZZRXVzqGnlv397boYmLYOAo6Lg4A6HnOM1LqDr/bNtqBvXhtUjSMLbfLC8pO0ggdACcAc9ulb/iPSruTUdOi8mZtkoa5nScLtIUj5x1dCD0HcA0uZQsns9fmt/8AhjNK5n6bcS2EmmabqumH7Hq+0PDCMwxMOQ4bkAc9PTPoK6K4WSK1hEe1I4QVjhjbaAv+znv9aXw/pcVoJksoEgUkySLbM4gUdtqt90k5yBW54bSK81Pn5lhUuVPr2rlrVkm5W2/r5dgcuROTG+HLDV007EEXkk8rJOcFs4ySo96h12z1ye0ura5kgRZImETIfl37eM/U8c9M1R8c+I30ZLi41SS5lSBwzLAAghjdwiswJGcE9a6rTroajoeowXgeRrUNC7yLjzPlyGHqOetczc4WrNLV/wBfoYtyXvaP9LnmHgO/toUuJbq5knh1BxHbPAo2xMrcgK3zZy3zYzxz0rvYome1aUvk4wAE5J6VwvhLwqNI1SLyI3aExGRW3hlkZm478EDI5wc+tegLOkEflDLbV6jLD611YxxdS8NbmyTS0Mi6uLPSr3SpNRthdLJcrH5rjd5T7ThsH3Bx7mrr6Lqn9u2dy5j+zR3DytOjMzvG33YypOFAyeRnPHSi6uorSze5uAxht1M2Qu5to7j3qS08TSXctimlRfbdJvU/dTpnG3GDk44xz1x0IrF+0teC7p9jOrzXujn73WUtNZ1BYbWIWXmMBtDKzbWRWUdmb5wQPQEcGqninRNQmvJ3snUCSYPwEjcnaF8tpD8wTPI6gf3TWjpvh02l1AHaQaZZO5gtllaQSSEk+c2cZbkj9c5q9q8jQOl59nkuTEjJGjEpu3Y4P97jceR7da6FUUJL2f8AXYtIdYWb6Xp86XMtuyNmbbGcQxbv+Wakn7owTngcngVBHrWdLa5eRfs5wIlWPazKRkMN3YjkHpWfqWn3GraHDbW98YZfP87zrkDa7ZJKEAcKDwPp+NaFh4eK2L2mow28iyEr5URJUKeQuWOSBnA9sCpagleb1uNaaMVb601K13T2sN9p8mXeCZP9TKAfnUjjp6fUelZWrJYWN54eYWIu0vHlAldMtbMEyq5HAB53Hvz3p0TaSjaloNrJcxXMAjedjCV2FiNmHxtJ5BwPf3rb0m4t9UsbmCOOWOG3uGt2DLgFl/iB9Cf5U3+795J2+7RrR/j8wdt0ed+F9Ws7TWvFE2p6bdXsJkSGMySefGgLEOBEcAdcAgdAOPXU8RQWR8Qpp0Vyq2MkbImmRgrE+M4IZSO/JPbB9a2dW8JfZbe58RNNKRZWzyfZEQ/vQoPII6nHbvxXO6GdQvrS31mytLGaW4iZRMJtzxJltrbCfULkFfXuK6lOE37WD8t+ttN/Tp8hJwu7O5ZZ4/DyRz3djAml3EbLfMkpYRTjKxR7VO0BjjJPUHk8UyxS7mlltJ9N0+OyhgH2gGXfJHLnhD2VQAOADnPXPW3cI1rpFtZ2Gmyakl3Ov2uJ5/LRWbAO89cfTgVieLLqyktdSifTpRqEU6tPBauylnztAhJyMKG5AHU5HrTgud7av+tr/wBaDV09SxrmsWk0N7Bpl1bWU1raGbcxJjhOcYz03dgF5BI9aSw8Q6o1rcxTabE/lpGnnl8pckr8zAKfxx2BqbVZ9IiuRqOp2VtFc3Sx2U6rGStwSFCgp0LLgEkHt2IrKbRJdE1xJZZrWx0q0u/9Fl87dLelgE8x5CSAu1VXaMZAPB5NVFQcbNff+n9db9xuTTRtwfZLS9NiqNaalfxm5gi2tscYwdvXrzlT1/SoZvDttJpcdnZWdpHqMjrdRKQwjaUD51AOQ3C5/ukgdOah0mdbW9022ivZLlYBM06OrExy5ZmUHouMDkH1NdFbQm3WO8sAYxI5d1ySEY/exn7pJPIHXmsZuUHo/wCtbDS5jF8thqFpb6rGU1+O033EsQURkMQcqQcHhlzkY+bioYPtD6vcxTw3KWqujeZJJ5JLAgnuSwOQMAAYBJ5qG7vrn+1LotfWmoWOnh7hpLiIJLbxtyLXfxuQMOCM9fpVy0lk1GwZLaOCCaeb7UfMcOB1wgI7AZYA46rnIFXZxV3/AMN1+XoKLdrPcHa/1HVL2N7O2jlnLISsy4mjbjOxvm3AHpjBx2o0c6bpd7oen2OpW2GnkubuMAM80AJVwrZO1VPG0kk7c5yDUraRBNe6fOsfnSxSeWY/KWR5eMA7iQUx1wDz3pNQ0qztNIma3t7WIsJXhJ5YqwOV3EZUHGDjnjvWblFrl6f0v+D/AFo5Qexm6XJceHL/AFXTUN5qsELGeCzDCeeTzWABZtuFUADjnk9sk12N1bvd6D9qiZUhnOShIEgIIyrEDGeo9Olcf4cTUP7Mhl0+WKw1COJBJAXKPKv/ACzxIv8ADjB6cYxWneanPZ6mz3lqZLaO0UyXQk2JcS5+aJc/3jwBySSeMUq0G56br8f+H+Ylp6F7w5pRtLwvAssaAbo0c5Z+vJwcZIPI74GAKk1HQLSTU5rua6u38xB8mEURtkchvQ+gAPUVl+Ftbvp3a5exuI/PkYMj4CxAcqU4yQffGOPpXTXOXuw0u17cKR8jZEhx/e9D+lY1PaQqXbGld3K0Nu9uxKgzMoyAcKD7DtRWvBFDDdrCqs4x5cmBj5+5HoM0VzSrJbq4pTS3MIazp665FpLzSG9aP7Rs2naFHct0HTpUmr3NtBLGxmgZ1PmhWYfMAeSB+PbpXEeOdQ+x+I4bWxYXEUdqrvKx3hnxu257A5Ax+Vb2n2Mb6XGLuKB3bMrQhciLPQDPTgCtnQjFRm+plDVmbq1nJd3MUySbJCd06lyoYt0IPp71nmEz2Ma2d2Irn7UBIZCzRjkbgSBjnA59uatLc6hfx3GmXbGOWzYmKVY8pLEzZxntt4475rT05ba7tltoGjgjgO+UY4LA5OR2Brq5nTVn0NFrqT63qMT67eJsVrJmAidTgTDAUheMMc88ehrkLzTLaz1y8vLlJJdOkePakUmx5JgeGY9l+lbYnttBt7m2snaa2kkaYNKAzoZG3FUPTg9xioNV0xbnT7r7KGjWaMQXPz4dmC/eU9tx59s1VH93pstvy+5iV2lckvYr5raZHiVNOmt2eSV3PGemfTj8fzqhaQaSbxYfDtnfsLRXhN3NgozBPvovU5bjBPTBq3odzeNayw65NLJYzRHyYpSCsCRjbnPUlhjIyee9Ph1a30mS00uGK4tjdqot0RQdu/JBweedvOKpcyvFb+W3r8vuHa9m9BICb/ws8OqalNYTXxWC3utuxo3Eg6d8YBGfQmpbVr77d/Y+pWzadE0klusnmnIyPlk3HIGeDuGBzVXXrq2v9VT7XqMFtaOSkNuwYMfLI5DEYAB9SPxq1Dc3VxeXmnajqKTJOgNmkaANFGQcDP8AEc/w5PSjldr/AD9Omnp1EnrctyeHtumNpTz3EMzKYDMrfvFI/iz6+9F/Zq9rNfQWtteS28aQpHcjdK8aEAMxHJPVvc5NXIZZYhc2uHluYbdoQZDzkpgMcdKyUtLsWP8AahkinvdpWa1dwYzJtwBkHkYx9KiDk3dv/g3/AMzSbvYs/DIaJA+pxSQzra3VwJLZ75doUEj5FB6DIHP0rb8Tm8LXKQXIgkCFzJHHlk+YZbb1JA4x2zmuR01NWS+06PU7+1MpidPs4UHyyVyig+3+c13tnOuq6fY3d7CkU15brM8cnRJFO1sH6jOazrrkq+03v8/629DNK3zOdi1q/tr9Qs0cNoCRFI6BzIQoZck4J3HI4yc5HUV02kBdMa71iCB98gUGGKLc7BjnBA9M4z2A71aj2F8RgyybSRgZ6dccdvasO7199JstQ1MlooLOLzWbnu4Qbu/JPXGMZrF/vVyxjbZeoSSs7mh49t/DWti3tvEonW4IST7PbyhZJF4IVh1wcdOK1ptThn0aWKzV4g7iJc4JcYBJ47c4rz3wB4o0/wCIOo3NpeabFDfFJJILiPLhuMMC3BU44zkfrXX7DDZR/Z4QXijKJGBgfLwoH+HU4NTOj7PlpTvddL6fIiFNXV+hqQovlxwxSKruQDxt59q4vVNe1rQPEFzGsclj5crFfNTdbywjjDZ4Zj94FSCc49qht9euFujBDFcXxaTZkqEUkDLMpC8LwWAJyBzzXoWk6i2pWSo83mRMpI34wRkgg/QiqcXh9ZxUk/6/rQdRO190ZcGrLcWNrc3sEWn3VyGItnkxlh1IzzjoenH60uj3IlidI4DDGMP5QGwYYnB29s9aVtXglE7SxGWO1wk8iqG8vdnqvUng5IqvqVxNbanDb6ZaCcXGxw8bBg6Hvg8n046deKhRveNrfP8Arp8xppe6zckYyGFcleCuRzxx+tYVwFt9Wm1NblzYyKVNrNkLHwoGSTj73fjqa2L26htrkCVgzE7VVfmGeATn0FVjpTXOnX8E97JKtycq7DiHngr9Dj2qKbUdXsxXskyp5lrd6dLdcxG0DRyojK+CvXBGQGHH/wBasGy1G7v9WEDMCxjSURQoxWOMno7tgbiD0APrmtuDSk0fT73fexxm6k3KiIAHc8FucZZicknA5HQCtTSLWyi06TyrdxcKWzsABLgdFA4x269629pCCbWvYftEtzPu1dbCea1jE1xEC0aAj5mHQH070umQhVQxxGJ5Tunj3E4dhz16jPSq/h+6XVLO31QQ3Fs15FnyLhNrQjcRg/Uj8c1p3Gmi90+WV53HkTpKYk6yMpG0A/55qZPl9yRo5pK5keLNd1fyb7TIrf7BY2saSyX7OAk6cZiU9R74B6Y4zmsfTjpyaE3iPTVYNPA0MauuyOGKNiGPfBOB65wPWuo8VaBBrulx21xuS3eVGlXJBZVIOMjsDgmuKjtL280iVdVt41aOQSeQchSSeflLAnHbBA6e9dGH5JU7R0118/8Ah393zM6cVb3TS0S4bUdPWPdbWN5JMJLZbiba11ERx8uOG4I2jlsZ7VkXWkQXeoXp1ie3uXWdbi2t2dkedirDGDjoAMpg8DPeqnh6doLJ9RhuPMtYVdZtQv0RJdP3L8sUX3iy5weOeT072pINL1PSbOPWYLm81AQTSQahpsDFbcAfMFjJ+cttzgj5SccV0crhJtbeW6/r7+3QOZ27lC8gC2elX6TXlmst4zmxv9PxLFknDBGJUjrt6E5zVrSY/Dt3Y6loWryXt5qGnETSM9tiAgfcZWOM4J64HPAGOsNxeWN1FLrN7czyrMqObm+j2ssYyP8AVgkhgSeR2A5rVTUntZoDe6y1zZ3VgZIIIIiPNEYyCMYJIPQ9/wBaqfNy21v922ttumu9gs2k76nO6hfSz22pwy2l7DcWUaS3CojBbku2FPy8tgHJBzzirF/c3gMcGkXwjutyOY5hmRowozwAdxyeR+Aq/pd+yX2ltZ2k08eoEK3k8SW65wgfd9889iODTYbq91XS9ZnRbVL6zeVbGaxwZntxjcgyCA5GcEjIzTbtutP6W3r+Bdykby9keyt9b0OOSKe4h+3QXEQTFs+FMp5yGyCFbdxt6DOKv+D7ddHvX86G1h1jLXF1ZRP5hijbiIHPyrwVJTdnpzycYsOnw2KaOtjI2lajeIzPFdO0ks8WcCNVxxnAPvz+PS3W7T/7VubWG0u7e4sVkhjjIa6mkAHDt1zndwSR8y4Gc1FW1uVbP/hu9v8AhuliVdvUdoOqapqWpRadq8MU0seJBewQhY1Tk8MuN/QrxwM45p/iHw7/AG9HZnUQJImkE6AEjYwA9CBjrgdv50/C9pZeHdJivL5l04XEYVreZg5hLNnGR0YkntwOav6zrN1P4evfs9vBNcoHiMLycEDAILgjnB9vr3rGV41b0tFt21LjEwvtV7pgt4dNtV1/VTNw1mAEtoG4jjBHDgAHk4K55qxfSyRnWPsdrZ6vd6fP9rW3eTesLnCtyCMBe3Pr6YqLR7Ix6emg2lxPpJe3VWjtxueOSUgkq5IzkcZzwCcd6dqmjw2ukSabbW0U0MziK6ZZD50jDcVI65Ulm+XGDuPetXyqVv6tf7rdrd9+orSegl1e6rfXWr6HHJYm0vYYmZJbjiKRuQEkjy20nAGV+bnnFTx3d7ZQWmmaHbTxXllEvmW1yo24Gd4LcKSpI5OOCT1FUtL0qS1sILvw/p32PU1ljj3zygmNVYkuoIwWJAPPTsoNXpPEOt22t3Fje6ZZ3tnJdx2wngKp8rEZeTt364HINS0m+WCTt021Vlft+IrW1fU6K91C8u7K4l/ci7ijVmiSTed+B8oIHTrziisUTLa3T3+qaZNb3ttcfZ4xvwJVJxuI6Y5yCCPTviis4R5FaME16/8ABHtoWNR024l0Oe60myW5v87IwNu9RnBYZ7gVW8O/bxF/xMwsQPCxEfOpHUHI5rpkjktWxE4TdyVxx9frWXqybyZPOZpEOTsXkZ789K5IVOZcj+/qZK7HtG0Mk5EWI7gbS2zB+mfr+lYH2CdR50cIju79HWRgh2yyjheO3QZ+lSSW95PaXtnul+zzQmLzAT+8cjO8enOBgVnaBb6xbXE0d7cTXKyiNhGSWMe1emfXOea6aceVNpq/9f18i17xYlsbnT5Vi89IV8vY++IkI4PBwB0z6du1WNFkksYxBcFbpyGWRgcMrHnOPQVqXWpyXWV1WFI5oiCARjIJzyemc9q5SwCy6nqFxZRWgsnddksBZ3Mg++HY89e3T+dXC9SDU0UjQ1q5uJ4POgtIZlQeZtT/AJZoDzvHqOeOKhsNTg1W9t75rtWsbmJmgVVAl81R+8A65HBxg+nQ1b1J2tDJewvthCCTcuVZsfKcjvz61mLdiDVLD7TpLeVIf9DkhQhQmck7VwOTyMfzrSKTjov6/r9RO5Qnvba70iCHU4CttqU8kQaWLa8SgDb0755689OcVvWNtdWOlTx6lfQ3k/km4hs0jCMwQYUdPft2zWTqWseXLpl28rxadMZVlRoPMl3pk7scjOPcfzrY0q80uaJfEVvavcuLeW1tA83LLyG8xf4WyMeh7cVdTmUVp/w99tdttbdFchPtuS6Hq3n3iwXMRtJY7NZpLcvuMRwBgMegIOTn19qqtBcrqWn3mjyx3Wj3oPlAR/JbsuSznByzFhj8celWtDupbuyu5by3FtqQtmkdcAhIydqqW6N1GB7/AFqlZ2Gq2PhC50ie9EN3aBpoblI90knGWyM4GSSB68VCspO2nTv8/k7fIvVopy6XqC/bLrTLmbTp79VeY3MSb7U4PC913E9R24r0LSYlFrCtxK6oY2KK0pcJtCguu7lQeuzt+NcpZyx3+j6VcW4ksr2WZZZ4pV/eFQAN59cn8sjitq116zufEg0iAS/aBF5ijy/lwygg784yeOO1ZV+aa22vf5af0+wJJalKJGummtRc3du7xgCa3kKurDHzIw9+cd60NLkn0lw91ENTiuUNvqCvGP8ASFI+/t6E/wB4e9YN9pUv9pRXS3kcCuzrcxcoV242lQPvux44Hf2rpNMuHWGGB5YhfLy8aHGGPIXHt09qKqXLpqn/AF/XyYOKlozX0640zRNKksvC+jx6bbnJYoigDPU+pP1qG3J8sCLdu+8mOSD3qG21K31WUyWF1G32SYxXMcOG+bGdrgjI9QRVk+WWJAY9QMcjrXIo8ujWvX/ghThGK90yzo9zLNcJBcLBZ3BVmjMfKY7DPX6nkZxW7HizhhitVMjx5O5iBz356ZPaqclsLu4tZk1GW0S3dmkjiUSCUHjZIMdu2ORVqGe1vJ7qC3kkd7YrvV0K/QjPGPcU5yclr+Xy1B2M4wC2uEu7NN0ogeBkmYELn/aAyVOSTnnPQgZzs6ZZCx06KDiMMSwij3YVe4XnKj/GsvQXtJ4vKDTuN7bXaMqH2n5gCeuKsp9rbVWnYysd2DkkRqnPygdOMAgjk5OaVS7vHsTJK+heu9Ohls3iSFUSUhm2EliB057Ulq88VtJJOkclyvymJDtD4OMc+tLEqzeVcTSyRrAz7tzbEbnGT7AD6Cq82s/brU3GkecnnBD5nlc8gFffBGT6884rNKT90i7+FmfqOhXfi6W7sr4LHZyypIZ0DB4URiREMjac8H2JPoBXYww2s2pXHlX0Unlx+WYUdSYsew96zbi7NjoE8l7N5KpCTLMxKlAeOAOc89AM1x/h/R/7Mu4r+xlQqu5eMhiCAcHIGeCD71XK6sXd2S200/rRf1vMabqJ2la2xS1/+0LnW72WfElhCy7VWTbKkijLMFIIIIbr/snpit4PezaRazyPIWdFaXyFDlnxnHI4yCMHHscdal1G0W4iE8yW4kViBNLnChs5X6c4/GtPRBttmRCW+d1Rgu0deSo9Pr3Nb1Kq5FZbGsvdQ+K6kGgQfb0aO5ZQcEjjnnp7fhxXFeMdN1KybV9Y0Wzs9Yt7zyTJYXEnlmNVChtrHj+FSAfVvpXS6zp3/CQW0drp+q+Wq3aG6a3cO0iDOYODwCev0qFYlMtxZNIxtZFEa7DtIQDBA7g/r3qKLUHzLfqvK6IhFO9v6ucPrmvRxzJpI0mK4vzhhZCPKmDyySWC/eOAwyPY5zirun6OtlrNvqNlqV5pvnTpcvDLLgOioSsB9FZvvE56mum1PR9P0rwJdW+lrb75IPIt2dd5JfC5yOeme9cLcWun+GrG3a3s7qZjItssbj5oV5Py5ODkk5OAegGOa7aU41YtU7rp6/5FRtNO602N3X47+80WO6n0uOG7vLcx3VkWDKsnQ46/J3GSMc9cVz1npelx+G7SPxDf3+h3drdMIGsW/fGLG0oCeFTPOeM5IGetXtEnttHbVP7Mt3vIr4NeSSGXcGdTt2K/RRuIGDk/MewFOvtBi1V9TutVvJry2vJInNlOMJb7DyDg5PPoBVx9z3G7L8fTW/49iuRyjy32Legrc6JpyWmh2VyrWl0LeS71KNVMkR3MTFkZC4J+bvx6YrndIhttUNoLa+upRpmoSKSkO0tKvaQDjYcgbu/I4qzoFhNJcl9VZb6+QFbi4eQrBNEuSEQYyFGB6jI6CtG+upNPjtLe50+4a0uZUVrtsxiA4IWQ8cj5m5zj8cU/hk0tW/6/z7DjotRYdTfxFIlxZapbpZ2l0YbjZGrG6G0Aru6xr94fL1B9q1dL0rSNHsDYaaP38UbGGDfvZcnG/OenTH4Vj2FheNJPZ6daNEtptT7Q6hVuS6/O5wAN3P3gSeOcVsXcyQz6d9mma0nFxHA8iRK7XiBSQvXOMk8exrCore5B2X9b2/roO1tUQXDwXGsR6Ld2sdxZtHMLmZWEi2U4UPGuMd/TGfmrA0ixvNQ8OzR2Or217bLOVuZXVwXVyPlAK7lxg4BwBuHJArV1GwOqa9c6dZ2xtbm6iOoXFykpji85Sdqlz1J9hwD71zFtql6scNw149nqdnNNHPDYgMk5DLneMkEdc9T34NaUotx93fT9deu+33ML67m2fCltFpl7YWCqyyzb5RNMzqsI3bQuCPmzgAHqDzVnwl4cuhqcs+v63DJq01qbVYYUIiVA3A4wPMHT/GtfRLm31bSGXE0N46MvA2lCMAujf3/mHJGQDx3qjcEeHorl0sjKu+PzUIaV8MMJJkEFtu3J5Ge5HUYyq1Jc1NvX+l1E7bovXnhFrK4g+xXlpELKJSsH2kquOFDSLgnnB+buc1zurae8Pjm9isbO7fUNT09WF2EEloZcBQV7AggAkHv0rqvDmn2N3qN/qtxas+pXa+RcTSglpguADjJC5G3KgnBFTa9bXxi06HT9SuNPgiuhM9tbBT54HPlknop7gdaxhXlGfLJ306/076/f5Gac/VkOnwXyaPayz3EVy8ZVCXYcEAZbdgAgYz6HNFW7dPt0rQM8kZm3SQqfuyMOGx6kcfSis3KN/fsjWU+V2ZmQO87sdzHnls1UinX+2rix8uUTABgz8BxjsO4/wNaV5aXaOhslVot2GZkGR9KW6YXEqrJaoZoiUSQrkoO+01KkuhmpdiqZC+1MM8bHDgsflHqPp1rH1qLbp9/Bau0TyxsI54n2+Zgngf3TnH5Guv0ebS51a2t5UN1zlHXYxx1PPUfTpXN+L3t7DS5jM8trKsoKSRRCQBT/ALJ9DWlCd6iikNTTOO0bTtRtgs+qalPDMpAW1TBVkx92TOcjPP1rfga58q5t7lbZX8wlBEAqhQc5K+ucE+1U9NTUrO20u3bypLXyiJL2SXDBixwcHJYHPSoNWtLXS9atLm8sRd3KoAk9nuKTFgRuYH7mMfN+HArvk+eVnb5eX9eo4tLQ6hrD7ZdM187W1tdAzu6vvLrxkqei8847VQur3yfs6Qo3nwxJPFCp4wWPlh89AcZrSDxR6M8DqCJOVKHdsJIzj8BWfq7TBLeOxeKSNyImzL5hwD90E9AD27VzU9XZ7FWaRmWg1l7V5LdorbVJVG+d0Zo4gGO/CD+MDIPXrTZNAiTSrzSoU81Lsh28xzg/N8uAMH6Y61q3UFpdalbtbXjILYNE6wklS56sffpjIrH1y10vTNK23V3qkqW9zGI57gb5S+SR838IyO3IH1rphPmatpfy+4hq2421kjee2tr/AFRo/wCy4Nly8CExKhGEiCg8nB5HPHNaP7rw14e1ZZJfKit7dXimYs3l7mOFyOxLD25pBbGeWxstWijV9R3TyGG3DEquSu5h0c8cntVu5uLl5721vYo4tPaOCG2kX5lm2tkjaePUn0PWlKV2l00/Pp+PyKXYztCvPtj6e16yJeW9uJLqEEkIz8oOeMMAGwM44rudGjeGO4kvXMt9MqRJIp2r5KnIwMcNknn2rj9UvLqfQdM1yKw8yKGQJ9njASSYK+0BsL8wA9eneu61aFre+una4jSNAJWZiF2DHfP4VzYh3str3/B7fe/+HFo9GWXtoYD5sccZBBBB6sPauGi0LUdP1mc2hWWyuGZ2k+XBOPkLZO4OPmJKjnJ7V2V9rDWVhAdMit77VLtglrGWJj5/iJH8PTrxVLSJ5E1G+hklN5Ehw0vlbCWH3l29CATwRj0PI5yozqU4t9H3EpXbTLEUAUfKoDSffwoBbHQn3FcNrPiW9sbu8Tzri2xIsC7UDRxxEEsecfP0wwPUY713jSrBM6MUZSBjpk1CU02+E00mI2RT5jMduBgdfwxV0pxg7zjdGkldHG6dLIbuWTSXuJIoIFnzNCu58jBVvm+Xke45GPU+g226e2jYD/WL88Z/hPQjI/nWTp+laU9mItPs4vJgkyVxgoSOCwzk9cDOR9K1dKkhY+XCJAVGApXFGIqKeqW39ak9NwTTXsv37yOYYQfLUtgJkAEkeuBjJ5qtZ66L64MCwOj7jGqsOcqBkDscZ5xUNnpklpcpMYWF2wxcyGQssrZ4CgnIBGSR0zUevqtg9va6dIqT3DlmZmCsI15O3P4cew9KhRjKXK3d9yY26m9D5bw3EDsUWXqy/wAD9dwH5ceoqlpehJoMd/em7M73RaTyUDCMucYcL2IA7evNVNK1S2W4h0/U7xPtUq/KUADSe445PTpW29uysVRsFQu72yP/ANXFZy5oNxvo/wASZxSla5Tu9LN/PGwyLZ5PMlfAYlccKQTwQexBBxTY9FhigSDYfJB37cn5mJzz+PbgD0qHW11GG8t7jTFTdwko28MMjqR2xSXVteSa1E8PmGGLLoVYjjjOezDHAHrknNUuay97QItrqWNe1UafIlukP2hkj8x1V1UqhJ+Y5+9yCSAOACTwKcb63Omi7k3/AGWWPkL1KkY4/Pr0wKbf2kVzE1/LbJNdW6NsCkhjjnYSCMj1U8fWnaSbua0hnuITAx4SAfIAoOAMfrU2jyK3TcSWmpHFb2fhrSLiSwEpnZCxZowCink4AwNxPU4P6VU8PawNUs5hLAIHgQhpFYNGR7H1H0GT+Na5keMyyHb5UQJZyc9eTXJWGpyXrta6Lbix0+YO4aO19ypdzxhs4ZRg5AwfQaQjzxk2rvuOMbGVr2lvfvdWU2qyyXLXEQ4Ecdwo246JwV3YOOoJ54xWbayX/wBut7vVnjsrXTVaK7hklDTuAuFYjJweeD3xnHIxof2alo7jUJLqe/ghN5Jc29y/mStFMHjAyvBfnd9F56Ybqk9pr3iS2vra0tkttYtTLcpK22ZXQ7QFwcn7o+YD8RXoRlpyvbv/AJeqv9xcbppM0La/gmtLqy022kFpAoZSke6OXf3UfxDr69aoyeIf7Ht/O1TTQGgZFjitsh8OcHOT82CT04yOKtF3OjXP2W5TR7mzkUJ5zLiSINtQDnCbiAMc8AZ6msuza2n8Q3M1pd6lYXNncEXJMatHJCScKQCRywPBH3cEdM1MYxd7rT5/mu/zKlK2iLNhb6ZoR1iGW2vbPTbH/STqVw5mjnB2kkALnhgqk/N7+9q71rUbbS7u7mtNWuktp1CWsYaXzEYAbwpyAq5HOMdKhtdLubeDSfD3iXUBf21/JJBc3cV8VmV92eHXPIJAZW7EelR3P9rXnioPay/Zobby45LdpXZGiXCkg5O5ioBBPJycnpmbRlK8tfPp29ddfQzTu7I3NGmkdExHi3Kg8qMdCOMdRj9RVG6v7qPUYLWztIo7J4nZ7tudrgkBWA5yTjjnOT0xT/Ed/bQ289nMk8Vs1o8zzW7KHiyNq7UzuLenuaxbgyRaBYyaM17rs8gjgEsrFJFjKkCQMB146noTycCohBS95rf+vT7za/QZarrUms2nm3sRvLWGWWNk+W1upXQqqSDAJVDyeO/0NUfDUd5eW1nELm606+sbvfOqtuF4GQElR1K4JQ9uvPanaJePKzT2qajFBawTvDaXCCJtRccEjoR03cY5B9c1Fd3Eupa0P7R03+z5ptOVo2efZLnqYwq9SBuPY8fhXTZptWX9X6fP5EWT1PQtIis41vIdOAhKPt34wDxnA7nHOc/Xpik1bVRp32dpIoLmd/3apIwj3cZIVuufb61maVJDp2j2CSXE95BBADHeXKsz7ywHQeudv+NWtRtrTUbIMgjmjJz85wRwVYA+uCRnp/KvPcFz3lqirX3H6fLc+JJLeK1S3t7fZ5kMUbEREZOCCMZPDdcfQ07Xf3GiC5u9WgtCzmDzWyzJgEMxI6d6ZaWc8VgtrpkzWskMJWOdFH7olcbz/eI9/SqltZfbfDsGn312mrNbR+VLMRsaRsk7hjkHnGc54+tKy5tHon8+vy7CUWmZEss2iy6No4u7q50qYSNYnywfLPUsZOpBJOPQetFb3iC/tFu9E8PaDb27SLB+8eY+X5EKYyBnknr7f0K2VROKlLS9+2ur1t/V9zWhKPLZqxrLPaLETLMytzuQg7hjt71BpEks00N1JalNqkiJ5V3qCeMjtTHxFsQOGiZTgnggZ71FZyrBPMUQK7j5s9RXncvuuxxpdiPUzexeLLW5h0yC3tlVmnvZJ1beSMBVQcg+/esrxJ9su9dgw7T2E0Tie3CBlMi8q2cHbj1roo7cTEShg23JKZI/GsKye6uLa8h1eKOBpHkiiSIkfu+2cdzzXRRaT5tNFb+rlQiloZml5uNBuI9Q2G7EjD7IhJaReTkMeuOefbNUU3anFYaVo8qWerSyFtkrYYoecHqDwOv4VrJoqwxlmlkMsfzLKwzhRxwOmexJ655ql4k0DTf+Efu9WkW3W9MHkRs0hACgckAchh1yK7Izg5WT3enr/l+JbbSJrh3iVdPlfZIrshXYfvKwAHPQHOR9KfZJpUZm0qIiadYmuZFiVsRtnBIY8e3B9areEGE2j2we6S9bCsbk5Ysoxxk857fStSye+itYLOcObuVpQJAxZI4znaX9h6emaUrxvFf15ju92V7aO2N/bFIoVI5LMu1hwcOf73+9Tr+4m+2JHcWuYH3YcLuEarzlhjnNZ+kX17eWExu2Wa4sZ/KkYRbUmAblhxynOAeBx0rTna4+ylLZUiRoSI7iQkqGOcbvUDhcHnmm01LX0GtVdFuO7i1BWurOKYrODmMoUEeePmHYAZxWDcX0A1PTLN5ZL97gmSG5CZRHB289MEYwe/TrmtyzkdIEtJEhiAjAby1AG7A/h6kYye2AK5vVdGabSJvt9yY4bRHnk8gY3LkYJxjdgBc8ZIp0lG9mDujX/tS81txp9k8thaWc3kXPmoI2MQGD5WR1JrpdT02yn1eO48ob4Y2ggdpCNkZA3AsTg525JOelct4b0GfVTY3GvzRtBBGtzHJGAvmZYFE2kZ5AyenHHU5rpdXeKXSbkTymBf4nUEkEnjAHJJOFA75rCraM1GD+7z/P+kSurLFvZWL2lr/Z97bTpE5Mf2aTDZHXb2I+mfpUumyRpfRWdlYjyNzLcySSfOjHlSR1ZWzwRx9KyfCGmedqF1qGoxR2sFjtgeCOTD+evILADgkEfKpx0zmq+uyX1v4k02/sraee2hJW98pckKfu4APzYP6VHJzSdO99Px/rYUVz3RvSSPBfXUckCzWZUYVUAeN8jB3f/r7dOapatBeRHTr+xtYZ7XzPLuY0jAlGeM88EAHuD1BrZnMV67vFI0L8K+xsBgD70qzjTGRXG5J3CmPPf+HFRGo1ay17D1t5mTonhr7JrH2i2vp7iBj58kpf5VY53rtHUt8vGOMfStzWXGmaTfXllZfarmCIyrBDgPLjrg+uB09qfd3LQjfDFMrK2yRI0DFxnHT27n0qneXzQyoFdlLkl5cgCLHOQOvp+tQ5TqyUpa/8D+v6Znyt9Qs9cS4NusNqyfaE8xVkI3uMZOfQ545/rVnVdGTV57aaOUxtHFgZOFdSwOD9D39zTJ7h4Ml7O3kEjhxcW7BxuPGQe30z61YhmcRbSAoAwCG6Um3F80NPxFyy+JGY/hK3/tldbmjYXdsh8mXBAVugIB/iHrWosTJcl28zYWL5fJGcdM+5yarRaz5l/CJ5x5QfblxlUJ4BIznrgfjV8XM16ZYHCxEPtJUBsnocGicqj+Pt+A3z394rRajLcSG2jRflGNy9DnqD79KqXN7NpltbkjNzLuXcT8vBxgnH+FdHa+VaX0litlKkEcQlS5YBkk5wyk9QRx9a55mnZ45FZHj+8ibBuDEkZH1H9KVNqT20/MmnJTb5VZfmXjKF0a4htIBFeiPCxk7Qh9QfT0P8q5nwY+qLJP8A2hby28SfJiaUuZJN2d65JOOo7duvWt9TI0DXUsSxqi4lDjBCrnO4/nmo02uVMbiRXAKMvIIPOfpitItRjKNty4wWqJJrWdLS9nhkW9uU/e28EygITnO3A6nGcZ74qzFdTXWiwyahbCz1CaNg0Ctu2DJwfbjBwehOKy21WK0uXWU7Np/1ixttUf7R7jvntg+lKk0YvW+1XcbyXDZt7VXHmzY67RnJUc8+3FQ4N7/15dvMl09byZzOr+F73Whc28tlnTIAWjun1Ao5lUdSoyWAznBI6fSsawMst9Dc2mqaddXFpbyRFkjyxkwfUZVdxHIAzn3zXcvoomlvpdLtoUupgsl0eQZwAQFbHUnpz1rzg3CqJ9b0qzTS57RpIJ0mjKlkwPnReedwA5zyM16WHm6icf61XXV7+X3G8W23cvyW9tqVpDB4kFpctFtumliAwuM8yZK7SOScZ9MGotU1+X+yUvLDVtPe2vAgsw3yp5/+0MHHByDjAzz0q9uS1XStTnXT7vUrllQ/aFCiRRxyBjc/PC1n6zpNjH42uZ9L0eCTSdROJpZIiIg4BXbGBjb8x5b09Mc6xcXK0ttfTTdCd72QzSdAMzX6WU39n6tLGiG8nQvBcOw+Yxqfu4I65II6YyMdFHJcbY7dPtLmCFInMqhchfl3Ec/w/gO3asKCX7El1pei3Eo1CONRDBcodkBB54b+8WIz3Priuh0hryGxFpcrHPqd0DEUjGA3lqrPt9AWKgc/hwazrN7v+vP0/pDSSMCKG9uNZ1S6vdLgit7udLcytIrb4Nu3EgZvlyQvQDgY5PWvZa7Nq2sWcWh3c9vplu8kcgSP5rkoQFRTjgHGOMEHt0qxpT2+oaHbx6tAyrdyyCBbp9zs+7GwKQpPJ4H4c8Vo6N5ml+NYr1riZbLnFsq5QStnMjDPXoO2MVUmldSWqWnbTTz/AOADWl0cxrega7p91Dea1psMs0zt5ksbGORLVMMAmCQG45z14HcmtZ5NN8S6XHFa3sNhriRK0FwArTRI2SV254yB97qOfcVa8aa3ezaZ4hOr2MKRhPItmM+UuIGOCSF5T+9wc4HtXMWGm2lj4h0su1nYxtZxCK2jVpZS4U8tJ6Dn68nA61UHKdNSno1tbVbX8+mj/EUb7SOp0K4tb7WtWsXu5b6dAsN7vQ7RKBxt4x1HbHOccVY0ZbibSJv7OuUkErfuHP3SQMNjPXgA49RzWHpFtqM1lObjxJDf3FzcgrPYIHSEDgqTgHqeBzjj8dSPSU8VaHHbaXM0dppl4zKUtVUyBIwBGjclckD5gMj69caiUb3emnp+S9CpStG5o6BptzIZ0vFnff8AK2JC0mMHJLHjc3GQBjAArb0vS7bSQVZpWmkABacgMcdPlUYGB6VT8KXd1EsllIcwQqFjk8lkcAcFWLcP9Rj0Par2ufa59IuoNPvWtL102xzqoZkOevSuGrKTm4XsmZtt7GLf6vp9hcSy61Zz6NskMMN7fRKFnGDu2bSWIABOCB270VoWNtBOtqbh/t93Zoyw3N9GkkhB+/tYjByAO3bGetFVzQWjv9/+aYr1Oj/r7jDe4mbylYgYBHHoeadf3Ms8cTpKkLXAPzsm4Ky9FHIGSO5OOaxdejvPOghthGwPzSPI+1eoySe/0FWLW4t4o54rx0+xbhHmVC6ucZO0Hk4rT2aSUkPQ3dJnlN/dQLNDcBFj/fxZCndzgjpke3Bq5a6ZKmoEzo6k5kyecgnrVAX8FpoV4bOMkbBhFURkA9iMcHBBp+m3kupaQJpZGMiKY/vHcuOOfyrCSlZyWi2Fqauo3VvcLFbIdqqScjsR/OuR1l47WF7WyihW4ug23fHv5xggA8YNGmaddx3zGA3MssuC/mBFihYcLsbOcEEkjj0NaAvrT7U8hEbrCjRl/RuRjP6ZrWnBUnaOqGkrWMPRZW0lCUCBDuldShxKAMFVC9M/pV6ayvYrG5UXk7EW0kSIjf64ydm9hyffFVbu+t7bWLK1ltZTHdM7JKqArtHJwew/Crlzd+dFbWsioktwxRdxwOSNoBH8XNdEr3Urb/1/mU7NMzvCfiK2Syg0zT1aXT5UlgaUxtvV0B53H+HtjnOaZpslv4k0+e01GU2EkbgqiqwMgBHR84zg+lZ9td21lf38FxNNCzMHMQTcY4x95lB6nIA4x3NbqR2N3etcaYxd1iT58EDbtOD6Z5yfXNazjGDcopq+t/69bCsQ6m0q6k0VvLJqWolfPsdP2kKjr8oJGQCADnJOOuak0nT4rzxE1tc+eL/Rm3XEiy5X5xllB/u/55rMSfUbSOC7tVh1LWY5n8q5c+WFjzhlz1BHoRyOma7LWNWnF5aPY20YjvIgzTIAwZsAc45Pp+FRNyjaMeqevp+lr/O4a81+heC6vp7wXsrQNYsDG6Bv3fl4wAFxkvnaRyMAHNUte3R6bEo0u41GC5dYpVjfYFU/xluuB7VX8NBrezZ7+R2BnZls5QQDLjPTsCcZzVnTtX1v+07dLq8jl82QQSaabcq8OU3MWG0fKOMMD3xzzXK4uMm1bT1V/wDhu5Lk4/MSS3S2tL6107UbW21CbCxm5cSOr7cIxTvgE9TnJyQabPcy2s0dltnmvn2iO7ZyF/d7QUIHClzvJz1/LBqnhe1XxEbsXUyosonWAD5dxHzHOfYHGKtXmuafZXS/b2BJBwsQLSEdM5+6APr3qrp25fe+X9f5FWVuY19P01LB5plaZnkBkfb8xPHXA9uMDiktvLllikVVIDB1Drl4z7eo9Ki0vUWlEj2zyF+Y2EsZVgB1VlIBBHT8qp2txHBrlvpscEhF0xjVgC3lsEyGP+yB0HWsOWTb5txPTV7D31uJdYWzCNJvk8kSI2Rn+LI9M8Z96v6hpEGowyOZjbTKwnUMAVl4GVbjIyFxkY6856VnWkemG/jMF401zGC7ybdu5gfmYeoz3AA+tbsLLLGHPIxkU5vkacNBPVXTMvwUusW321tYs8rcKHig81T5TMW3AA8hcbePUHgVR8XTRCWxg+1z27CUbkjAHmHHyqWJGDlWwAct6VsSadJc3TtCdhl3ZlMhQRqQAenUgjIzwKq68ltqV5O1nf7ZIjgiIIz8j72GBwfRhgjJx1qoTTq8/wDwy/MmK97QXT4I70wzSvHG8xDMF3KrkfdyDjngcEZ4rqoRLaWiRCCKZACcKdjZ75HTNYD+EoYdPspGkn3WuXWGMnB3f3z1OPbp71o757ZGPmJcxRnbmVtroexY9CP1rCtKNT4XdGdSUaukXcZreopBpU7TkQWqYEhZ/mGewH9PrWZf65p9paWV1Bm5jnOIzGONoHJycdOw6nHHSn63pC6pd2V1qsaXMKkvaxxSAo7ZyM88j9DnBqLderNs1yztre1kKtDbjnLIR85Knoc8AAdPStKcYcq699f6bKikklEpwa2jahNZOIri1luZYjHnLoMD52GeA2eMjpjnnFP0+WKXW5UsNThNjbxLF/Z0cIUxN3kDdxjjA4pmrarY2t/5lxEWm+558aZjj9AzAfKD29c9KqahBHY6Sup6WyTyhfKg8uPDAHoXxnO3Pp1NbqKeytf7r/16GtkblxDbXTFLlWJcHaAzD3IyOoOBkH0rD8TaeunRPrNrBcXFxZkXH2eKXaJGGArMCONgHGPf1Nb2myLLZxy3TBJTGrnbwN+MnPtTYTIS0tzLCEXl2zkDPTPt7fSsoTcJeSHbcoeHrvU5tdh1eNSmny6eN8LuR5k7HdwPQf3j6nHFYU2iatZxatrD3z6xqhcs1ptEZPQgR8cjHpn0rorjUJEF1cW5hvrdVXyxbsWfcTht3bA4P51zt3ZQ6h4jsdU1K6vrdYZxCHtZ1MKqA22TnorA84OcZB6mt6btJy0St2vtrbuSlZ8y3OXu7jTtTc2MkbzJaX0k8sjymJ7EsgIBBwCvHHHUda0vDWiSaXFeCO/a+sT5clrujChUOeC+cHfnB4HIHQ1T8SaXN/a+pG+vrOx05LgSSXDsqi9j5Plk9WbgYwDx+BqfTbqy1e3f+y5pLZGg/wBHniiZfs5cHaGzxu4PHtmu+TvT916devn/AFY1SW5Hpt5JYtYzQ3P9q3y3Js7iORyXtGySUOfmyOQobgZPoK1LrT7jUd0zl0tbW+jmWQyGIPEqnfg9hlRkDg4HvTjBqFoNOvp9YcpbROt9GE/4+3YYV2J5bAHQ5PAxya6q7mtrvwhAL1SY3iKbfus6tnnHUbgc46jNctWrytSit3a/9W/pk66RZxniHUtGuho6aoZhP9rbyI3gcPG20YypGRyVIzwcisO31iC10SWQ3GqXsen6h5KSTDb9smySqFl5Kg8+pz7itxIANQu9Ugdbm9s7cyi2d1OcgBWfqQM4B74P5YN7Y31vpoaS+mtNZ1do8xxJugiKHkKB90gtjPJ7e9dFNQso+n9bduo3fYualG9voy+Za3ptp42mkmWBZY9OkjQuVfuW5xuPLA59qINd09o9P1e8SS2meGCzS/8ALO6c5xsCH7ueevYH1qWSNrzwoZtDuA0krSWcraivkBZFcK28cgswbKk8HOMA5FVZtcjQWGnW95p0Vhp95Fp9x50R6tkMYjg5J2yEnqOOinNCXNpbr/X36LXf1J5lvcsG28P6NP8A2tp93eSRxXEhdLcnyon4+RwcE5A47ADqMCus0rWYLXSN3iN7PTriS6ZYPLkwJA33AFHQkdsZ45rgzJFo99q+k6lNDbWcMe5NMjX9/ED91t+OW5DZJ59hWp4Gi0dLuysQs15d6fCbhrm9G50kdjyg7Hg8gn2PFZV6SlC8m35+X5fn8w32Oy8l4rqSWS5AkVWcFjy3bqfwHTmrsfmORt+83astTY6istzBc7ogVEio3Dc8Accda1mLJIrKdpHIPHHHYV50/PcsiexVdhUtEVJBkT5sgnJHtn1FFT2eoQzXBhHLkEjpyO/HYUVPPKOjJPO9auzb3Ji1CWS2LITFIi7goGMsueCfzqfR7i41PUC0FmLiG1gAgmjQBZWJ5ZkPGcDpW9HcAMsRXfblSG3IHHboD680qPHA++KFYUj+YADAPpwO9bup7tlHX+v63MuVsz5VuYVvZ5QDNMI4mdl2FeeZMDoxOOD07dqt6NeNaaHcROqK6HPmkluCMsB/eOc/MfWqF1cXH9p3v21mgdRm1UHeZfUMBzkg1cjJuJBDJwsiEfKNoU9jx70SV4rm8mUldFuDVreWyQm1tCuAVjK7m+u/gZ74FVrq+0jS7JDrEaRW8jmJXVCSJG6EBe3UnNZ40mJL43MbsFkLPJEAcB8Hn3zx9O2KsafdNqOnSedZhHZyjrchSuBj269xxkU/ZxWqvb7ilG0fMydb0W/t97S3NtKyNvtGWQqiBhgLgce4/rVnTow1taDUXitr+I/aBbCTc9uvO1uPcfhxV25063vZPtlkLZ5RIVugCV3YXjap6HP/ANbFMs7C3t/EL/u7d79bcYulcA7c5xt79ucdRWvtLws3qvKwLca2lWoVJozHJcSIQZGUEuDkkHPUH0qK31C4muLRtOtP9Gdij28qbJWxgcA+3HFXY3+1wXEl9bPCsb4O4BRg/dwOhqnfPpjatbb75HvhGY4Qz/NgAnvxx06jmhNu6lqU2U72wvlh+3WmizR3M7Hz7VwTJsBxkhSCAR64x1q7ef2hpmiRHQrZ5Y1IPkQsW8sZ5Ut1wCeo9KnmedbY2668Le6naOa3yg27OcoGxyW5GTnB71orp891q+miG+mt7u3iZpIFAKz+uew64PrTdS1ue1l6/wBeVyejuGg3dy+p3EVzZsNNmKmW5G18zAfMgPX5T19q6i2W0tVx9pW5nzg7Dkv7fSsYFIiBaAqkcZJby+TgHJA6k1XvtbSz8KSXukeXdJkeUN3DOWAAJ4789RxXHODqNKK3shSiad2kmozylYZHJwAFBOAOCK5278I2ksTwZk3u8km6WIyks3bGQMdOuRx0rM8NeO9T1i909dUihtre9ZrNri2LBllXGMqSflbOeBxxya763jubaK4VrrzEX5wzMCW9Tx69q0k6uGfK9P6sCneNihoFjc2KiWV2lkZt8pZiwPQBQW5wMDBNaUVxZW99uby4r2TIi38depB/Xj6VYuI5AYEUhCpyZRlhjr6VyEsjxa/GNXkj+Ut5caqDGvYHdnLMcghcZBNZxXtm230FpJWNXS9Bj0u9M8jp55QRts5+VcYLN1PTAXoOcda0nu1jlMKBicbsMMCqdzY3wuLh4rgvA8ZCRgbTG2eCSOc4Bqq9hqEyqttqMVuVh2MHTcN/dsnP8s/TrVaVPenIatbua0jLPGUfhSPmG7A+nNVRoUOmQXd1pk7rLGm5hMSy44Yn17Dr2qfTtCWOzEUNzNPJEuxzPkNKD9OhJ6Y6cVItxu02S0hjcHHkymRwdoPGBj24qOZp2g9OpLd/gN2G/stZ0uRg+I3Qq6sdrRkdR+Brk9WuLi2tRpWhQi6aRd8tzMAYk5wAQThiecj0+oo/s+zsFleGAv5rmRz1z/tDt6dKsWsgdv3OzywAQccD2pU6cabvHVeYqeHUE7PQn0Xw9Z21sLSyLWiRbvLjQfJGCdxCgnpmp3urjXbWCzFq0Mm3L3LopMQ74HOGI/KqYM0sjFwPs5G35fUd/wBK6vSIljtPlJ3N175rOtNx96TuzPEP2a5pavp5HJ+IrXw9p7RLcLcwNtCTTRF1DKM48wjgnJ478mnR6hpFuEWxtmliVBk4MZHYAA8mu3PKkEZHoeRXG65YRXmsyOrgRKoAVegbv/SnRqqp7s29PP8Ar8xYWrGq+Wd9PMrzeRNLKsUMqW7OGi74PBI64K57VmSPbyT3Wg3AuY7qdRMJIkBUnGdwY5yc5+99Ksar50FlClttJifC5XdwTzx61FqF3dQ39rDCC/nNtaFgQCgGSwI7j344NdUI9v6t1Oxx7GYbGe3URWnnXCooBjlkxv7bWOcqoHQDg5xWT4l1uWx0jULKbSHC2ccKwXRiEsLSueBs4yqjOfoRXW3V85HlxQpJOVP3QS3H6/0rO1fULnT/AA3ql95KyxpbuYiCxVmJCIuevLEHjp7VvTm3JOUb6rr5inZLscp4xXQoPEN7dXEkV42oSRTadHKhaJykWAsYA4HO0g8DgUt3qQ1HS7Gz1PTdQtLfVMboLNgiRlMFWkYgYRT0yDnB5+Wpri31ODVfDt8FW5hXdBNFDtMcMjKA0qsxJUEnOM5XGOhpmutNfxXNrolzct/Z1z9kvra+iCGQs3/LFjn5QVO48EcHvXVG1oxvt1vtbT5dPnsydEuVnReDZJbqx06e5uo9ShFw0bSeUwXaOACGALYODk0njnXoDdalY217HaXdvbLKJXiMiRIWGcgc5I4HH41l6RNZaJLczWF1cXLwxRWjWryqVibcSWAHO5y24lufw4FPxbKirc6hcaGk9vKRAZUkXmIDh2B4LDJwpx25rnVJSr83TpsPld+Zh/ZJ1Wa+v2uTJZaraAOYIzG2EUOGV8noyZ27Ru8zDZwMctov9p3eoRGzv7yKyviJI5bq3xHaqpO9XQE5ZucEfeyPU43tIk0y3uobS5k86SyHnwRGVhOAfuvtz2OMgk8cjpmuxsvPNpfW1yI3N0sbKFA/dspLFh+Hb1reVV0k1a+3b+trfdYfL1Rw/iBbrU45dMvrGDUJo77z7WOKYxyRQMCASRj5sjv0xnk0lwVGmzz6s1kdPRwLMyQqWVwTgkFc7tijJOckZBI6uTUrrQ9L1VItM1eaE3sai5k2BpUyMPheoH94k9eTmppVvNcsroaTqUEqrc+S0U0Afyjt3dCpyTkkMAc4IyCRVq6SWy7/AHetg0v5kWuNfQ63DqWntZ6hfRadFFJBHGd8in7pkOCSuCuDwRhR7jNsdb0yxlDW99e2zalfm3S8eMSYuEUfKxHLIrOvJGcEdhXY6m/kW+pTyvH9vji8uRFCkwNgY3KCSCcAhTyARXMtqV+raHBq08UaQ6hPaXv2OECNZAAx3Aj5XAIJx2DY6VFOXPG1v637BJWSs7HY2qSx2NlbawlvHqLDZOlphY5HBID/AFIHp/hXRxlbi0Uj72CD9elZV3BAFjucxu6p5TzqcsxT5cFj1INWIbyNNOkAhElwV3RPEc59B/nrXm1PfV0Ul7qC1tZbSTzbhFzFnEobqgGAMfqc0Vztrr15rsN9aaRKlvdjbIt1IOAD1j3AHBHoM9/eitfq93+8kk/68mZuXkZz6vIklw0jJDaQxB97Llmduihc55GTXQaZvvYYnjRgHUEgnGM9uapvp0QZpNvLABzjJfHQHPpng+9Z+tahq8NzZxaRL5EJB8xfLLYI6Fj6Hp/9epaVXSGj8ybtLU6JNGt5r1pJYpVkncHl/lbbgDPYdBxWRbTX91fSJbWc9qbRyGab7kqg9FPp/wDXxWxqd81nZwSPBJI8h3Og5aQ9FRewx97kUtrt+zXb+ZcLGikCN8ffwABx+lZQnJRvLXsCIoA1xKSo+TcQGXGAeuPrUWsXFpb2rQ3JlTeNwCLu+oPoP1qreRzR3UzQ28pVxvt5o5c+XgcIV4GM8ljz6U7WxBqWpNANy3EUYV3BypOPTj161rGN5K+xbd3Y0dDkiit5JUlabKc7l69fX0FLfafbLdDW0Qm+mi8t5QcfLngFeh4zz1qtZNDpdu0bFpPMULz1Zs+/Faen3lnq1vJb29nLHcchASpYuO5IJFZSvGTktv0JejucZpf/ABNbS5s7+382GVzvUswbenKbTnr6/U1e0JJNRvXXULDTIVguPkSJmcunTknoT/Wrd9Amqrdw6NcLPKhJeSL7yy8b8dM49veoNKtb17JEu3uGjO3y5IWw0EisTuIPVSCOCPWuxzUotrTy10/r9CrdTatI7oz6kurQWZtTNmyEEYxEpyCMEccBencGremhrO6STbE10pIRixyEIwcY4znGM1larq0sd9NBHCpSFFbMkm3G7nOPT73PTIrXs3JTCggSRI7kr8yqScZ71yTT5bvqKy5bFwz43yIN8kaqm+TG5eemOh71Wc2b2RtLuzt5rBgwa3KAK+Tnp0qjea9pVvfiwuHuknmwoZBlBkdGz/hVpot/ysBlTjPPY1Cg42bTQ4pPRmTBp2laVceZp+nLCXJWMQruKjOdqgnjufp7cVZF6q3JkexuYbWdQiXMpUqzL2wDx/jVfxHBKbWGbyphIj+bF5WNyle4+hxx6VS1HXL3XruOWSyvI0ijWNfMXBLnAO0DuW7/AErrjF1LSevd3N4wWltjr5rWOS3hMk9zH5S72KN98dwaintrY3S3PlymY4l8svlcgYVip4Bx6e3pVfR9YttYmlgWP7M9sSk7ORyykrs6+ozz2xWNDpN/PqMksyrFBLIrtILnfkA/OuBnuM547jHSsIQaupO1jBb6nZHUTFbmQBnc4IXpz1GT6VnaLqhubh4ZY4fM8xgZIjnLE52keo55o1C5toY2jvnmiiuA8a+R94ZGMjsMZqPRtFbT9MubawnCXl1EUjlPOxuxOeg44H86hQgoNvd/1+ANRjF6HRXHlw7jIkR3NhM9cDrWJEzT3zNbwwxxRlhIij+EDO7PucAD3rJu7O9ktbeOab7dIqqrmVmUT465xzjp0q5oIg8q5ltpIxYriNEWTcI3QYcZycc4468HPWqVNQi3e4lDkW+o9JjeXIIYrGoGOSG2kZzjuDjGKmbdFeMlscZIVmVSF+vuae+Ut3a1xvf51bOQxHQn8a53RL27XUbiy1aZWvJVM0YDhW2jqwX6j15weK0jHmTa2RqtDbtvtEss0EciI6f6zc2Mc8cVvaZq/wBnjMPkNNGhIDRuAcjsQf8AGsSYC81MXIuYEZYfLuI2Ql3PY5B6Y780htFmktfIlMbq+cK/yy8cA+vOD+FZThGatIipGNWNpo3rnV5rqEmKNolYcBiN2K52+uZLe7Co4ZFQNKoUsVGfvE54HT8jWs6nyVBU5AwQeoNZWuSKkdorIMyyCLzi+NmSMLjPzA9x1xmlRjFOyRnTjGCtFEsl5Ah2yyMZdu7ZGpYsBxkAZOM96kuIRdWLIZCg4O7gjGQeh/Wso3Er6lM8jbYgQsSxfvI2CgDGRjaQd3GcnJznFaEs5U7iNoweMdz2rRw5bWN0mzF1PDXMwglhisbZo0dTcN9pkeM7shAAApU464OcdcUeJ9ZFho11tupYQsvkGV1EbNIxDDH8IHOc9OPWk8TarDb/AGU5nF6gJiitkQyFQeXJYEbAOvT2IrlNI1x9X8RanbvufT5yEgE7AJvUK42qer5Vu4Aya66VJzSm1otf6/r8iEuX1LGmXFv4h0S7t7W9e6BZYbnahjME4X5XjU9NxJ579CKy9ItJdesptI1sTx/2eYYpRBKjzSkE7kkBORnjn/ZB7im6XbQ3kN5DqZvrLUZ75ryGFYvLLlW+8do2gE5yeSTjHFXSk2kxarc2WnRXsF1KUitrRx95iAXZgMqwy4Iz1YYAxXW1ytqO+lvX8F/ww7N7hpcBtPEN/bTWUQt5sLv8zfuVBklecfeIBB5JOa7h/Dc2lSRs7ym1mf5o4pVDAnLAHjgjpjPIJ71j6J4ejgFxDFG8VpHCXKMM+YWYMwDdcgqAT3x0ruNQlt4dMlt2iaQ4Aj6nnHDc88etefiq7cko69/8yJtppI8wtDfW/iC4jXT9KNhGoVL4xKxuSX3FA3VVyTkDuDnOansb2/0u7llvE1HUoLrUvLhWOFVFnHzt6ZJXtngfKe9ZWpz2vh3VRe3886W14RDHbMu2OFhjc456DGABkncfSrUl/aQ39lr9ndCDUr+1Gm2cZkLKVLYA+UHPJ6tgdeM11ShzJaXuvx/rdo0lptudJomos2h3dzfWENgx3ZMjgJCgJ+bJ6DoT9KyYsX1vqI06PS4NHvIw9tdWtxtmkZvvs6/wDj2yOh5yMu1tIpbu7ttT1f8At3VLJPK1SGxDKm8AkIjEBcjy8HHGVJIyKsaS91cT28q6T/Z3h423lKl0AxSQHA3MFA27cEDH4cis/ZpXlH/gfi7vy6W9SVLms0UdNtoNH1OwisL7TreDY17fLdyZeQZO0p1G32BBOcnNRWE2svaa1A0VuJ57o3aT4VYLoOSrSccsTzye1SmKyn1m5GpbtSk1KFltdPghJd4o1IkRpAAsYyAN3LAA57Cqdw0X9lWOmJYPoEk6bzDFL57LCDgZLHcSc/w/gBXR8T11emv4+r7bW6Arc1uxs2luklzqKiSK0vBc22I7icyW87Roc7YxhlUsScDkkA11MEVnpmn7ZbpdqgOMsMt+A9zjA6VxN5fSRQ2caarpsAgRRYQXjnLAMVJkk2dSMqBk5x25rQku7jWDc2dtBplpcWUyW+p3UkGBGoOSEByCzEED+g5rmq05Stfb/hl/W+ugXsZutTWt74ksLee0MJjvgLJLVygnZlz5047qOvGOM+hyVuadc2dp4GMLvdarenzJ5785j3MGLeUAck4AA2jI/lRVpSmuWKemnr59Aim9WjT05o9TxJazRum7ON2MqPf6/lVO+uJLtbhZIkstwMMcq4eRSO/PFEYSzjh8hGR3AIBJ5XnkUzFvtWN4/kLHAVjnPqTXDFJO626Epdy/pYsbfw/Z21xLLdNCgQtJkyuc43Ng8dfyqxa3tjqcd9p9rBdW5tBujfaFjmYccAds/j3o1q6XTbJVtIolVchSYy2PU/yx9aoWGqSTXUawlV3E42JjOOp9ue3tWai5xc167kpIin1W+8PQXM726zKq7/JcZzj0/r9KwvDPjOfxBrT20yQK7ruCr0Az0HQ9+tdT4qkumu7Z9OigmkZAJI5QGGO456A98c81QuvC8Wja3p13CkawKhQKAN3zckZ9BXRTlScPeXvNafI2VtH3NGdbe1tZTcSFpJGUkADCDr1PQ+tZ8t0mmzQQwW589pAwkVyFHtxwO9b+uWTX2nxLYKhwm0Kx2hgcZBODjOPSubu7RrZ2e1RLu9jKoYHn8tQgOSRk8kZOO5x6VNGSmtSIu+5pafZWmnOk2m2pQSzky7SRlz1bP07VpWqNb22Qz5X5iCOTzwfpVB9HH2O41Wy4vDGEcqxZlQHllUnGR6YFZvh7U3uru3hRp/LuEGy4mXYXkU4fA9MgH25pOPtE5J3tuNNbG2Xt7y/iguUjaVXVUHlb2jZuhJIwOh4qtf6pFoVxcvrFzBDC2IztO5gQSASAeFPPNaN9JBogOp6jIojVxEJPvYd2wOnP3ifpkmsLwXo+m3d/q0WrXOm3Udsj288UfBkZ2JkkkbqzHgZ7Y4ojy8rnK/Kv60/Azc2riXNtdXt5Hc28MF3GqbraSIqNj7sgkk4I+vI7V0/lSSW6SMUaYrmUIflLdyPbNY/h+2vre/ltnZ10qHMVvFuGwRg/LjvwOp681vXCyW/+kphSnQgcYHb3FTWm7qOmhoik0sojWNlWRA2dr9M/0/nVKe6t31dYb5rdLTyyqwkEs0md27PbGKvSXto0oAeNrgFTLCsgLR7j8pIHTIzjPpWaunG71csFZTCX2kKTtyCDk8A/TkdMiqhbVy0Lewzxt4uuPBd5Y2en+H4Lu3urZpjcuw+W4JOA/fBAyT1OfauqtLiDVPDem69bReUs8Uck0KL8rA9SB6jkg9xXB/Fnwh4h1m903U/DEDXsH2b7JNah1UxMDkScnnI4OORj3rsPk0PwdoPh++uoLS/EEMLx7/7o6A+5GPzqZxpunTlTfvN66/fdHLeLUeR+9fUzdXvHk8QSIdOkUIFW1kWQMjryfNbjG0g8YPt1rRtUEVvuuFmWVU3CLOVHoMd6ZcX/ANntY4REPLtwP3gAA69ABwBkVsW139qsJJ3VkdTuGTnvzSnJqKstDd3hFKxzkPizzNT/ALOktIgpyRuyHYZ6jtj26jnNQaD4cttE0uez02aR4ZZTcDzm3kE44568DGTS395pOlXUE16yRSXcq28bbCx3HHPt0GT+daV20lmxcBJI9pABbb83pnHStW+VWgrJ/jYpRinpuYdrczW15cm4jSKC3BH7gNtLk5woJ5/l1qDUfEGnw3ljctZs005EP20QEMsf90nsOSSPrVqyul12CSC4SVUAJbaAhjPQpgEkY56/rWjbQQQedZlpo3dWmYNHnfyMtnGB9B+VatxT95albowPDfidtTsHljt5zI8rRwRXBCeZsHUN0wffuMVu3t81raJLcWxhkd9pRmxtOOSSPfJz6Cm6mLWKdZUnFtAjBYXtbUSeZK244OFOwZAJOBjPWrmoX9u+jxJcWsVzeTho57UgsrAjjJ/kRzUScZSTjHR/16f1qTzNuyRb0NprmGNkjKwTRLKN3VCex/I1Yv7N/JYXEX7sYO4dves/w5qi6ZbR2VztRMjBA6LwAD6ema6DX9WgXS7gROJHkBT6Dua5ajnGrZLQxn7WNVR5dGcvOpSOTyd+GYsGxwT/AC61j2Qu5NUMs14Psq/O0TJ8wAzwewPTOfXjpWhpqXf9pebLOv2c5+UAYwR0x6ZrltS8Z3qLeQaJDLa6utw0FktwmVuMEBivoQD0967oQlK8YpP/AIJ0ydlY121yzs9Jv7+9v7aFL64FlpVvAu6V2wPnLc8EnpjA4zyQKLfwzEyQxPJbyTRRt5SOoUjcRnJH8WAfxrA0nTLuDULa/t7GNbtbcRNYExmK3lxncjZBGcc85G45z26aM6lFqE0rYks5RtKMgVVAXggnknPf3x71c4+z+CX5elv63JjfU5nSbmWa6gu7ZruXRpN9rNHdnyWgdcHJDYyMEdPmyeeKy2jsYY7a2nubrTjdXOEhuATt8rgEvgFeWAGec+o5rpPEVtJq/g/VYdTgN1ZwssqQgHcJCwUEEEE9857Z4rPv9Si1XR7cK7/aLi0DIY42JiCMq7gW4+6CCMk4xmuiEr6pdbfqv6t0E73szqpTNZ6EUjmFxP5YHykjJz6HkDB/So4NSv77TdPu4DESV8vc7BiMMRwRwen6Vz2iyajd2cdhqGqW1zeQyq0tsqDzVhIwfM453ZHHUAitrTIrfSLqx0mxt/JsEhdyskjN87NnGTyByAPoa5JwUbp6u9/lYrfWxY1q1SdN0sUbs6EOZOijJ6A9PqOa5PUJtVsLrd4ctTEukzRo0LWSSfahJl98MhySBjBPBXcCfSuvvJIX1B1lxujhD7t+AQcjGOnT+dQ3zx6Np8s94yWEUUY3FwQUB747Z4x+HHOaKc+VJNX8v68glFSVmYGgaNPp+t3BubdYdKkP2qJYSBIsvUlj1d8g59Qc8dKrNp8GrxR6rbajd6Y73RdnldV809SG3epIHfH3farWs6jaafYWWrxXkV0HT9xNmTJU8uRxnOB1AwMHnNOtNHs4bKG01bT4bmXzluLSXfuIV8EhyCOr57cHue2/M/jl6fdvo/kTpeyNXRNDi0/QW06OJBC7yNIGYsPmYs/fp0zjjjpXMXFpPqGkwr4QvbX7IoZBdgB3jVWBOxuo4LDAwenarvia7hudMh1nzkuraC4bZbNP5Ns88bHO/IzkfN1wOPTrBctcW3iHRxpN2lnp0UP2lba1/dpMxXkFRjqSPz/CppqfxX1d3rtoD7LYZPDJYX2nW1vY2s2npIlxKJI1LGXohQE/LgjPHAye1NgjudK0yTSpdSgv9ZcS3cMcRA3AnJA/vkHnP1xwDS6poMUzahqcRkuTqifZbtRKwWJRgHYP7wxgZBHUc5qO8Fva3lm1mLKyj0tEiNyxM1x5J4aNlHKEnjdg8HjrirTUkv61/wCH003QWd72Kum6rN/ZkcaanbKtnF5Zd8yFZSyhmGOoO5cYHvRWheWy21/KBFFF/alv5lpe/Zw1vKv39qjAIbnnIB47Z5KtSpvVrf8Art3BJtaG3fW8sExRgPJD/u0ByAMc4NRMGFuzkHAJOOuKpW1zLPpdtCY3zGWDPz3xx+FSXFxdlVgijxHtycD65z/nvXnKL2ZKfuo1H1WyvtsDSP5id+CM479cfjUkV1aPZW72s8M1uCWjkiO7OT8xzXGCKazcnUZZGtmdSRlczMMlflHoD6961pLD7PaQWWnWpaBW3hI0yD1bb7Z9+lN0IqyT/wAhJGv4ru7GEC4E4a2WNNu0fMzH0HrWSPEtrsW5uZJ5SSIV8+QR7cnsSCB+PpVXT9Jur2C4h1eG4SADMchOCXLZ57AYA+tR6zpbWdjHHDI6Ij+Y8iKN2/qPwx6c1rTp01am3dju+U6e1vxJE32dmBLMjIOec8j0qjpem3lt9pnmZcNlw0uOm7p7fU/oKj8KxvBFGjRhzuwvlEsH+nrVvUre1m1uG31bWPsdyoKi1ikAkGc/dx6g8is7qEnBf5jbtE3LS+httMeWVzNJcbk8pccA55z06d6xNDjg0fUFuJQ0zlG8pMkgZ5J5PU1raTqai8Gmw2yR2kKnBIzuAHena/pcd5IsdqJInkOYPKAG71Hov9KwjJRbhLRSJVtUzD8SXEk2gXMOsyiK3uWUxMmN+9WDIUxwF4Oc89a2bbTrJpzOhSxlmYPtK7CSefmb15qPXPCWqX9jYQmKzlMBzgzlSh6bumG47Uur6VK3iGGW5IW4cdVYkOABwg6c7QT+taKpCUVGMrb7fLp8hRa+yy5rlzJBam8jiXbv2MR8yqp6E+xI+lXbedbnRbcAFpZARyw7cE/Tqc1zsGo3dumqqsEwnjjHko7qYmQ5ycZ+vX9MVPbynUND1S1ug+NqrHMFCucgEqcY6HjoM81DpNJLs9/69Rta2JdWt47Pw5/aWnpaXFwkqPcyQMH89chR8wHzY6VNqglj02WbSCGa6cSNuYNtJAGMHG3p34pmk2kVharoU1xCNUuJheSRIAqtnnZg5wMDgZznmrjIFLtswBlAuMHOfun/ADzRzWdt9fvXT/gFQd1qZUd4t1bm4e5voJYD5MpguGiWR+OD03ADuOeRzVm0lS9u44VOJivDN8zAddwY59Ouc0/VbWSRFjVy1yspPOCTwAeDwMds1U0uE2V/HcSIEwixRxnAKjGCe5546+9ae643RcV1RvNJbQKsUduHSPgAdCR1yOuevNUZL3z7sWk0kVrC0Bk6/KcZzgeoHPeie6j+028Tyot5IfljkG1n7Z+lS6skQgjBixvV083AJTC8jn15HHasopJpPqK1vU4nxNf2Wpw6Totnqk0FtKsbwXdv++Ak3/IUY4zzwfTkdq7W61Owu9SXSBLuvjHuJkGwbgOuR0Jxxj1rzSSa98P6TewLa28tm1ystiLRixSJ/vA4OQDjg8c55wa6XwvbLdmC4vxBbavEJFiiBbZNHnKhWPGR2B5yMV31qMVBSvor223fX/PsJLXU9G061tLSMLbId+0FsjknHX/PSs+98S28czKkUlxLGwjZoCpVG64J6+9SXk6/2VOqjD7BsKvjtgnPXByDn3rj9I05rmVJJrdLRoj8xTkkAbeCOMkZyRnr37edSpRnedR7GMafM25HTXN2mpJ80ZHmpzJC37wg+hxx/OpLXTrLT1jSzhCRDgK7kk/Unkmuc1DVNai1NLbR1Coeu1AcYHB55I7cdPWtnxDfz6JYRGSxW7vHieR4gvyooXlyx6DJA/GtHTlHlhHr0uaSXLZI5SCzfStf1XWPEV0JPNDxRJGMKELDGR3I6D6109sbV4RMnlNEy7g4wRj2Nc5r1gdU1Dyi0MV5ZkebAJATjOQykEjHYnGeo4rT0+1W20+O2kZ5RjLs46gknJx6k101LSipX1/Q6efn1CzWSTWpL6G8uorKKMxJbqyiOQn+IDqCCc5qhrD6tewPPZaTBJcwSmNVnZQUwpUvEffjPPrjIrZTTI7SKNkDDymLMW58zII5x2qTXLbXp9A0g+GpWieN2e7jikEUsmQNu0nggE85PHv0rNVIqStbtrp99u5hUlyK/c5vwo2p6PdJb629rdF3DRypGcY9GA4B4x36e9b88ivKfPuAiyH5GY4wc/yqxrUMdvcRmTyJL0Rq7PGCEEuPm2+gLVzmpXzR6TYXGu28drIwkaWQxlo4gDgAKuWJboAOn04qk/bSU0t/60RcZLlUi9q1vqKLDHBNEgWbdJDkb58DKxjPBz/XPauc0a7vIEuZ9dUNDFKWUSyb0towpLRxlTkj1XntW74jtH1C10mSCK5uZYoGmksIHxJIoG7GCQSBgD9K5yDS7y5tbGXSdPmtxa3Bja11QCN8bfvEEnfx368AEc1tR5XC0rf5b9fMXMm9RfDiy6re3s8iWMCzwukUsZ8t2jwTh2JO3GDz361oeH3sLbQNLt0k+1qcwrIJvPCMWLKu/ggc5B6dqqQS2v8AaF/b3CfYZdwhid/kFxJHn5Ap4IwOQOMEfSqgstRFtNYw2lv4fs3TzfPwGk3B13bCrcM6nABA2r6ZrSS59HotP6/4b/gBLSzRsXms3Wi28F3FZ/bbpZUjgiIDFeTlio644/H8Kx9WhMsdrp97qMy3WsXckQuniaRT83BkH8KcgfT0GTVzULh2fStVWxtgYZJGE07MhhRQDxjg5xk579AaoT3aa3YIlhqklvZTzZidPknmmUYeJgTgjHAAPvz0ohG1na3d/wBX238/xE97IzGuLewsNTsoL1rK6GpGGRr6HzljmbKlURRgIQpwewA9c1oq+oWPnwyJYXt2GUJDBIQViG752A6dsDkA55waRre11q7GsW95cQK8itct5fTZgKduQT0wD26dhS32qC58SQw6NNaxfaLeRrqaZFBMAzgn0wVb5eoIBzitHrpbXr5W/wCGYloWdRuWstOXTYdIW9hhAWKFYgIRlc4HXjIx0OM89zVW51a4k1DT7qOzN1p1nJ9nnS2UCRwqttfDEDavyksODj2psOpXH2jToYbm0vLMqWutRMgZUTnO3uW49PXGK2QdLn0uZY7YG0kQ/apLlDG6pgMY9oY7Rt5PfkjArN2huv6/r5lu8tEVdY1ua204IkcN097IptVijDxjGSMlemWwB79cVkW8V/Hq1pqWpeG49Pluo3bUd0rBYgi5UCM9N3GRzk96sPaQ6taSbdS8rQWkAtXtfllDqfmT5l3KRhsknsCKyEn1iO9stImkmlYPI9zPKfMjKA8IzHJZiMgdB8w61VOCSajv13/r18zOWrT6Ho3iTVvtfge2k01bJIiRHJkb47ZF4Yk44wAB65OKK4aKaeTR4tPnkt71oXPnafGDGFy3BGFBJHXPOOnNFFCkqSa83/WoknFaHWaiXK7IxsaQ7UOOWHSs+9knsLSBF8uBpZFhD3MnyKTn5ifp2z1p2pf8f+o/9c/6msq8/wCROh/6+B/7LXDTjey8yObQ0dMFpfz6npWsz/JEokS6Me3ymDfeH0Pf6VteHtT0651+8ewuftENuhG5OQ7cdcdD/SuHH/IO8Q/9g/8AqKX4A/8AIH1f/rsv/oNVXo2pSnfsretrj6HTJq2pXd7IlxIkMEpxJCU4VR0BPt65rZlRIoDLuE8YTcdi7iMD079OlZ57/T+hqSy/1UH/AF2P8qymlulY0UbRMw6i93pYuVtZ4BOzELJ8sgXOQeuQT6UuhaVbabp8badD/pAL5muPncFueCeef/rVef70v4/zrTh/5Bd1/wBdf61pKdo2WzYONrCW97FFOizYW4eL7irln/rjg/lTbrU9Ri0c31oWS1e5EckwOHCnnjPAyTjPt2qrqPXR/wDrk/8AOm/8wi4/6+D/ACFZqEXZtb/5gkr3sZUvjbVvDeuaaxaW+0e8lMU0DkyyRknhkPXPt3rsfF9+mpzXml6bciO8to2ikYkrsZgG2q2DzjIyOhNcho//ACMWlf8AXYfzrBtv+Pmb/sO/0NbvDQc1OKs0vv1YVIRVS67HoWgadqa6UkM8MYY3BYSABDGu0YUqDgZbPA/xqtBrD6bqM+iPbyXl0GWX7cyARKOCVK5yciu1X/kHzf739K4y/wD+P+6+i/yrko1FWcuZf8P/AF0Jp+9oWdD0pG16O6kuVkYO0ksjKVaRgxbJyTg8jpjhcdOKfpeo3FxrHiC/kAi0z7WBbTyYIGEVXcD0JHH1qhL/AMe1z/1yb+QqhD/qbX/rn/7MK39nzttvy/U1hRUnc2tUtZLnS7r7JfRTxzAxPcQt+8hDfxHI4Nc6fC050i1s21Kd5IW3GRiCSApxye+ec/8A1q2tN+/qX/Xs381qrrP+ouP9xf8A0IVdKU4PlT69huFnYzJ4ZdK8H3Maa1GskcCGK8h/eXTTFyZMDqi8hQAc+9WtPktPEiXcSRJFqEMUcV1csCpdCmegOU4wTjHPaqY6X3/X0a0vDf3tb/6+o/8A0WK3muWDl1/4YhLqYia5MtjJPb6cltrVtKtpI7xlYmIG4AqegIC8/wCTJqGkyapoMGrT6LeyT2zPPHZxSMFaU43LlScqeDgckDj0rcf/AI+PEn+//RKqw/8AIwav/wBd7T/0E0e0S96Ct16+Wn4haysOht9Sfw/p8mkFdOlAQS2N1uZUAH8LEnoeGUY+tRWF49pr9xPbpeXdzcbU8qVSLaPnBHQkcjjoRiui1H/WD/rn/hWXrX/IGt/+u0n/AKC1YxqKS1W//D79S+WyDU/Gdx4at4RqlkIrqWN7lBGuUcI+DGCxyHAYcHg+orV1UWmo6PDqmqtEba4VfK81iN+7DKpXncMjJU56V534h/5JT4G/65N/MV0vjr/kX9B/z3FaLDxvBx0bcl9xhF82pa8OaNqGl6xJJfyJMsuZdwQRj5lADAAY2hQFAB456ZroLqB7jVYbuxu1TTljdZItodZGONpLDkY61Jqn/Iqx/wDXjF/SovCX/IFm/wB9/wClcs6jmnVe60Gpe7zE885trW4uJrdrlYYWkCF8biBkDAGcH1xXE+HdT17TrMXD2c14lxOss6XU5RbWN+ixl+Tt6e+O3Wu6l/4+R/uj/wBBrl/iN9zQf+uU39KrDuMmoNfEVva/U5rxF4jtvEsWoWMM95ZyFg9rqEa5t3KMPlG05HXHPrzWtpOtLqhtof7U1ZWmhVopPKRoZMHB8s8lTwfxU9a4fwX/AMgyw/7CM39K3rX/AJEKf/rjN/M16VahCnHkXR+X+XkVTfNZs7S1FpZN5sM2J5ZQpnlky7MeANx/GkvZkuGkhur66jRGZfNgAaRMn0Ix6Gsjxz18Nf8AX5B/6AKpaj/x6x/9fg/9DWuOFLnSm3uUndGt4yjgsYY9YN1Lc6ZpypHHeXKbpbd3cDk4B2kkc84ps8s8Oo3IgtpHnTyZftLAlJDJksqckfLnkeuK6W+/5ErVf+vNv/Za5rwh/wAgTTv9+T/0YazpzvTbfR2/X/P7zOnq3HojFvBp+h69Hc3GoSW/mJseOYb4enyjHbJ68Z5NUIZ4da1KFtPFtFqOlwG4+xxoEikQnPmLtGGA3AnuQTjuazvEf/IY1/8A695P6V1Ft97Tv+vCx/8ARb13NcsFJ6u39fmEn71jmTYtezaqNcs52vntEkuFhk2MWBDfJ2O5SpxyFB7Va0C8u9ZmXyLRYdLSx8sqyiRy/wAvO7GcEc4zgg9qj0r/AJDmr/8AXnD/AOiI66H4bf8AIq33+/N/6KFOtPkg3ba34glaxW0DVdGhmltdGitZLm1BeOOTeq2+S2GYD72W5xnjPvUDX92vh+aJJ9P/ALUG/wC0SypiEY5YBV79Rg8etQ2H/ITX/t1/9Fmpbv8A5CPiD/r7P8qhwXN32evy/wAzWGwyOWW08NXuo2WnvcWtoiqbSBWAZieegyBjLZq9aFjpQlti4D4kMczjdGCOgIXsMZPHatzw3/yLGpfQf+gis7T/APj0m+qfzrndXmlJW2Yu9yGy0wxQHUpLMqDIvnzRRhTcE9AOvU9cde1FejXH+vtf+uLf+i6K54V3Wu2jlc+dn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The multilobulated appearance of a thymoma is lacking. This tumor is composed of highly atypical cells with pleomorphic nuclei and a high mitotic rate. Although immature lymphocytes of T cell type are missing, a lymphoplasmacytic reaction can be prominent. (Hematoxylin and eosin, magnification 50x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34837=[""].join("\n");
var outline_f34_1_34837=null;
var title_f34_1_34838="MRCP and ERC versus EUS";
var content_f34_1_34838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Comparison of MRCP/ERCP and EUS for the detection of common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bile duct stone missed by magnetic resonance cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP), but shown by endoscopic ultrasound (EUS). This demonstrates the superior sensitivity of EUS for small bile duct stones. A) MRCP showing dilated bile duct with no apparent stone, incidental pancreas divisum. B) EUS in same patient showing very small bile duct stone (&lt;5 mm) (arrow). C) ERCP in same patient showing dilated common bile duct without apparent stone. D) Endoscopic view of extracted stone after biliary sphincterotomy (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of ML Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34838=[""].join("\n");
var outline_f34_1_34838=null;
var title_f34_1_34839="Investigational biomarkers and the evaluation of acute tubular necrosis";
var content_f34_1_34839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational biomarkers and the evaluation of acute tubular necrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Uta Erdbruegger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Mark D Okusa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34839/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/1/34839/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H732288866\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI), previously called acute renal failure, is a common clinical problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Although measurement of the serum creatinine concentration is widely used for the detection of AKI, it does not permit early diagnosis of acute tubular necrosis (ATN) since tubular injury precedes a significant rise in serum creatinine. Investigational biomarkers have been evaluated in patients with possible ATN in an attempt to detect tubular injury at an earlier stage. None have been approved for clinical use in the United States.",
"   </p>",
"   <p>",
"    We discuss here biomarkers that are being studied for the diagnosis of ATN. The pathophysiology, etiology, clinical presentation, and evaluation and diagnosis of prerenal disease and ATN are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to patients with acute or chronic kidney disease, the possible prevention and management of ATN, and renal and patient outcomes after ATN are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961934\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of kidney function in acute kidney injury (AKI) is most easily detected by measurement of the serum creatinine, which is used to estimate the glomerular filtration rate (GFR). Although the serum creatinine is widely used in diagnosing the presence of AKI, it is a suboptimal biomarker. It is a lagging marker of change in kidney function, therefore it has poor sensitivity for the early diagnosis of AKI and, as a marker of glomerular filtration, it is unable to differentiate among the various causes of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, the rise in serum creatinine is slow following the onset of AKI. By the time a change is observed in the serum creatinine, a critical therapeutic window may have been missed, particularly among those with ATN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, different urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of ATN. There are promising candidate biomarkers with the ability to detect an early and graded increase in tubular epithelial cell injury and to distinguish prerenal disease from ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Biomarkers are used in clinical investigation to facilitate early randomization to different treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/11\">",
"     11",
"    </a>",
"    ]. These vanguard studies using biomarkers may lead to the identification of new therapies and the practical use of biomarkers in routine patient care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/8,9,12-14\">",
"     8,9,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many candidate biomarkers have been identified, the following steps are necessary before they are used clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Validation in different settings of AKI (cardiac surgery, sepsis, contrast induced nephropathy, emergency and pediatric medicine) and in different clinical centers.",
"     </li>",
"     <li>",
"      Development and testing of rapid assays.",
"     </li>",
"     <li>",
"      Development of a panel of biomarkers. It is unlikely that a single biomarker will suffice; rather, a panel of biomarkers will be necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition the optimal method of reporting biomarker excretion has not been determined and hinders comparisons between reported trials. Urinary biomarker excretion may be reported as an absolute concentration or normalized to creatinine excretion. One study that compared these methods showed that the biomarker normalized to creatinine best predicted death, dialysis or the development of AKI although the absolute concentration best diagnosed AKI on admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732289043\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC BIOMARKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961941\">",
"    <span class=\"h2\">",
"     Urinary tubular enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tubular enzymes consist of proximal renal tubular epithelial antigen (HRTE-1), alpha-Glutathione S-transferase (alpha-GST), pi-Glutathione S-transferase (pi-GST), gamma-Glutamyltranspeptidase (gamma-GT), Alanine aminopeptidase (AAP), Lactate dehydrogenase (LDH), N-acetyl-beta-glucosaminidase (NAG), and Alkaline phosphatase (ALP). Most of these are released from proximal tubular epithelial cells within 12 hours and 4 days earlier than a detectable rise in serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. No validated cut-off points currently exist to help distinguish prerenal disease from ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961948\">",
"    <span class=\"h2\">",
"     Urinary low-molecular-weight proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha1-Microglobulin (alpha1-M), beta2-Microglobulin (beta2-M), retinol binding protein (RBP), adenosine deaminase binding protein (ABP), and urinary cystatin C are urinary low molecular weight proteins. They are produced at different sites, filtered at the glomerulus, and reabsorbed at the proximal tubule with no secretion. Although promising prognostically and to help distinguish prerenal disease from ATN, increased levels may be observed after reversible and mild dysfunction and may not necessarily be associated with persistent or irreversible damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/9,16,17\">",
"     9,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961955\">",
"    <span class=\"h2\">",
"     Neutrophil gelatinase-associated lipocalin (NGAL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil gelatinase-associated lipocalin (NGAL) is markedly upregulated and abundantly expressed in the kidney after renal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/18\">",
"     18",
"    </a>",
"    ]. In this setting, NGAL may function to dampen toxicity by reducing apoptosis and increasing the normal proliferation of kidney tubule cells. In addition, by enhancing the delivery of iron, NGAL upregulates heme oxygenase-1, thereby helping protect kidney tubule cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NGAL shows promise as a biomarker to help diagnose early ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/23-33\">",
"     23-33",
"    </a>",
"    ]. Furthermore NGAL can differentiate prerenal disease from ATN. Using an Ngal reporter mouse, the Ngal-Luc2-mC reporter responds to endogenous signals that illuminate sites of injury (NGAL expression) in vivo and in real time. They found that following ischemia reperfusion as evidenced by a rise in creatinine, the kidneys illuminate indicating NGAL production at the site of injury. Interestingly, following maneuvers that lead to significant prerenal disease associated with hypernatremia, there was no NGAL illumination indicating that prerenal disease does not induce NGAL expression. Thus NGAL may potentially be useful in differentiating prerenal disease from ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NGAL has been tested in multiple studies that have included a total of more than 4000 patients at risk for AKI due to sepsis, cardiac surgery, exposure to contrast media, or after renal transplantation. In these studies, the average sensitivity and specificity of NGAL measured one to three days prior to AKI diagnosis was 76 and 77 percent respectively for cardiac surgery patients, and 73 and 80 percent respectively for patients admitted to the intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/33\">",
"     33",
"    </a>",
"    ]. Examples of specific studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary NGAL levels were determined in 196 children following cardiopulmonary bypass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/26\">",
"       26",
"      </a>",
"      ]. Ninety-nine patients sustained AKI defined as a greater than 50 percent increase in serum creatinine. Urinary NGAL levels obtained at two hours following procedure correlated with severity and duration of AKI, length of stay, requirement for dialysis, and death.",
"     </li>",
"     <li>",
"      Urinary NGAL levels were determined in 635 consecutive patients assessed in the emergency department [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/27\">",
"       27",
"      </a>",
"      ]. Thirty patients had AKI defined as the new onset of a 50 percent increase in the serum creatinine level (compared with historic baseline) or a 25 percent decrease in estimated GFR. The mean urinary NGAL level was significantly elevated in patients with AKI compared to those with normal kidney function, chronic kidney disease or prerenal azotemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961962\">",
"    <span class=\"h2\">",
"     Urinary kidney injury molecule-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney injury molecule-1 (KIM-1) is a type 1 transmembrane glycoprotein that shows marked upregulation in the proximal tubule with AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/35\">",
"     35",
"    </a>",
"    ]; the ectodomain is shed and can be measured in urine by immunoassay. Kim-1 has been tested in a number of cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/29,31,36-38\">",
"     29,31,36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study that included 123 adults undergoing cardiac surgery, urinary KIM-1, NGAL, cystatin-C, hepatocyte growth factor, pi-glutathione S-transferase (GST), alpha-GST, and fractional excretion of sodium and urea were measured preoperatively, postoperatively and at the time of the clinical diagnosis of AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/31\">",
"       31",
"      </a>",
"      ]. At various postoperative time points, cystatin-C, NGAL, KIM-1, alpha-GST and pi-GST all demonstrated ability to diagnosis stage 3 AKI. Preoperative KIM-1 and alpha-GST predicted the development of stage 1 and stage 3 AKI, possibly reflecting subclinical proximal tubular injury present at this time.",
"     </li>",
"     <li>",
"      In one study of 38 patients, KIM-1 was very useful in differentiating ATN from other forms of AKI and chronic kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/37\">",
"       37",
"      </a>",
"      ]. The normalized urinary KIM-1 levels were significantly higher in patients with ischemic ATN (2.92) compared to levels in patients with other forms of AKI (0.63) or chronic kidney disease (0.72). After adjustment for age, gender, time between the initial insult, and sampling of the urine, a one-unit increase in normalized KIM-1 was associated with a greater than 12-fold (odds ratio [OR] 12.4, 95% CI 1.2-119) risk for the presence of ATN.",
"     </li>",
"     <li>",
"      KIM-1 was tested in a case control study of 20 children who underwent cardiopulmonary bypass surgery both with and without complicating AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/38\">",
"       38",
"      </a>",
"      ]. Urinary KIM-1 was increased 6 to 12 hours following cardiopulmonary bypass and remained elevated up to 48 hours in patients who sustained a greater than 50 percent increase in serum creatinine within the first 48 hours, but not in children who had normal renal function. The increase in KIM-1 was paralleled by that of NGAL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rapid direct 15-minute assay for the detection of urinary human KIM-1 has been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/39\">",
"     39",
"    </a>",
"    ]. Using this assay, more urinary KIM-1 was detected in the urine of patients with AKI than in the urine from healthy volunteers. Biomarker dipstick such as for KIM-1 may provide a sensitive and accurate detection of kidney injury in clinical practice or in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961969\">",
"    <span class=\"h2\">",
"     Urinary interleukin-18",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary Interleukin-18 (IL-18) has been shown to be elevated in patients with ATN, compared with patients with prerenal azotemia, urinary tract infection, or chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Its predictive utility for AKI following cardiac surgery could not be demonstrated in one prospective observational study of 100 adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440297015\">",
"    <span class=\"h2\">",
"     Urinary liver-type fatty acid-binding protein in acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary excretion of urinary liver-type fatty acid binding protein (L-FABP) reflects stress of proximal tubular epithelial cells, and correlates with severity of ischemic tubular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/44\">",
"     44",
"    </a>",
"    ]. A meta-analysis of 15 prospective cohort studies demonstrated that in hospital&ndash;based cohorts of patients at risk of AKI, L-FABP can discriminate for the diagnosis of AKI and predict the need for dialysis and in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/45\">",
"     45",
"    </a>",
"    ]. Further validation is needed in large cohort studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22961976\">",
"    <span class=\"h2\">",
"     Panel of biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biomarkers are now investigated in panels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/29,46,47\">",
"     29,46,47",
"    </a>",
"    ]. In a prospective study of 90 adults with cardiac surgery KIM-1, NAG and NGAL were evaluated for early detection of AKI in the postoperative phase. The combined analysis of these three markers enhanced the sensitivity of early detection of postoperative AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another prospective observational study, NGAL, cystatin C and conventional markers like creatinine and urea were measured at different time points before and after cardiac surgery in 100 adult patients. NGAL and cystatin C (in patients with initial estimated GFR &gt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2) were independent predictors of AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another multicenter prospective cohort study, 5 biomarkers were measured in 1635 unselected emergency department patients at time of hospital admission. Urinary NGAL and urinary KIM1 predicted a composite outcome of dialysis initiation or death during hospitalization. These biomarkers could detect a subpopulation with low serum creatinine on admissions who were at risk of adverse events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparing five different biomarkers in a prospective observational study of 529 patients in two intensive care units, performance of biomarkers could be improved by stratification for time of collection with respect to renal insult and for baseline renal function before injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of panel analysis of renal biomarkers has yet to be established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteomics &mdash; The role of protein profiling with laser mass spectrometry in urinary samples of patients with AKI is being investigated. This method allows identification of new and early markers of AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others &mdash; Additional novel markers that have been evaluated include serum cystatin C levels, isoform 3 of the sodium-hydrogen exchanger (NHE3), perforin and granzyme B, CXCR3-binding chemokines, endothelin, ProANP(1Y 98), tryptophan glycoconjugate and cysteine-rich protein 61 (CYR61), fatty acid binding protein, tumor necrosis factor receptor-I, plasminogen activator inhibitor-1, netrin-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/51\">",
"       51",
"      </a>",
"      ], activating transcription factor 3 (ATF3), and monocyte chemoattractant protein (MCP)-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/8,9,52-55\">",
"       8,9,52-55",
"      </a>",
"      ]. Prospective studies need to be done to evaluate the utility of these biomarkers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732289067\">",
"    <span class=\"h1\">",
"     PROGNOSTIC BIOMARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biomarkers described above allow early detection of AKI but do not predict severe AKI. Measurement of urinary angiotensinogen may allow the prediction of severe AKI and other adverse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732289075\">",
"    <span class=\"h2\">",
"     Urinary angiotensinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary angiotensinogen has been identified as a possible predictor of the development of severe AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34839/abstract/56\">",
"     56",
"    </a>",
"    ]. Among 99 consecutively enrolled patients who developed AKI, the ratio of urinary angiotensinogen to urinary creatinine (uAnCR, expressed as ng per mg creatinine) correlated with the maximum serum creatinine and the maximum percent change in serum creatinine. Patients with the highest uAnCR had a higher risk of worsening AKI compared with patients with the lowest uAnCR (OR 5.0, 95% CI 1.2-21.5). An elevated uAnCR predicted a longer hospital stay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H985398586\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury (AKI), previously called acute renal failure, is a common clinical problem. Although measurement of the serum creatinine concentration is widely used for the detection of AKI, it does not permit early diagnosis of acute tubular necrosis (ATN) since tubular injury precedes a significant rise in serum creatinine. Investigational biomarkers have been evaluated in patients with possible ATN in an attempt to detect tubular injury at an earlier stage. None have been approved for clinical use in the United States. (See",
"      <a class=\"local\" href=\"#H732288866\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Various urinary and serum proteins have been intensively investigated as possible biomarkers for the early diagnosis of ATN. Before any such proteins are used clinically, validation in different settings of AKI and the development and testing of rapid assays is necessary. It is possible that a panel of biomarkers will be required for clinical utility or serial measurements of a specific marker. In addition it needs to be shown if there is an association between levels of biomarkers and outcome. (See",
"      <a class=\"local\" href=\"#H22961934\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Promising biomarkers for the diagnosis of AKI include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and urinary interleukin-18 (IL-18), L-FABP among others. (See",
"      <a class=\"local\" href=\"#H732289043\">",
"       'Diagnostic biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary angiotensinogen may be useful as a prognostic marker for severe AKI. (See",
"      <a class=\"local\" href=\"#H732289067\">",
"       'Prognostic biomarkers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/1\">",
"      Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clin Pract 2012; 120:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/2\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/3\">",
"      Hsu CY, McCulloch CE, Fan D, et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/4\">",
"      Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/5\">",
"      Xue JL, Daniels F, Star RA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/6\">",
"      Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/7\">",
"      Liangos O, Wald R, O'Bell JW, et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/8\">",
"      Bonventre JV. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Contrib Nephrol 2007; 156:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/9\">",
"      Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB. Biomarkers of acute renal injury and renal failure. Shock 2006; 26:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/10\">",
"      Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 2013; 28:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/11\">",
"      Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/12\">",
"      Bagshaw SM, Langenberg C, Haase M, et al. Urinary biomarkers in septic acute kidney injury. Intensive Care Med 2007; 33:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/13\">",
"      Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol 2007; 156:203.",
"     </a>",
"    </li>",
"    <li>",
"     Nguyen, MT, Devarajan, P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol 2007 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/15\">",
"      Ralib AM, Pickering JW, Shaw GM, et al. Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol 2012; 23:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/16\">",
"      Herget-Rosenthal S, Poppen D, H&uuml;sing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/17\">",
"      Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002; 323:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/18\">",
"      Herget-Rosenthal S. One step forward in the early detection of acute renal failure. Lancet 2005; 365:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/19\">",
"      Kjeldsen L, Johnsen AH, Sengel&oslash;v H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268:10425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/20\">",
"      Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/21\">",
"      Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/22\">",
"      Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/23\">",
"      Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/24\">",
"      Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/25\">",
"      Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/26\">",
"      Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008; 3:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/27\">",
"      Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008; 148:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/28\">",
"      Wagener G, Gubitosa G, Wang S, et al. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008; 52:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/29\">",
"      Han WK, Wagener G, Zhu Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/30\">",
"      Siew ED, Ware LB, Gebretsadik T, et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009; 20:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/31\">",
"      Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol 2010; 5:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/32\">",
"      Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011; 57:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/33\">",
"      Haase M, Haase-Fielitz A, Bellomo R, Mertens PR. Neutrophil gelatinase-associated lipocalin as a marker of acute renal disease. Curr Opin Hematol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/34\">",
"      Paragas N, Qiu A, Zhang Q, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/35\">",
"      Vaidya VS, Ramirez V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290:F517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/36\">",
"      Steiner RW. Interpreting the fractional excretion of sodium. Am J Med 1984; 77:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/37\">",
"      Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/38\">",
"      Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/39\">",
"      Vaidya VS, Ford GM, Waikar SS, et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/40\">",
"      Zhou H, Hewitt SM, Yuen PS, Star RA. Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise. Nephrol Self Assess Program 2006; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/41\">",
"      Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/42\">",
"      Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/43\">",
"      Haase M, Bellomo R, Story D, et al. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care 2008; 12:R96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/44\">",
"      Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/45\">",
"      Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis 2013; 61:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/46\">",
"      Liangos O, Tighiouart H, Perianayagam MC, et al. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/47\">",
"      Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery--a prospective cohort study. Crit Care Med 2009; 37:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/48\">",
"      Nickolas TL, Schmidt-Ott KM, Canetta P, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol 2012; 59:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/49\">",
"      Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int 2011; 79:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/50\">",
"      Ho J, Lucy M, Krokhin O, et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am J Kidney Dis 2009; 53:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/51\">",
"      Ramesh G, Krawczeski CD, Woo JG, et al. Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2010; 5:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/52\">",
"      Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/53\">",
"      Liu KD, Glidden DV, Eisner MD, et al. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. Crit Care Med 2007; 35:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/54\">",
"      Zhou H, Cheruvanky A, Hu X, et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int 2008; 74:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/55\">",
"      Munshi R, Johnson A, Siew ED, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34839/abstract/56\">",
"      Alge JL, Karakala N, Neely BA, et al. Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol 2013; 8:184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85837 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34839=[""].join("\n");
var outline_f34_1_34839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H985398586\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732288866\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22961934\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732289043\">",
"      DIAGNOSTIC BIOMARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961941\">",
"      Urinary tubular enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961948\">",
"      Urinary low-molecular-weight proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961955\">",
"      Neutrophil gelatinase-associated lipocalin (NGAL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961962\">",
"      Urinary kidney injury molecule-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961969\">",
"      Urinary interleukin-18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440297015\">",
"      Urinary liver-type fatty acid-binding protein in acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22961976\">",
"      Panel of biomarkers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732289067\">",
"      PROGNOSTIC BIOMARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732289075\">",
"      Urinary angiotensinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H985398586\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34840="Infections and antimicrobial resistance in the intensive care unit";
var content_f34_1_34840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infections and antimicrobial resistance in the intensive care unit",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Dror Marchaim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Keith Kaye, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34840/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/1/34840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intensive care units (ICUs) account for fewer than ten percent of total beds in most hospitals, more than 20 percent of all nosocomial infections are acquired in ICUs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/1\">",
"     1",
"    </a>",
"    ]. ICU-acquired infections account for substantial morbidity, mortality, and expense. Infections and sepsis are the leading cause of death in non-cardiac ICUs and account for 40 percent of all ICU expenditures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of nosocomial ICU infections and antimicrobial resistance in ICUs will be discussed here. The most important nosocomial infections in the ICU, namely catheter-related bloodstream infections (CRBSI), ventilator-associated pneumonia (VAP), and catheter-associated urinary tract infections (CAUTI), will be discussed briefly here and in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the advances in modern medicine and intensive care, the incidence of sepsis in intensive care units (ICUs) continues to rise. In an international study of 1265 ICUs, 60 percent of ICU patients at the time of survey were considered infected, with infection being a strong independent predictor for mortality (OR = 1.51, p&lt;0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/2\">",
"     2",
"    </a>",
"    ]. The risks of infection in general and with a resistant pathogen in particular increased with the length of patient stay in the ICU. Several factors contribute to the high incidence of these infections in ICU and the associated poor patient outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with patients in the general hospital population, patients in ICUs have more chronic comorbid illnesses and more severe acute physiologic derangements.",
"     </li>",
"     <li>",
"      The high frequency of indwelling catheters among ICU patients provides a portal of entry of organisms into vital body organs and sites. The use and maintenance of these catheters necessitate frequent contact with healthcare personnel, which predisposes patients to colonization and infection with nosocomial pathogens. In addition, equipment associated with the proper maintenance of these devices might serve as reservoirs for pathogens and be related to horizontal patient-to-patient transmission of pathogens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/3\">",
"       3",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococci (VRE), carbapenem-resistant Acinetobacter baumannii, Enterobacteriaceae that produce extended-spectrum beta-lactamases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      carbapenemases (eg, ESBLs and CREs, respectively), and carbapenem-resistant Pseudomonas aeruginosa, are all being isolated with increasing frequency in ICUs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Infections caused by these resistant pathogens are difficult to effectively treat and are associated with increased morbidity, mortality, and costs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most studies of ICU-associated infections come from industrialized countries, the rates of infection may even be higher in developing countries, as illustrated by a multicenter prospective cohort surveillance study of 46 hospitals in Central and South America, India, Morocco, and Turkey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/8\">",
"     8",
"    </a>",
"    ]. Rates of device-associated infection were assessed between 2002 and 2005; an overall rate of 14.7 percent, or 22.5 infections per 1000 ICU days, was observed. The following rates were found for specific devices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventilator associated pneumonia (VAP); 24.1 cases per 1000 ventilator days (range 10.0 to 52.7 cases)",
"     </li>",
"     <li>",
"      Catheter-related bloodstream infection (CRBSI); 12.5 cases per 1000 catheter days (range 7.8 to 18.5 cases)",
"     </li>",
"     <li>",
"      Catheter-associated urinary tract infections; 8.9 cases per 1000 catheter days (1.7 to 12.8 cases)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent study by the same international group had reported results obtained from 2002 to 2007 from 98 ICUs from Latin America, Asia, Africa, and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite the fact that device utilization was remarkably similar to that reported from ICUs in the United States, rates of device-associated nosocomial infection were markedly higher in the ICUs from the developing world. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25151042\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a rapid rise in the rate of resistance among bacterial pathogens recovered in intensive care units (ICUs). A comparison of the reports from the National Healthcare Safety Network System (NHSN) at the Centers for Disease Control and Prevention (CDC) from 1999 and",
"    <span class=\"nowrap\">",
"     2006/2007",
"    </span>",
"    demonstrates increasing prevalence of multidrug-resistant pathogens in ICUs in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VRE (from 24.7 to 33.3 percent of enterococci isolates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MRSA (from 53.5 to 56.2 percent of S. aureus isolates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      P. aeruginosa resistant to imipenem or fluoroquinolones (from 16.4 to 25.3 and from 23.0 to 30.7 percent of P. aeruginosa isolates, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A. baumannii resistant to carbapenems (from 11 to 30 percent of A. baumannii isolates)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enterobacteriaceae resistant to third generation cephalosporins, mainly extended-spectrum beta-lactamase producers (from 10.4 to 25 percent of Klebsiella pneumoniae and 3.9 to 9 percent of Escherichia coli isolates) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link&amp;anchor=H11#H11\">",
"       \"Extended-spectrum beta-lactamases\", section on 'Epidemiology'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enterobacteriaceae resistant to carbapenems (CREs) (from 0 to 8 percent of Klebsiella pneumoniae and from 0 to 3 percent of Escherichia coli)",
"     </li>",
"     <li>",
"      The prevalence of carbapenem resistance has also emerged in Enterobacter species. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/10\">",
"       10",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=see_link&amp;anchor=H21045519#H21045519\">",
"       \"Carbapenemases\", section on 'Epidemiology'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another survey of 35,790 unique gram-negative isolates from ICUs in 43 states in the United States during the years 1994 to 2000 showed an overall decrease in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    susceptibility from 86 percent in 1994 to 76 percent in 2000, which correlated with increased use of fluoroquinolones nationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/11\">",
"     11",
"    </a>",
"    ]. The most common gram-negative bacilli isolated were Pseudomonas aeruginosa (23 percent), Enterobacter spp. (14 percent), and Klebsiella pneumoniae (13.6 percent). Cross-resistance to other broad spectrum antibiotics was frequent among isolates resistant to ciprofloxacin.",
"   </p>",
"   <p>",
"    The emergence of broad-spectrum resistance among gram-negatives is particularly worrisome since therapeutic options are scarce, and sometimes no effective antimicrobial agent is available at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple risk factors are associated with infections with multidrug-resistant pathogens in ICUs, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/2,13-15\">",
"     2,13-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of functional independence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of underlying comorbid conditions (eg, diabetes, renal failure, malignancies) and higher severity of illness indices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long hospital courses prior to the ICU admission, including inter-institutional transferring (particularly from nursing homes) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Receipt of antimicrobial therapy prior to the ICU admission, which creates selective pressure promoting the emergence of multidrug-resistant bacteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/14,16\">",
"       14,16",
"      </a>",
"      ]. One of many examples of this phenomenon is the emergence of piperacillin-resistant P. aeruginosa in patients receiving fluoroquinolones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/17\">",
"       17",
"      </a>",
"      ]. In a study of ventilator-associated pneumonia, patients with piperacillin-resistant strains of P. aeruginosa more often received fluoroquinolones prior to their pneumonia (OR 4.6; 95% CI 1.7-12.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of indwelling devices such as central venous catheters, Foley catheters, and endotracheal tubes, which bypass natural host defense mechanisms and serve as portals of entry for pathogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent surgery or other invasive procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent manipulations and contact with healthcare personnel (HCP), who are usually concurrently caring for multiple ICU patients, and whose hands can become the vehicles for transfer of both susceptible and drug-resistant pathogens from patient to patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/18\">",
"       18",
"      </a>",
"      ]. Appropriate hand hygiene and contact precautions (ie, use of gowns and gloves) can help to prevent transmission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/19-22\">",
"       19-22",
"      </a>",
"      ], but HCP are notoriously noncompliant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/23-26\">",
"       23-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Outcome of multidrug resistant ICU infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by multidrug-resistant pathogens are associated with increased mortality, length of hospital stay, and hospital costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. Patients with infections due to multidrug-resistant organisms usually are chronically or acutely ill and at risk of dying from underlying serious and complex medical illnesses. However, a number of factors related to the difficulties of choosing antibiotics for multidrug-resistant bacteria independently predispose to poor outcomes. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multidrug-resistant pathogens are more frequently resistant to empiric antimicrobial regimens than are susceptible organisms; this leads to a delay in the institution of effective therapy and, in some cases, increased mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/29,34-37\">",
"       29,34-37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H17#H17\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Antimicrobial regimen'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antimicrobial resistance often precludes the use of optimal &ldquo;first line&rdquo; antimicrobial agents and necessitates the use of \"second line\" agents, with inferior bactericidal activity and unfavorable pharmacokinetic parameters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/34\">",
"       34",
"      </a>",
"      ]. When \"second line&rdquo; agents are required to treat a resistant organism, adverse patient outcomes sometimes result [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/31,32,38-42\">",
"       31,32,38-42",
"      </a>",
"      ]. As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      is commonly used to treat MRSA since anti-staphylococcal penicillins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      ) and first generation cephalosporins (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      ) are not active against the organism, but vancomycin does not possess strong bactericidal activity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another factor that may contribute to the poor outcomes among patients with infections due to multidrug-resistant pathogens is the virulence properties of the organism, but this issue is subject to continuous debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention of resistance in the ICU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to prevent the emergence and spread of multidrug-resistant bacteria in ICUs can be separated into two major categories: strategies that attempt to improve the efficacy and utilization of antimicrobial therapy and infection control measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Antibiotic utilization controls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms have been used to decrease the overall utilization of antimicrobial agents. These measures should, in turn, decrease selective pressure that can foster the emergence of resistant bacterial strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/34\">",
"     34",
"    </a>",
"    ]. Such measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic evaluation committees (often involving physicians and pharmacists), whose primary responsibilities are to promote the effective and safe use of antimicrobial agents, to evaluate and guide formulary decisions, and to implement educational programs to improve antimicrobial utilization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protocols and guidelines to promote appropriate antimicrobial utilization",
"     </li>",
"     <li>",
"      Hospital formulary restrictions of broad-spectrum agents",
"     </li>",
"     <li>",
"      Preferential use of narrow-spectrum antibiotics (such as first generation cephalosporins and aminoglycosides)",
"     </li>",
"     <li>",
"      Mandatory consultations with infectious diseases specialists to improve the appropriateness of antimicrobial therapy and decrease the utilization of broad-spectrum antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antibiotic cycling by regularly changing the antimicrobial class used for empiric gram-negative therapy of potentially infected patients in a given ICU",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infection control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to prevent the emergence of multidrug-resistant organisms that do not involve changes in antimicrobial utilization primarily involve infection control (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of infection control\", section on 'Hand hygiene'",
"    </a>",
"    ). Careful attention to these activities has been used to contain outbreaks of resistant organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/19-22\">",
"     19-22",
"    </a>",
"    ], and adherence to these requirements should be followed on a routine basis.",
"   </p>",
"   <p>",
"    There is",
"    <strong>",
"     no",
"    </strong>",
"    substitute for good hand hygiene compliance. Alcohol-based hand hygiene is more effective than traditional soap and water in cleansing hands of bacteria; in addition, no sink or towels are necessary, and alcohol foam is no more abrasive to hands than standard soap and water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Alcohol foam is not appropriate for hands that are visibly soiled or for healthcare personnel caring for patients with Clostridium difficile infection (or other spores-forming organisms), since the foam does not inactivate C. difficile toxins. Barrier precautions (gloves and gowns) have also been used to prevent the spread of multidrug-resistant bacteria (particularly VRE, MRSA, ESBL, CRE, and A. baumannii).",
"   </p>",
"   <p>",
"    Active surveillance or screening patients for asymptomatic colonization with resistant organisms is another strategy that can be used to rapidly identify colonized patients in an attempt to control spread of resistant pathogens in ICU settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\", section on 'Surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27721?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, prevention and control of vancomycin-resistant enterococci\", section on 'Surveillance cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additionally, surveillance for infections with multidrug-resistant bacteria within the institution as a whole and within specific units is critical for the early identification and control of epidemic outbreaks and endemic increases of resistant bacteria. The incidence and prevalence of isolation of multidrug-resistant bacteria (eg, MRSA, VRE and CRE) should be monitored, and these data should be disseminated to nurses and clinicians who work in the ICU through a form that is easy to interpret. It is useful to compare data from different time periods for one ICU and to compare different units within the same hospital. The United States National Healthcare Safety Network System also provides comparisons of rates among participating hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/5\">",
"     5",
"    </a>",
"    ]. Comparing rates among different institutions helps to identify hospitals or units where problems persist and can help to gauge the efficacy of interventions aimed at controlling rates of endemic and epidemic resistant organisms.",
"   </p>",
"   <p>",
"    Daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    bathing is an additional established intervention that can help to reduce the incidence of colonization and infection caused by multidrug-resistant pathogens in the ICU. In several studies, daily bathing with chlorhexidine solution (2 to 4 percent concentrations in the majority of studies) instead of plain soap and water was simple, cheap, and associated with a reduction in the incidence of colonization and infection caused by MRSA, VRE, and A. baumannii in the ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The major impact of this intervention is on the incidence of catheter-associated bloodstream infection in acute care settings (up to 99 percent according to one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/52\">",
"     52",
"    </a>",
"    ]). However, it was postulated that chlorhexidine bathing might also affect the rate of ventilator-associated pneumonia caused by A. baumannii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preventing infections and decreasing the length of hospital stay of patients will decrease antimicrobial utilization and decrease the risk of becoming infected or colonized with resistant bacteria. Limiting unnecessary use of central venous catheter and bladder catheter, and endotracheal intubation decreases infection rates, decreases antibiotic use, and decreases selective antibiotic pressure on resident bacteria. Clinicians should assess on a daily basis the need to keep each of these invasive devices in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTRAVASCULAR CATHETER-RELATED BLOODSTREAM INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters are frequently used in critical care patients because of the need for hemodynamic monitoring and intravenous therapeutics. Bloodstream infections involving these catheters are common in intensive care units (ICUs) and are associated with significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, in the United States, the cost burden of these infections on healthcare facilities was exacerbated after the Centers for Medicare and Medicaid Services (CMS) stopped reimbursing hospitals for catheter-related bloodstream infections in October 2008. These infections are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VENTILATOR ASSOCIATED PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilator-associated pneumonia (VAP) is infection of lung tissue that develops 48 hours or more after intubation in mechanically ventilated patients. Nosocomial pneumonia is the second most common hospital-acquired infection and occurs frequently in the setting of endotracheal intubation and mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/56\">",
"     56",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CATHETER ASSOCIATED URINARY TRACT INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection (UTI) is the most common nosocomial infection, accounting for more than 40 percent of all nosocomial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/57\">",
"     57",
"    </a>",
"    ]. While the majority of catheter-associated UTIs (CAUTIs) do not cause severe morbidity and mortality or significantly increase hospital costs, the cumulative impact of these frequent infections is large. CAUTIs are responsible for 900,000 additional hospital days per year and contribute to &gt;7000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. CAUTIs are the second most common cause of nosocomial bloodstream infection (ie, urosepsis), which have an attributable mortality of approximately 15 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/60-64\">",
"     60-64",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In October 2008, the Centers for Medicare and Medicaid Services stopped reimbursing hospitals for CAUTIs, which further increases the cost burden of these infections on hospitals in the United States.",
"   </p>",
"   <p>",
"    In addition to actual infection, asymptomatic bacteriuria often leads to significant laboratory testing and inappropriate antimicrobial utilization in the absence of an established infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. The urinary tract in catheterized patients also serves as a reservoir for multidrug-resistant bacteria, which can cause either infection or asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34840/abstract/63\">",
"     63",
"    </a>",
"    ]. The clinical features, diagnosis, and treatment of CAUTIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426464\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections are especially frequent in intensive care units (ICUs) because the patients are likely to have chronic illnesses and acute physiologic derangements, indwelling catheterization is common, and multidrug resistant pathogens that are difficult to eradicate are isolated with increasing frequency. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common multidrug-resistant pathogens isolated in ICUs include methicillin-resistant Staphylococcus aureus (MRSA),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      -resistant enterococci, fluoroquinolone or imipenem-resistant Pseudomonas aeruginosa, and extended-spectrum beta-lactamase producing Gram-negative bacilli. Carbapenem-resistant Gram-negative bacilli are also increasing in prevalence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antimicrobial resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comorbid conditions, long hospital courses, receipt of antimicrobial therapy, indwelling catheterization, and frequent contact with healthcare personnel all increase the risk of colonization and infection with multidrug-resistant pathogens. Infections with such organisms are associated with increased mortality, length of stay, and hospital costs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Outcome of multidrug resistant ICU infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Restricted and judicious antibiotic utilization within an institution can decrease selective pressure that promotes emergence of resistant bacterial strains. Infection control measures to prevent the spread of multidrug-resistant organisms include hand hygiene, barrier precautions, surveillance for such pathogens, and reduction of catheterization utilization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention of resistance in the ICU'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter-related bloodstream infections are one of the most frequent life-threatening infections encountered in ICUs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Intravascular catheter-related bloodstream infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link\">",
"       \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nosocomial pneumonia is the second most common hospital-acquired infection and occurs frequently in the setting of endotracheal intubation and mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ventilator associated pneumonia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=see_link\">",
"       \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary tract infections (UTIs) account for more than 40 percent of all nosocomial infections and are the second most common cause of nosocomial bloodstream infection. The major predisposing risk factor is an indwelling urinary catheter, and the risk of UTI increases directly with the duration of catheterization. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Catheter associated urinary tract infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/1\">",
"      Fridkin SK, Welbel SF, Weinstein RA. Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am 1997; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/2\">",
"      Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/3\">",
"      Kaye KS, Marchaim D, Smialowicz C, Bentley L. Suction regulators: a potential vector for hospital-acquired pathogens. Infect Control Hosp Epidemiol 2010; 31:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/4\">",
"      National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/5\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/6\">",
"      Schwaber MJ, Carmeli Y. The effect of antimicrobial resistance on patient outcomes: importance of proper evaluation of appropriate therapy. Crit Care 2009; 13:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/7\">",
"      Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/8\">",
"      Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/9\">",
"      Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/10\">",
"      Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/11\">",
"      Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/12\">",
"      Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/13\">",
"      Ben-Ami R, Rodr&iacute;guez-Ba&ntilde;o J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/14\">",
"      Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000; 14:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/15\">",
"      Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/16\">",
"      Kaye KS, Cosgrove S, Harris A, et al. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001; 45:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/17\">",
"      Trouillet JL, Vuagnat A, Combes A, et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002; 34:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/18\">",
"      Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 1991; 91:179S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/19\">",
"      Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/20\">",
"      Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/21\">",
"      Haley RW, Cushion NB, Tenover FC, et al. Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis 1995; 171:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/22\">",
"      Dembry LM, Uzokwe K, Zervos MJ. Control of endemic glycopeptide-resistant enterococci. Infect Control Hosp Epidemiol 1996; 17:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/23\">",
"      Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992; 327:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/24\">",
"      Albert RK, Condie F. Hand-washing patterns in medical intensive-care units. N Engl J Med 1981; 304:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/25\">",
"      Conly JM, Hill S, Ross J, et al. Handwashing practices in an intensive care unit: the effects of an educational program and its relationship to infection rates. Am J Infect Control 1989; 17:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/26\">",
"      Pittet D, Mourouga P, Perneger TV. Compliance with handwashing in a teaching hospital. Infection Control Program. Ann Intern Med 1999; 130:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/27\">",
"      Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/28\">",
"      Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA 1996; 275:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/29\">",
"      Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/30\">",
"      Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412.",
"     </a>",
"    </li>",
"    <li>",
"     Cosgrove S, Qi Y, Kaye K, et al. The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia (SAB) on Patient (Pt) Outcomes: Mortality, Length of Stay (LOS), and Hospital Charge (HC), 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2001.",
"    </li>",
"    <li>",
"     Engemann J, Carmeli Y, Bronstein M, et al. Outcomes Attributable to Methicillin Resistance (MR) among Patients with Staphylococcus aureus (SA) Surgical Site Infections (SSI): Hospital Charges, Hospital Days and Mortality, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/33\">",
"      Neidell MJ, Cohen B, Furuya Y, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 2012; 55:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/34\">",
"      Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/35\">",
"      Kollef MH. Antimicrobial therapy of ventilator-associated pneumonia: how to select an appropriate drug regimen. Chest 1999; 115:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/36\">",
"      Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/37\">",
"      Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/38\">",
"      Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/39\">",
"      Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/40\">",
"      Gleason TG, Crabtree TD, Pelletier SJ, et al. Prediction of poorer prognosis by infection with antibiotic-resistant gram-positive cocci than by infection with antibiotic-sensitive strains. Arch Surg 1999; 134:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/41\">",
"      Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/42\">",
"      Menon KV, Whiteley MS, Burden P, Galland RB. Surgical patients with methicillin resistant staphylococcus aureus infection: an analysis of outcome using P-POSSUM. J R Coll Surg Edinb 1999; 44:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/43\">",
"      Marchaim D, Kaye KS, Fowler VG, et al. Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/44\">",
"      Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/45\">",
"      Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/46\">",
"      Classen DC, Burke JP, Wenzel RP. Infectious diseases consultation: impact on outcomes for hospitalized patients and results of a preliminary study. Clin Infect Dis 1997; 24:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/47\">",
"      Lundberg J, Nettleman MD, Costigan M, et al. Staphylococcus aureus bacteremia: the cost-effectiveness of long-term therapy associated with infectious diseases consultation. Clin Perform Qual Health Care 1998; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/48\">",
"      Widmer AF. Replace hand washing with use of a waterless alcohol hand rub? Clin Infect Dis 2000; 31:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/49\">",
"      McNeil SA, Foster CL, Hedderwick SA, Kauffman CA. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis 2001; 32:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/50\">",
"      Yokoe DS, Mermel LA, Anderson DJ, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/51\">",
"      Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/52\">",
"      Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009; 30:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/53\">",
"      Borer A, Gilad J, Porat N, et al. Impact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unit. J Hosp Infect 2007; 67:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/54\">",
"      Landrum ML, Murray CK. Ventilator associated pneumonia in a military deployed setting: the impact of an aggressive infection control program. J Trauma 2008; 64:S123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/55\">",
"      Marschall J, Mermel LA, Classen D, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/56\">",
"      Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/57\">",
"      Lo E, Nicolle L, Classen D, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/58\">",
"      Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents 2001; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/59\">",
"      Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991; 91:65S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/60\">",
"      Bryan CS, Reynolds KL. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. J Urol 1984; 132:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/61\">",
"      Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis 1983; 148:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/62\">",
"      Paradisi F, Corti G, Mangani V. Urosepsis in the critical care unit. Crit Care Clin 1998; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/63\">",
"      Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis 2001; 7:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/64\">",
"      Wagenlehner FM, Naber KG. Hospital-acquired urinary tract infections. J Hosp Infect 2000; 46:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34840/abstract/65\">",
"      Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med 2000; 160:678.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3810 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34840=[""].join("\n");
var outline_f34_1_34840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H426464\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIMICROBIAL RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25151042\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Outcome of multidrug resistant ICU infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention of resistance in the ICU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Antibiotic utilization controls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infection control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTRAVASCULAR CATHETER-RELATED BLOODSTREAM INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VENTILATOR ASSOCIATED PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CATHETER ASSOCIATED URINARY TRACT INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H426464\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9754?source=related_link\">",
"      Carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27721?source=related_link\">",
"      Epidemiology, prevention and control of vancomycin-resistant enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34841="Binge-eating disorder: Overview of treatment in adults";
var content_f34_1_34841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Binge-eating disorder: Overview of treatment in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Robyn Sysko, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Michael Devlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34841/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/1/34841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H103238174\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binge eating disorder (BED) is more prevalent than either anorexia nervosa or bulimia nervosa, and is associated with numerous psychiatric and nonpsychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, most patients report some degree of impairment in psychosocial functioning (home, work, personal life, or social life), and 19 percent report severe impairment. &nbsp;",
"   </p>",
"   <p>",
"    The phenomenon of binge eating was first formally described in obese individuals in 1959 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/3\">",
"     3",
"    </a>",
"    ]. BED was first formulated as a distinct diagnosis in the 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    This topic provides an overview of evaluating and treating patients for BED. The use of cognitive-behavioral therapy to treat BED is discussed separately, as are anorexia nervosa, bulimia nervosa, and obesity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8646?source=see_link\">",
"       \"Binge-eating disorder: Cognitive-behavioral therapy (CBT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122329\">",
"    <span class=\"h1\">",
"     DEFINITION OF BINGE-EATING DISORDER (BED)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binge-eating disorder (BED) is not formally recognized as a psychiatric illness. However, the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) includes research criteria for BED in Appendix B, Criteria Sets and Axes Provided for Further Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, patients who meet these criteria for BED are diagnosed with Eating Disorder Not Otherwise Specified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In the World Health Organization International Classification of Diseases-10th revision (ICD-10), patients with BED are diagnosed with either &ldquo;atypical bulimia nervosa&rdquo; or &ldquo;overeating associated with other psychological disturbances&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/7\">",
"     7",
"    </a>",
"    ]. This topic will use the term BED.",
"   </p>",
"   <p>",
"    Key diagnostic features of BED are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes of binge eating, defined as consuming a large amount of food in a discrete period of time. Patients feel they lack control over eating during the episode.",
"     </li>",
"     <li>",
"      Binge-eating episodes are marked by at least three of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eating large amounts of food when not feeling physically hungry",
"     </li>",
"     <li>",
"      Eating more rapidly than normal",
"     </li>",
"     <li>",
"      Eating until feeling uncomfortably full",
"     </li>",
"     <li>",
"      Eating alone because of embarrassment by the amount of food consumed",
"     </li>",
"     <li>",
"      Feeling disgusted with oneself, depressed, or guilty after overeating",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodes occur on average for two days per week for at least six months.",
"     </li>",
"     <li>",
"      No regular use of inappropriate compensatory behaviors (eg, purging, fasting, or excessive exercise) as are seen in bulimia nervosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no weight criterion for the diagnosis of BED. Although the prevalence of BED increases with increasing weight, the etiologic relationships between obesity and BED are not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/8\">",
"     8",
"    </a>",
"    ]. Approximately 50 percent of individuals in the community with BED are overweight or obese, similar to the community at large [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The remaining individuals with BED are of normal weight, and they are less likely to present for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The effect of binge-eating cessation on subsequent weight course",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical comorbidities of obesity are not clearly established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103238672\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binge-eating disorder (BED) occurs more frequently in women than men, is persistent, and associated with many other psychiatric problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pooled results from nationally representative surveys in 14 countries estimated that the lifetime prevalence of BED was 1.9 percent, with a mean age of onset of 23 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large, nationally representative community survey in the United States, the estimated lifetime prevalence of BED among women was 3.5 percent and among men 2.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1\">",
"     1",
"    </a>",
"    ]. Prevalence rates were not significantly associated with race, marital status, or employment status. The mean age of onset was 25 years. The prevalence of BED in clinical samples drawn from weight-control programs varies from 15 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of BED occurs in a variety of ways. A study of 284 patients seeking treatment for BED found that becoming overweight usually occurred first, compared with dieting or binge eating first (63 versus 21 and 16 percent of patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BED is often comorbid with other psychopathology. One community survey found that 79 percent of patients with BED met criteria for at least one other lifetime psychiatric disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common comorbid illnesses were specific phobia (37 percent of patients), social phobia (32 percent), unipolar major depression (32 percent), posttraumatic stress disorder (26 percent), and alcohol abuse or dependence (21 percent). These rates are much higher than what is found in the general population. As an example, the lifetime prevalence rate of specific phobia in the general population is 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to individuals without a lifetime history of an eating disorder, individuals with a history of BED are at increased risk to develop comorbid general medical disorders, including chronic pain, diabetes mellitus, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, individuals with a history of BED have a higher body mass index and are more likely to be obese.",
"   </p>",
"   <p>",
"    Among individuals with BED in the past 12 months, impaired psychosocial functioning was found in 47 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/11\">",
"     11",
"    </a>",
"    ]. Severe impairment was reported by 13 percent. &nbsp;",
"   </p>",
"   <p>",
"    The course of illness appears to be chronic among patients presenting for treatment. The mean lifetime duration of BED in one study was 14 years, significantly longer than for bulimia nervosa (6 years) or anorexia nervosa (6 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/14\">",
"     14",
"    </a>",
"    ]. A study of 68 inpatients with BED found that after 12 years, 36 percent met criteria for an eating disorder diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/15\">",
"     15",
"    </a>",
"    ]. Body dissatisfaction, impulsivity, and a history of sexual abuse were associated with a poor outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118452871\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of the patient with binge-eating disorder is necessary in order to plan treatment. The evaluation should include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22437814\">",
"    <span class=\"h2\">",
"     Psychiatric status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and mental status examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Attitude toward body weight and shape",
"     </li>",
"     <li>",
"      Self-esteem",
"     </li>",
"     <li>",
"      Comorbid psychiatric disorders (eg, depression and substance use disorder)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22437822\">",
"    <span class=\"h2\">",
"     Medical status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination should focus upon the following parameters and comorbidities associated with excess weight or obesity in appropriate patients. Further assessment with laboratory testing may be indicated for overweight patients.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body mass index &ndash; measure height and weight",
"     </li>",
"     <li>",
"      Waist circumference",
"     </li>",
"     <li>",
"      Hypertension - measure blood pressure",
"     </li>",
"     <li>",
"      Diabetes mellitus &ndash; measure fasting blood glucose &nbsp;",
"     </li>",
"     <li>",
"      Hyperlipidemia &ndash; measure nonfasting total and HDL cholesterol",
"     </li>",
"     <li>",
"      Coronary heart disease",
"     </li>",
"     <li>",
"      Hepatobiliary disease",
"     </li>",
"     <li>",
"      Gastroesophageal reflux disease (GERD)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea",
"     </li>",
"     <li>",
"      Urinary incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation of obesity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22437830\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lifetime weight and dieting history",
"     </li>",
"     <li>",
"      Current eating pattern",
"     </li>",
"     <li>",
"      Types of overeating (eg, overeating at meals,",
"      <span class=\"nowrap\">",
"       snacking/grazing,",
"      </span>",
"      and night eating)",
"     </li>",
"     <li>",
"      Frequency and intensity of binge eating episodes",
"     </li>",
"     <li>",
"      Physical activity and exercise patterns",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should also ask about efforts to compensate for overeating through use of laxatives, diuretics, induced vomiting, fasting, diet pills, and intense exercise. In addition, patients with diabetes mellitus may deliberately skip insulin doses to prevent weight gain, and patients with hypothyroidism may overuse thyroid hormone supplements to promote weight loss. Regular use of compensatory measures in the presence of binge eating indicates a diagnosis of bulimia nervosa rather than binge-eating disorder. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122336\">",
"    <span class=\"h1\">",
"     TREATMENT PLANNING",
"    </span>",
"    &nbsp;&mdash;&nbsp;After evaluating the patient with binge-eating disorder (BED), the clinician needs to determine the treatment setting, type of treatment that should be used, and who will treat the patient.",
"   </p>",
"   <p>",
"    Treatment goals determine treatment selection and should be clearly established. Goals for treatment may include reducing the patient&rsquo;s:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Binge eating episodes",
"     </li>",
"     <li>",
"      Excess weight when present",
"     </li>",
"     <li>",
"      Psychiatric comorbidity such as anxiety, depression, or substance use disorder",
"     </li>",
"     <li>",
"      Excessive concerns with body image (ie, enhancing self-acceptance)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is useful to distinguish treatment for BED per se from treatment of obesity in patients who have both. Overweight or obese patients with BED have varying goals. (See",
"    <a class=\"local\" href=\"#H130122394\">",
"     'Treatment of obesity in patients with BED'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is not clear if binge eating causes negative medical consequences in normal weight patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/16\">",
"     16",
"    </a>",
"    ]. However, such patients may wish to undergo treatment, because our clinical experience is that the disorder may lead to excess weight or obesity.",
"   </p>",
"   <p>",
"    Different types of treatment are available, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psychotherapy adapted for BED",
"     </li>",
"     <li>",
"      Self-help treatment",
"     </li>",
"     <li>",
"      Pharmacotherapy",
"     </li>",
"     <li>",
"      Behavioral weight loss treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H130122373\">",
"     'Psychotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3060670\">",
"     'Pharmacotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H376660\">",
"     'Behavioral weight loss therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H103239749\">",
"     'Combining CBT and pharmacotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reviews have consistently concluded that psychotherapy is more beneficial than pharmacotherapy in treating BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,17-21\">",
"     9,17-21",
"    </a>",
"    ]. Thus, standard, first-line treatment consists of psychotherapy, such as cognitive-behavioral therapy or interpersonal therapy. Medication is also efficacious as a second-line treatment. It is not known whether there are different subtypes of the disorder that respond preferentially to each of the numerous treatment options.",
"   </p>",
"   <p>",
"    Although BED tends to follow a long-term remitting and relapsing course, nearly all treatment studies were short term. Some of these studies have collected follow-up data one to two years after the end of treatment, but there is limited information describing the status of patients more than two years after treatment ended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122345\">",
"    <span class=\"h2\">",
"     Treatment setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for BED nearly always takes place on an outpatient basis. Inpatient, partial hospital, or long-term residential treatment is considered only if the patient has additional psychopathology or medical morbidity that requires a more intense level of care, (eg, suicidality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060059\">",
"    <span class=\"h2\">",
"     Treatment team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with BED receive individual psychotherapy, although group therapy is also commonly provided. Pharmacotherapy may be provided by a clinician with prescribing privileges. Thus, the treatment team typically consists of a therapist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychiatrist or primary care clinician, particularly if medications are being prescribed. Nutritionists (registered dieticians) may also be involved in providing behavioral weight loss therapy or nutritional counseling. Primary care clinicians who typically do not treat BED may refer the patient. (See",
"    <a class=\"local\" href=\"#H3058077\">",
"     'Cognitive-behavior therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122373\">",
"    <span class=\"h1\">",
"     PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy is first-line treatment for BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. A meta-analysis examined six randomized psychotherapy trials (five with cognitive-behavioral therapy, one with dialectical behavior therapy, total of 301 patients) and found a large clinical effect for psychotherapy in reducing binge eating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17\">",
"     17",
"    </a>",
"    ]. By contrast, the same study performed a separate meta-analysis of randomized pharmacotherapy trials, and found a medium-sized clinical effect. None of the underlying trials involved a head-to-head comparison of psychotherapy and pharmacotherapy. &nbsp;",
"   </p>",
"   <p>",
"    Psychotherapies that have demonstrated efficacy for treating binge-eating disorder (BED) include cognitive-behavioral therapy (CBT), interpersonal therapy, and dialectical behavior therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. There are fewer data supporting the use of psychodynamic psychotherapy, but the consensus of clinical experts is that it may help reduce binge eating in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The psychotherapy of choice for BED is either CBT or interpersonal therapy, based upon the results of randomized trials that have evaluated each treatment, either separately or within the same study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17,23-28\">",
"     17,23-28",
"    </a>",
"    ]. We suggest CBT because there is more evidence supporting its use. In addition, CBT has been adapted for use in different formats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3058077\">",
"    <span class=\"h2\">",
"     Cognitive-behavior therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest clinicians use CBT to treat patients with BED. Reviews and treatment guidelines concur that cognitive-behavioral therapy (CBT) is the primary treatment for BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17,18,20,22\">",
"     17,18,20,22",
"    </a>",
"    ]. CBT is suitable for most patients, and there are no specific contraindications.",
"   </p>",
"   <p>",
"    CBT is usually provided (therapist-led) by a clinician to either an individual patient or a group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23\">",
"     23",
"    </a>",
"    ]. Alternatively, patients with BED can receive CBT through a self-help program, which requires either limited or no involvement of a clinician (guided or pure self-help).",
"   </p>",
"   <p>",
"    Treatment of BED with CBT is discussed separately, including its theoretical foundation, the format for providing the treatment, self-help forms of CBT, specific interventions that comprise CBT, and termination of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8646?source=see_link\">",
"     \"Binge-eating disorder: Cognitive-behavioral therapy (CBT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122508709\">",
"    <span class=\"h3\">",
"     Evidence for efficacy of self-help CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have demonstrated that self-help based upon CBT is efficacious for treating BED. In addition, self-help may be as effective as specialty treatments such as therapist-led CBT or interpersonal therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of four randomized trials (152 patients) found that self-help provided a large clinical effect for reducing the frequency of binge eating and concerns with eating, shape, and weight, compared with wait-list control (no treatment) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2008 review included six studies of self-help interventions for patients with BED and found that self-help was superior to no treatment (waiting list control) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/29\">",
"       29",
"      </a>",
"      ]. The review also found that patients may respond better to guided self-help that specifically addresses BED, as opposed to nonspecific self-help focusing upon obesity or self-assertion. In addition, symptomatic improvement with self-help was consistently maintained at follow-up, which occurred between 3 and 18 months after treatment was finished.",
"     </li>",
"     <li>",
"      A randomized trial evaluated eight sessions of guided self-help CBT in 123 patients with recurrent binge eating [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. At one-year follow-up, abstinence from binge eating was significantly greater in patients who received self-help CBT plus treatment as usual compared with patients who received only treatment as usual (64 versus 45 percent). Thus, for every five patients treated with adjunctive guided self-help CBT, there was one additional patient who recovered from binge eating. In addition, self-help resulted in significantly more binge-free days and lower costs, and provided medium size clinical improvement in concerns about body shape and weight and in depressive symptoms. However, self-help did not lead to a reduction in weight.",
"     </li>",
"     <li>",
"      A randomized trial assigned 259 patients with BED to either therapist-led CBT, guided self-help CBT, pure self-help CBT, or a waiting list [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/32\">",
"       32",
"      </a>",
"      ]. The content of the three active treatments was identical. At the 6 and 12 month follow-up assessments, there were no significant differences between the three active treatments in remission from binge eating.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36401440\">",
"    <span class=\"h3\">",
"     CBT compared with other psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found the efficacy of cognitive-behavioral therapy (CBT) for treating BED was similar to the efficacy of interpersonal therapy (IPT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], and comparable or superior to behavioral weight loss therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24,28,33,34\">",
"     24,28,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In three randomized trials, the efficacy of cognitive-behavioral therapy (CBT) for treating BED was similar to the efficacy of interpersonal therapy (IPT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H130122380\">",
"     'Interpersonal therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 205 overweight or obese patients were assigned to 10 sessions of guided self-help based upon CBT, 19 sessions of individual IPT, or 20 sessions of behavioral weight loss therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24\">",
"       24",
"      </a>",
"      ]. Remission from binge eating at the two-year follow-up was significantly greater for patients who received guided self-help CBT or IPT, compared with patients who received behavioral weight loss therapy (62 and 68 versus 44 percent). Attrition was significant higher for guided self-help CBT or behavioral weight loss therapy compared with IPT (30 and 28 versus 7 percent).",
"      <br/>",
"      <br/>",
"      A secondary analysis identified four subtypes (latent classes) of patients with BED [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/28\">",
"       28",
"      </a>",
"      ]. For patients with high depression scores at baseline, IPT was significantly more effective than guided self-help CBT or behavioral weight loss therapy. For patients with greater eating disorder pathology at the start of the study, guided self-help CBT was significantly more effective than the alternative treatments.",
"     </li>",
"     <li>",
"      In the second trial, 162 overweight patients were assigned to 20 weekly sessions of either group CBT or group IPT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/25\">",
"       25",
"      </a>",
"      ]. Recovery from binge eating was similar at post-treatment for CBT and IPT (79 versus 73 percent of patients) and at one-year follow-up (59 versus 62 percent). In addition, there were no significant differences for other outcomes, including weight loss (slight in both groups) and psychiatric symptoms associated with other disorders.",
"     </li>",
"     <li>",
"      In the third trial, 56 female patients were assigned to 16 weekly sessions of either group CBT or group IPT, or to a waiting list (no treatment) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23\">",
"       23",
"      </a>",
"      ]. The frequency of binge eating at the end of treatment was significantly less for patients who received either CBT or IPT, compared with the control group (48 and 71 versus 10 percent reduction in binge eating). Treatment gains were maintained at one-year follow-up for both CBT and IPT (55 and 50 percent reduction in binge eating).",
"     </li>",
"     <li>",
"      In one randomized trial, 80 obese patients with BED were assigned to either CBT or behavioral weight loss therapy consisting of 16 weekly sessions followed by 6 monthly sessions. At one-year follow-up, there were no significant differences with regard to recovery from BED, number of binge days, or abstinence from binge eating [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/34\">",
"       34",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36401461\">",
"    <span class=\"h3\">",
"     CBT compared with psychoactive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial found that CBT was more effective than the selective serotonin reuptake inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . In the trial, 116 overweight or obese patients were treated for BED with behavioral weight loss therapy plus adjunctive CBT, fluoxetine, or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/26\">",
"     26",
"    </a>",
"    ]. Binge frequency decreased significantly more in patients who received adjunctive CBT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122380\">",
"    <span class=\"h2\">",
"     Interpersonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal therapy (IPT) is a reasonable alternative to cognitive-behavioral therapy (CBT) as a first-line treatment for BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPT was originally developed as a treatment for depression and has been adapted for other psychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. According to the theoretical foundation of IPT, binge eating is caused by an unresolved interpersonal problem in at least one of four possible areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grief, ie, the death or disappearance of an important person, recently or in the past, which was not adequately resolved",
"     </li>",
"     <li>",
"      Interpersonal role dispute, ie, conflicts with a significant other (spouse, partner, family member, close friend, or coworker) over different expectations about the relationship",
"     </li>",
"     <li>",
"      Role transition, ie, difficulty with a major change in the patient&rsquo;s life circumstances, including relationships (marriage or divorce), occupation (eg, graduation, leaving a job, or retirement), living conditions (eg, moving), financial situation (eg, change in socioeconomic status), and physical health",
"     </li>",
"     <li>",
"      Interpersonal deficit, ie, pervasive problems starting and maintaining relationships, social isolation, and chronically unfulfilling relationships",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic strategy in IPT is to initially identify the interpersonal problem area or areas that are most closely linked to binge eating and related behaviors. The clinician then focuses upon experimentation and constructive change in the relevant interpersonal problem areas, with little ongoing reference to the binge eating problem per se. IPT does not focus on weight loss and does not produce significant weight loss in most individuals, but it appears that the subsequent weight course in individuals who stop binge eating is more normal compared with the weight course seen in individuals who continue to binge eat.",
"   </p>",
"   <p>",
"    IPT has primarily been studied in a group format. In two randomized trials, IPT led to significant reductions in binge eating and associated psychopathology that was comparable to CBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. In the larger study, 162 overweight patients with BED were assigned to 20 weekly sessions of group IPT or group CBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/25\">",
"     25",
"    </a>",
"    ]. Recovery from BED was similar at the end of treatment for IPT and CBT (73 versus 79 percent), and at one-year follow-up (62 versus 59 percent).",
"   </p>",
"   <p>",
"    The individual format of IPT is also effective. A controlled trial found that remission from binge eating at the two-year follow-up was significantly higher in patients who received individual IPT or a guided self-help form of CBT, compared with patients who received behavioral weight loss therapy (68 and 62 versus 44 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practice guidelines concur that IPT is efficacious for treating BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In practice, IPT is sometimes combined with CBT, and this may be particularly useful for patients with more complex psychopathology that includes features such as perfectionism, low self-esteem, and interpersonal difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122387\">",
"    <span class=\"h2\">",
"     Dialectical behavior therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reviews have concluded that dialectical behavior therapy (DBT) is efficacious for treating BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/20,22,38\">",
"     20,22,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DBT was originally developed as a treatment for borderline personality disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. It has been adapted for multiple disorders, including eating disorders such as BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ]. It may be particularly useful for patients with eating disorders and comorbid borderline personality disorder and substance use disorders.",
"   </p>",
"   <p>",
"    DBT was derived from cognitive-behavioral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/38\">",
"     38",
"    </a>",
"    ]. For BED, DBT consists of teaching skills for managing problematic behaviors, such as binge eating, that are associated with emotion dysregulation. DBT includes protocols for managing therapy-disrupting behavior and sicker patients with self-injurious and life-threatening behavior.",
"   </p>",
"   <p>",
"    DBT highlights the dichotomous (ie, absolute, all or nothing, or black or white) thinking, behavior, and feelings of patients and helps them find a balance between polarities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/38\">",
"     38",
"    </a>",
"    ]. The basic dialectic underlying treatment is accepting one&rsquo;s current ineffective behavior as well as the need to change it.",
"   </p>",
"   <p>",
"    DBT promotes skills related to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/38,43\">",
"     38,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mindful eating:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eating with full awareness and attention",
"     </li>",
"     <li>",
"      Watching the ebb and flow of binge urges associated with particular cues and triggers",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emotion regulation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Observing and describing emotions",
"     </li>",
"     <li>",
"      Understanding the function of emotions",
"     </li>",
"     <li>",
"      Learning to balance emotion with cognition and self-awareness",
"     </li>",
"     <li>",
"      Decreasing emotional suffering by increasing positive events",
"     </li>",
"     <li>",
"      Acting opposite to the current, painful emotion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distress tolerance, ie, learning techniques to manage unpleasant or painful circumstances and feelings associated with binge eating",
"     </li>",
"     <li>",
"      Relapse prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials have shown that DBT is efficacious for treating BED, and that treatment gains are usually maintained at least for six months. A 20-week trial assigned 44 women with BED to DBT or wait list control (no treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the patients who completed the trial, abstinence from binge eating was significantly higher post-treatment in patients who received DBT compared with control patients (89 versus 13 percent). At six-month follow-up, 67 percent of the DBT patients remained abstinent. A review of other randomized trials also found that the efficacy of DBT for treating BED is superior to that of supportive psychotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of DBT group therapy for treating BED may not be specific to DBT. A randomized trial assigned 101 patients to group DBT or an active comparison group therapy that lacked the specific elements of DBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/45\">",
"     45",
"    </a>",
"    ]. Follow-up assessments performed 3, 6, and 12 months after treatment ended found no significant difference between the two treatments with regard to abstinence and reduction in frequency of binge eating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103240429\">",
"    <span class=\"h2\">",
"     Family therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available regarding the utility of involving family members in the treatment of adults with BED. One study found no significant difference in outcome between patients who received group cognitive-behavior therapy with or without a spouse&rsquo;s involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/46\">",
"     46",
"    </a>",
"    ]. Family therapy for treatment of BED may be more important for pediatric or adolescent patients than for adults, similar to other eating disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376660\">",
"    <span class=\"h1\">",
"     BEHAVIORAL WEIGHT LOSS THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;This treatment uses strategies designed to produce weight loss (eg, moderate caloric restriction, increasing physical activity) as a means to reduce binge eating. Although behavioral weight loss therapy does not specifically target binge eating, it nevertheless is helpful for some overweight or obese patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. A randomized trial found that among overweight or obese patients with BED, behavioral weight loss treatment led to remission at the two-year follow-up in 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate caloric restriction (diet programs)",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Improved nutrition (nutritional rehabilitation and counseling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest that clinicians base their behavioral weight loss treatment of BED upon the National Institutes of Diabetes and Digestive and Kidney Disease&rsquo;s Diabetes Prevention Program manual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians may consider combining behavioral weight loss therapy with CBT. In one randomized trial, 116 overweight or obese patients were treated for BED with behavioral weight loss therapy plus adjunctive CBT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/26\">",
"     26",
"    </a>",
"    ]. Binge frequency decreased significantly more in patients who received adjunctive CBT.",
"   </p>",
"   <p>",
"    Information about weight loss (as opposed to binge eating) as the target of treatment for obese patients with BED is discussed below. (See",
"    <a class=\"local\" href=\"#H130122394\">",
"     'Treatment of obesity in patients with BED'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060670\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although medication is efficacious for treating BED, its efficacy is less than that of psychotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. Given this, most patients may prefer psychotherapy. However, pharmacotherapy may require less time or be less expensive. It is thus reasonable to use pharmacotherapy as a first-line treatment for patients who prefer it, do not have access to psychotherapy, or decline it.",
"   </p>",
"   <p>",
"    A meta-analysis of 14 randomized trials (1279 patients) found that short-term remission from binge eating occurred in significantly more patients who received pharmacotherapy, compared with patients who received placebo (49 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/51\">",
"     51",
"    </a>",
"    ]. In addition, attrition did not differ significantly between medication and placebo.",
"   </p>",
"   <p>",
"    The clinical effect of pharmacotherapy appears to be less than the effect of psychotherapy or self-help. Meta-analyses found that pharmacotherapy provided a medium sized clinical effect for reducing binge eating, compared with a large clinical effect for psychotherapy trials and self-help therapy trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17\">",
"     17",
"    </a>",
"    ]. None of the underlying trials involved a head-to-head comparison of pharmacotherapy with psychotherapy or self-help therapy. In addition, a review found that CBT alone was more effective for BED symptoms compared with pharmacotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7221395\">",
"    <span class=\"h2\">",
"     Specific medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of medication have been studied in randomized trials, including selective serotonin reuptake inhibitor (SSRI) antidepressants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ), antiepileptic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/999?source=see_link\">",
"     atomoxetine",
"    </a>",
"    (typically indicated for attention deficit hyperactivity disorder) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,17,51,52\">",
"     9,17,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with BED, we suggest clinicians use SSRIs because of efficacy and tolerability. A meta-analysis of randomized trials found that the relative risk of persistent binge eating with SSRIs was 0.81 (95% CI 0.70-0.94; risk of persistent binge eating reduced by 19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/51\">",
"     51",
"    </a>",
"    ]. The largest study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    found that the relative risk of persistent binge eating was 0.63 (95% CI 0.51-0.78; risk of persistent binge eating reduced by 37 percent), and a second study found a similar risk reduction. Although topiramate may be more efficacious, the side effect profile of SSRIs is superior to topiramate, which may cause significant side effects such as cognitive impairment and paresthesias. Patients not responding to an SSRI may be subsequently treated with topiramate. No head to head trials have compared an SSRI with topiramate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103239749\">",
"    <span class=\"h1\">",
"     COMBINING CBT AND PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials concluded that in general, CBT (the treatment of choice for BED) plus pharmacotherapy does not reduce binge eating significantly more than CBT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the specific drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    may be one exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15040976\">",
"    <span class=\"h2\">",
"     Psychoactive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    may be more effective as adjunctive treatment with CBT than antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/28,53-55\">",
"     28,53-55",
"    </a>",
"    ]. However, no head to head trials have been conducted.",
"   </p>",
"   <p>",
"    Three randomized trials studies examined augmentation of CBT with an antidepressant medication (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ) for treating BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/28,54,55\">",
"     28,54,55",
"    </a>",
"    ]. None of the studies found a significant benefit to adding an antidepressant for the outcomes of binge reduction and depressive symptoms.",
"   </p>",
"   <p>",
"    Augmentation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    may further improve binge eating in patients with BED. One randomized trial compared the addition of topiramate or placebo to group CBT (19 sessions) for 73 obese patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/53\">",
"     53",
"    </a>",
"    ]. Remission of binge eating during the trial occurred significantly more often with topiramate augmentation compared with placebo augmentation (84 versus 61 percent of patients). Given the demonstrated benefits of topiramate monotherapy for reducing symptoms of BED, we suggest its use when clinicians attempt to enhance outcomes by combining CBT with a medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15040991\">",
"    <span class=\"h2\">",
"     Antiobesity drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that clinicians not use anti-obesity drugs in combination with CBT to treat binge eating because of lack of efficacy or serious adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 12 week randomized trial examined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    (an antiobesity drug that inhibits absorption of dietary fat) combined with self-help therapy based upon CBT in 50 patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/58\">",
"     58",
"    </a>",
"    ]. Remission of binge eating was identical three months after treatment for patients who received orlistat compared with patients who received placebo (52 versus 52 percent).",
"   </p>",
"   <p>",
"    We recommend that clinicians not use the appetite suppressants dexfenfluramine or sibutramine for treatment of BED, despite their demonstrated efficacy in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,51,59\">",
"     9,51,59",
"    </a>",
"    ]. Dexfenfluramine is no longer available in the United States and other countries because of cardiovascular adverse events, primary pulmonary hypertension, and valvular regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/56\">",
"     56",
"    </a>",
"    ]. Sibutramine also appears to cause serious adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122394\">",
"    <span class=\"h1\">",
"     TREATMENT OF OBESITY IN PATIENTS WITH BED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some overweight or obese patients with BED seek treatment to lose weight rather than to stop binge eating. Most studies have found that weight loss interventions, including low and very low calorie diets, are similarly effective in obese patients who binge eat compared to obese patients who do not binge eat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/10\">",
"     10",
"    </a>",
"    ]. However, ongoing or re-emergent binge eating is associated with an increased risk of regaining weight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13803211\">",
"    <span class=\"h2\">",
"     Behavioral strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of clinical studies found that behavioral weight loss treatment, including a low or very low calorie diet and exercise, is the best option for obese patients who want to lose weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients in these studies lost about 3 to 5 kg, which represented 5 to 10 percent of initial body weight. Unfortunately, long-term maintenance of weight loss is rare. Behavioral strategies for weight loss are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Behavioral weight loss therapy, which does not specifically target binge eating, may nevertheless reduce binge eating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24\">",
"     24",
"    </a>",
"    ]. Behavioral weight loss therapy as a treatment to reduce binge eating is discussed separately. (See",
"    <a class=\"local\" href=\"#H376660\">",
"     'Behavioral weight loss therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13803232\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy provides modest short-term weight reduction in obese patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of eight randomized trials (1236 patients with BED) found that the average mean weight loss was significantly higher with medication compared with placebo (3.56 versus 0.08 kg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/51\">",
"     51",
"    </a>",
"    ]. However, this represented only 3.2 percent of baseline body weight. In addition, the studies lasted only 10 to 24 weeks, and there was no follow-up to assess maintenance of treatment gains. A second meta-analysis of six randomized trials (236 patients) found no significant effect for pharmacotherapy in weight reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical effect of pharmacotherapy for weight loss varies among different classes of medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/9,51\">",
"     9,51",
"    </a>",
"    ]. Drug therapy for obesity in general is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13803225\">",
"    <span class=\"h2\">",
"     Bariatric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery (gastric bypass or gastric banding) has been used to help obese patients with BED lose weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/10,60,61\">",
"     10,60,61",
"    </a>",
"    ]. Limited evidence suggests that binge eating at baseline does not affect postoperative weight loss. However, binge eating that occurs after bariatric surgery appears to be associated with poorer weight outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=see_link\">",
"     \"Medical management of patients after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13803218\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapy is ineffective for treating obesity in patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. Patients who stop binge eating with CBT typically show a statistically significant but clinically modest weight advantage compared with patients who continue to experience binge eating episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. IPT and DBT are also ineffective for weight loss in overweight or obese patients with BED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103242082\">",
"    <span class=\"h1\">",
"     ONLINE AND HARDCOPY RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice guidelines developed by the American Psychiatric Association list several relevant books, workbooks, and online resources available for clinicians and patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/22,62\">",
"     22,62",
"    </a>",
"    ]. In addition, treatment guidelines for BED have been developed by the United Kingdom National Institute for Health and Clinical Excellence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34841/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130122493\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binge eating disorder (BED) is marked by episodes of eating a large amount of food in a discrete period of time. These episodes are accompanied by a sense of disinhibition and lack of control over eating. Episodes of binge eating occur for two days per week on average, for at least six months. No regular use of inappropriate compensatory behaviors is seen. (See",
"      <a class=\"local\" href=\"#H130122329\">",
"       'Definition of binge-eating disorder (BED)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated lifetime prevalence of BED among women is 3.5 percent and among men 2.0 percent. BED is often comorbid with other psychopathology, including specific phobia, social phobia, unipolar major depression, post traumatic stress disorder, and alcohol abuse or dependence. The course of illness is chronic among many patients presenting for treatment. (See",
"      <a class=\"local\" href=\"#H103238672\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of the patient with BED should include the patient&rsquo;s psychiatric status (attitude toward body weight and shape, comorbid psychiatric disorders), medical status (focusing on overweight- and obesity-related comorbidities when appropriate), and nutritional status (lifetime weight and dieting history, current eating pattern, types of overeating). (See",
"      <a class=\"local\" href=\"#H118452871\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=see_link\">",
"       \"Screening for and clinical evaluation of obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with BED, we suggest psychotherapy rather than behavioral weight loss therapy or pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H130122373\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychotherapies that have demonstrated efficacy for treating BED include CBT, interpersonal therapy, and dialectical behavior therapy. For patients with BED, we suggest CBT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). CBT has been studied more often and also has the advantage that it has been adapted for use in self-help formats. (See",
"      <a class=\"local\" href=\"#H130122373\">",
"       'Psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For obese or overweight patients with BED who do not have access to psychotherapy, decline it, or do not respond to it, we suggest behavioral weight loss therapy (moderate caloric restriction, exercise, and improved nutrition) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Another reasonable alternative is pharmacotherapy with a selective serotonin reuptake inhibitor. (See",
"      <a class=\"local\" href=\"#H376660\">",
"       'Behavioral weight loss therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3060670\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.) Some patients treated with CBT may achieve only a partial response. When augmentation is desired, we suggest adding a selective serotonin reuptake inhibitors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H103239749\">",
"       'Combining CBT and pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For overweight or obese patients with BED who are primarily interested in losing weight, we suggest behavioral weight loss therapy rather than psychotherapy or pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Psychotherapy or pharmacotherapy may be offered to address persistent episodes of binge eating. (See",
"      <a class=\"local\" href=\"#H130122394\">",
"       'Treatment of obesity in patients with BED'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/1\">",
"      Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     Mehler, PS, Birmingham, LC, Crow, SJ, et al. Medical complications of eating disorders. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell JE (Eds), The Guilford Press, New York 2010. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/3\">",
"      STUNKARD AJ. Eating patterns and obesity. Psychiatr Q 1959; 33:284.",
"     </a>",
"    </li>",
"    <li>",
"     Bodell, LP, Devlin, MJ. Pharmacotherapy for binge-eating disorder. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.402.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC 2000. p.382.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/6\">",
"      Didie ER, Fitzgibbon M. Binge eating and psychological distress: is the degree of obesity a factor? Eat Behav 2005; 6:35.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization International Classification of Diseases (ICD), The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines file://www.who.int/classifications/icd/en (Accessed on October 29, 2010).",
"    </li>",
"    <li>",
"     Devlin, MJ. Binge-eating disorder and obesity. In: Binge-Eating Disorder: Clinical Foundations and Treatment, Mitchell, JE, de Zwaan, M, Peterson, CB, et al. (Eds) (Eds), Guilford Press, New York 2007. p.23.",
"    </li>",
"    <li>",
"     Bodell, LP, Devlin, MJ. Pharmacotherapy for binge-eating disorder. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), Guilford Press, New York 2009. p.402.",
"    </li>",
"    <li>",
"     de, Zwaan, M. Obesity treatment for binge-eating disorder in the obese. In: Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), Guilford Press, New York 2009. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/11\">",
"      Kessler RC, Berglund PA, Chiu WT, et al. The Prevalence and Correlates of Binge Eating Disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/12\">",
"      Reas DL, Grilo CM. Timing and sequence of the onset of overweight, dieting, and binge eating in overweight patients with binge eating disorder. Int J Eat Disord 2007; 40:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/13\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/14\">",
"      Pope HG Jr, Lalonde JK, Pindyck LJ, et al. Binge eating disorder: a stable syndrome. Am J Psychiatry 2006; 163:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/15\">",
"      Fichter MM, Quadflieg N, Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/16\">",
"      Wonderlich SA, Gordon KH, Mitchell JE, et al. The validity and clinical utility of binge eating disorder. Int J Eat Disord 2009; 42:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/17\">",
"      Vocks S, Tuschen-Caffier B, Pietrowsky R, et al. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord 2010; 43:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/18\">",
"      Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol 2007; 62:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/19\">",
"      Wilson GT, Shafran R. Eating disorders guidelines from NICE. Lancet 2005; 365:79.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Eating disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline 9. file://www.nice.org.uk/CG009 (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     Sanchez-Ortiz, VC, Schmidt, U. Self-help approaches for bulimia nervosa and binge-eating disorder. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/22\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/23\">",
"      Wilfley DE, Agras WS, Telch CF, et al. Group cognitive-behavioral therapy and group interpersonal psychotherapy for the nonpurging bulimic individual: a controlled comparison. J Consult Clin Psychol 1993; 61:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/24\">",
"      Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry 2010; 67:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/25\">",
"      Wilfley DE, Welch RR, Stein RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder. Arch Gen Psychiatry 2002; 59:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/26\">",
"      Devlin MJ, Goldfein JA, Petkova E, et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005; 13:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/27\">",
"      Grilo CM, Masheb RM. A randomized controlled comparison of guided self-help cognitive behavioral therapy and behavioral weight loss for binge eating disorder. Behav Res Ther 2005; 43:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/28\">",
"      Sysko R, Hildebrandt T, Wilson GT, et al. Heterogeneity moderates treatment response among patients with binge eating disorder. J Consult Clin Psychol 2010; 78:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/29\">",
"      Sysko R, Walsh BT. A critical evaluation of the efficacy of self-help interventions for the treatment of bulimia nervosa and binge-eating disorder. Int J Eat Disord 2008; 41:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/30\">",
"      Lynch FL, Striegel-Moore RH, Dickerson JF, et al. Cost-effectiveness of guided self-help treatment for recurrent binge eating. J Consult Clin Psychol 2010; 78:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/31\">",
"      Striegel-Moore RH, Wilson GT, DeBar L, et al. Cognitive behavioral guided self-help for the treatment of recurrent binge eating. J Consult Clin Psychol 2010; 78:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/32\">",
"      Peterson CB, Mitchell JE, Crow SJ, et al. The efficacy of self-help group treatment and therapist-led group treatment for binge eating disorder. Am J Psychiatry 2009; 166:1347.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson, GT. Cognitive behavior therapy for eating disorders. In: Handbook of eating disorders, Agras, WS (Eds), Oxford University Press, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/34\">",
"      Munsch S, Biedert E, Meyer A, et al. A randomized comparison of cognitive behavioral therapy and behavioral weight loss treatment for overweight individuals with binge eating disorder. Int J Eat Disord 2007; 40:102.",
"     </a>",
"    </li>",
"    <li>",
"     Interpersonal Psychotherapy for Group, Wilfley, DE, MacKenzie, KR, Welch, RR, et al (Eds), Basic Books, New York 2000.",
"    </li>",
"    <li>",
"     Tanofsky-Kraff, M, Wilfley, DE. Interpersonal psychotherapy for bulimia nervosa and binge-eating disorder. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/37\">",
"      Fairburn CG, Cooper Z, Doll HA, et al. Transdiagnostic cognitive-behavioral therapy for patients with eating disorders: a two-site trial with 60-week follow-up. Am J Psychiatry 2009; 166:311.",
"     </a>",
"    </li>",
"    <li>",
"     Chen, EY, Safer, DL. Dialectical behavior therapy for bulimia nervosa and binge-eating disorder. In: The Treatment of Eating Disorders, Grilo, CM, Mitchell, JE (Eds), The Guilford Press, New York 2010. p.294.",
"    </li>",
"    <li>",
"     Linehan, MM. Cognitive-behavioral treatment of borderline personality disorder, Guilford Press, New York 1993.",
"    </li>",
"    <li>",
"     Linehan, MM. Skills training manual for the treatment of borderline personality disorder, Guilford Press, New York 1993.",
"    </li>",
"    <li>",
"     Safer, DL, Telch, CF, Chen, EY. Dialectical Behavior Therapy for Binge Eating and Bulimia, Guilford Press, New York 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/42\">",
"      Telch CF. Skills training treatment for adaptive affect regulation in a woman with binge-eating disorder. Int J Eat Disord 1997; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     Wheelis, J. Theory and practice of dialectical behavioral therapy. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2009. p.727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/44\">",
"      Telch CF, Agras WS, Linehan MM. Dialectical behavior therapy for binge eating disorder. J Consult Clin Psychol 2001; 69:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/45\">",
"      Safer DL, Robinson AH, Jo B. Outcome from a randomized controlled trial of group therapy for binge eating disorder: comparing dialectical behavior therapy adapted for binge eating to an active comparison group therapy. Behav Ther 2010; 41:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/46\">",
"      Gorin AA, Le Grange D, Stone AA. Effectiveness of spouse involvement in cognitive behavioral therapy for binge eating disorder. Int J Eat Disord 2003; 33:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/47\">",
"      le Grange D, Crosby RD, Rathouz PJ, Leventhal BL. A randomized controlled comparison of family-based treatment and supportive psychotherapy for adolescent bulimia nervosa. Arch Gen Psychiatry 2007; 64:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/48\">",
"      Lock J, Agras WS, Bryson S, Kraemer HC. A comparison of short- and long-term family therapy for adolescent anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2005; 44:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/49\">",
"      Wildes JE, Marcus MD, Kalarchian MA, et al. Self-reported binge eating in severe pediatric obesity: impact on weight change in a randomized controlled trial of family-based treatment. Int J Obes (Lond) 2010; 34:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/50\">",
"      Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/51\">",
"      Reas DL, Grilo CM. Review and Meta-analysis of Pharmacotherapy for Binge-eating Disorder. Obesity (Silver Spring) 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/52\">",
"      Brambilla F, Samek L, Company M, et al. Multivariate therapeutic approach to binge-eating disorder: combined nutritional, psychological and pharmacological treatment. Int Clin Psychopharmacol 2009; 24:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/53\">",
"      Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/54\">",
"      Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001; 70:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/55\">",
"      Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry 2005; 57:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/56\">",
"      Curfman GD, Morrissey S, Drazen JM. Sibutramine--another flawed diet pill. N Engl J Med 2010; 363:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/57\">",
"      James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/58\">",
"      Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2005; 57:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/59\">",
"      Stunkard A, Berkowitz R, Tanrikut C, et al. d-fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996; 153:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34841/abstract/60\">",
"      Niego SH, Kofman MD, Weiss JJ, Geliebter A. Binge eating in the bariatric surgery population: a review of the literature. Int J Eat Disord 2007; 40:349.",
"     </a>",
"    </li>",
"    <li>",
"     Mitchell, JE, de, Zwaan, M, Peterson, CB, et, al. Binge-Eating Disorder and Bariatric Surgery. In: Binge-Eating Disorder: Clinical Foundations and Treatment, Guilford Press, New York 2007.",
"    </li>",
"    <li>",
"     www.psychiatryonline.com (Accessed on September 15, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14706 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34841=[""].join("\n");
var outline_f34_1_34841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H130122493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103238174\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130122329\">",
"      DEFINITION OF BINGE-EATING DISORDER (BED)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103238672\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118452871\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22437814\">",
"      Psychiatric status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22437822\">",
"      Medical status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22437830\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130122336\">",
"      TREATMENT PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130122345\">",
"      Treatment setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3060059\">",
"      Treatment team",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130122373\">",
"      PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3058077\">",
"      Cognitive-behavior therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H122508709\">",
"      - Evidence for efficacy of self-help CBT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36401440\">",
"      - CBT compared with other psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36401461\">",
"      - CBT compared with psychoactive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130122380\">",
"      Interpersonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130122387\">",
"      Dialectical behavior therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103240429\">",
"      Family therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H376660\">",
"      BEHAVIORAL WEIGHT LOSS THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060670\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7221395\">",
"      Specific medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103239749\">",
"      COMBINING CBT AND PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15040976\">",
"      Psychoactive medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15040991\">",
"      Antiobesity drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130122394\">",
"      TREATMENT OF OBESITY IN PATIENTS WITH BED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13803211\">",
"      Behavioral strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13803232\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13803225\">",
"      Bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13803218\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103242082\">",
"      ONLINE AND HARDCOPY RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130122493\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8646?source=related_link\">",
"      Binge-eating disorder: Cognitive-behavioral therapy (CBT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34842="Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease";
var content_f34_1_34842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/1/34842/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/1/34842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) is the result of an intricate immune response following allogeneic stimuli. GVHD, which can be acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic, occurs when T cells of the donor recognize the presence of histocompatibility antigens in the host that differ from those of the donor cells. This initial antigen recognition is followed by amplification of the T cell recognition process.",
"   </p>",
"   <p>",
"    The proliferation of activated T cells leads to the production and secretion of a variety of cytokines, which are responsible for the inflammatory effects and tissue damage associated with GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/1\">",
"     1",
"    </a>",
"    ]. Much of the damage is caused by inflammatory cytokines, such as interleukin (IL)-1, IL-2, tumor necrosis factor (TNF), and gamma-interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    have delineated the critical events that lead to the activation of these alloreactive T cells and the subsequent amplification of the signals involved in T cell proliferation. These laboratory studies have led to an understanding of the mechanisms of action of specific immunosuppressants. Further, such understanding allows for the development and testing of novel immunosuppressive agents.",
"   </p>",
"   <p>",
"    This topic review will focus on the most commonly used commercially available immunosuppressive drugs for prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of GVHD. Discussions of the pathogenesis, clinical manifestations, diagnosis, prevention, and treatment of acute and chronic GVHD are found elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NON-SPECIFIC IMMUNOSUPPRESSIVE DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are the most widely used \"front-line\" therapy for the treatment of clinical GVHD. Drugs of this class have been combined with other immunosuppressants in the prophylaxis against GVHD. However, we still do not fully understand their mechanism of action. This has resulted in empiricism in the development of therapeutic doses and anecdotal reports of efficacy in certain clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164641633\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly utilized corticosteroid is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , which differs from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    only by the addition of a 6-alpha-methyl group. The 6-alpha-methyl group blocks the specific binding of this corticosteroid to transcortin, the protein that transports steroids in the plasma. Instead, methylprednisolone is primarily bound to albumin. The frequent side effects from methylprednisolone may be dependent on the albumin level in the host.",
"   </p>",
"   <p>",
"    The lack of transcortin-binding leads to a larger partition coefficient, resulting in a significantly greater penetration of this agent into bronchial alveolar fluids, which may provide a therapeutic advantage for treatment of pulmonary inflammatory states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/3\">",
"     3",
"    </a>",
"    ]. The molecular mechanisms by which the corticosteroids exert their effects on the prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of GVHD are not clearly defined. One report emphasized the potential effect of corticosteroids on the release of cytokines, such as IL-2 and interferon-gamma, thought to be associated with the development of GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are data to suggest that the major effect of corticosteroids is the suppression of pro-inflammatory cytokines rather than direct cellular cytotoxicity against lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/4\">",
"     4",
"    </a>",
"    ]. In clinical trials that measured cytokines, the levels of tumor necrosis factor (TNF)-alpha decreased after the initiation of corticosteroids used for the therapy of GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164641640\">",
"    <span class=\"h3\">",
"     Clinical use and toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are given intravenously when used as",
"    <strong>",
"     prophylaxis",
"    </strong>",
"    for acute GVHD. The drug of choice has been",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , followed by oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    when patients are able to eat sufficiently so that one can be confident that they will absorb the medication without difficulty. The doses of methylprednisolone given for prophylaxis have varied, but an example of one such regimen is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"mobipreview.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/6\">",
"     6",
"    </a>",
"    ]. This regimen, which combines",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX), and prednisone (beginning after all MTX doses have been administered), is the most potent combination for the prevention of acute GVHD, resulting in only 9 percent grade II-IV acute GVHD in the best candidates (first remission of acute leukemia or first chronic phase of chronic myeloid leukemia) for allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    A prospective randomized study comparing the addition of steroids to the standard regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    did not demonstrate an improvement in the prevention of acute GVHD in patients with more advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/7\">",
"     7",
"    </a>",
"    ]. The usual corticosteroid dose for",
"    <strong>",
"     treatment",
"    </strong>",
"    of acute GVHD is 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered in divided doses with a very gradual taper. Occasionally, higher pulse doses up to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    have been used. Most regimens taper the steroid dose to zero by +180 days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many adverse effects associated with corticosteroids. In addition to their immunosuppressive effects, which set the stage for infectious complications, side effects include Cushingoid features, hyperglycemia, occasional psychosis or neurotoxicity, as well as myopathy. Other chronic effects include osteoporosis, cataract formation, and aseptic necrosis of bone. Corticosteroids are sensitive to a variety of drug interactions, specifically anti-convulsants, which may increase the total clearance of unbound corticosteroids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is an analog of aminopterin, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist introduced in 1948 for the treatment of acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/8\">",
"     8",
"    </a>",
"    ]. As an antimetabolite, it functions as a decoy substrate for critical biochemical reactions involving folic acid, with the ultimate outcome being cell death. The amino group substitution found in MTX results in a less potent antifolate, but a drug with a more predictable toxicity profile and equivalent clinical results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164641602\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the precise mechanism by which MTX prevents GVHD is not understood, it can induce tolerance following marrow transplantation. In canine transplantation, MTX given after grafting was effective in controlling GVHD and in inducing tolerance when donor and recipient were matched for the dog leukocyte antigen system, but when donor and recipient were mismatched, 7 of 10 dogs died of acute GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTX was one of the first chemotherapeutic agents introduced for the treatment of malignancies. Studies have detailed its pharmacokinetics and mechanisms of action at the intracellular level. How these mechanisms translate to its in vivo effects and how it functions in the prevention of GVHD, facilitation of engraftment, and induction of tolerance are not well understood.",
"   </p>",
"   <p>",
"    At the cellular level, MTX exerts its cytotoxic effect by inhibiting dihydrofolate reductase (DHFR), the intracellular enzyme responsible for converting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    to reduced folate co-factors. The reduced state of the folates, namely the tetrahydrofolates, is responsible for the transport of single carbon groups that are required for purine and thymidylate synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/10\">",
"     10",
"    </a>",
"    ]. Once the single carbon group is delivered, the oxidized folates must be converted back to tetrahydrofolates by DHFR. MTX binds to DHFR, thereby preventing its ability to reduce the oxidized folates to tetrahydrofolate and blocking further purine or thymidylate synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polyglutamate formation is also important to MTX metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/12\">",
"     12",
"    </a>",
"    ]. The intracellular formation of MTX polyglutamates is through the action of the enzyme folyl polyglutamate synthetase. These polyglutamate moieties appear to be as toxic to the enzyme DHFR as the native compound and are retained inside the cell, which leads to prolonged antifolate activity. Differences in intracellular concentrations within lymphocytes, as compared to other cell populations, may account for selective toxicities and may selectively inhibit certain subpopulations of cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164641609\">",
"    <span class=\"h3\">",
"     Toxicities and clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects of MTX when used for GVHD prophylaxis are renal, hepatic, and gastrointestinal toxicity. Commonly, patients may have an elevation in creatinine and bilirubin levels following the administration of MTX. As these are also the side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSP) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506), dose attenuation of MTX and CSP or FK506 may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Common toxicities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Full target doses of MTX may not be achievable in patients who already have grade III-IV mucositis resulting from the preparatory regimen, as well as from previous doses of MTX.",
"   </p>",
"   <p>",
"    The use of MTX following allogeneic HCT has been exclusively via the intravenous formulation. The drug doses administered have been relatively small, given the inability to dose escalate MTX significantly. MTX generally is administered IV on days +1, +3, +6 and +11 following HCT. Initial studies in Seattle tested MTX on a weekly basis up to day +100 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/14\">",
"     14",
"    </a>",
"    ]. Because of the toxicity of weekly administration of MTX, the dose was changed to four doses and combined with CSP (",
"    <a class=\"graphic graphic_table graphicRef60951 \" href=\"mobipreview.htm?8/19/8509\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/15\">",
"     15",
"    </a>",
"    ]. This schema is the most commonly utilized regimen today. Patients should be very well hydrated, and have their urine alkalinized with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ; MTX should not be administered until the urine pH is &ge;8.0. Patients should be assessed for the presence of ascites, pleural effusion, or any other fluid collection similar to any other patient receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . If there is a known fluid collection, patients should not receive methotrexate and a different immune suppressant could be used. Patients with known fluid collection and who receive methotrexate are at risk of developing complications, including acute renal failure. The prevention and management of methotrexate toxicity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\", section on 'Prevention and management of HDMTX toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dose attenuation should be considered for elevations of creatinine or bilirubin or the presence of grade III-IV mucositis. One suggested schema for dose attenuation of MTX is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef79917 \" href=\"mobipreview.htm?24/26/25004\">",
"     table 2",
"    </a>",
"    ). There has been one report of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue after MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/16\">",
"     16",
"    </a>",
"    ]. In this small series, use of leucovorin was not associated with an adverse outcome, although this practice is not commonly used. Leucovorin circumvents the blocked tetrahydrofolate synthesis by supplying reduced folates directly, therefore bypassing the metabolic block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SPECIFIC T CELL IMMUNOSUPPRESSIVE DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its potent immunosuppressive activity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSP) has led to a considerable expansion of the field of allogeneic transplantation. CSP was extracted in 1969 from two strains of fungi isolated from soil samples; it demonstrated only limited effects as an antifungal agent, but was highly effective as an immunosuppressive agent. These studies led to its being administered to patients in 1978 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSP is a neutral hydrophobic cyclic peptide composed of 11 amino acids. Over the past decade, much work has been devoted to understanding its mechanism of action. Moreover, CSP as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) has been used as a chemical probe to dissect the pathways of T cell activation. This understanding may lead to the generation of novel immunosuppressants, which may be more specific and potentially less toxic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152830127\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;While CSP and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are distinct in their molecular structure, their mechanism of action will be discussed together, since they are almost indistinguishable in their cellular functions. What is known thus far is that both agents block the calcium dependent signal transduction pathways distal to engagement of the T cell receptor (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"mobipreview.htm?17/21/17746\">",
"     figure 1",
"    </a>",
"    ). This block interrupts the activation of T cells, since the signaling from the T cell receptor is prevented. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Tacrolimus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In dissecting the signaling pathway, several critical intracellular molecules have been identified and include: calmodulin, calcineurin and the nuclear factor of activated T cells (NF-AT). The activation cascade includes calcium binding to calmodulin, which leads to binding calcineurin. The activated calcineurin may dephosphorylate the cytoplasmic unit of NF-AT which allows translocation of the NF-AT from the cytoplasm into the nucleus to form a competent transcriptional activator of the IL-2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytosolic binding protein for CSP was isolated in 1984 from lymphocytes and named cyclophilin for its high affinity for CSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/19\">",
"     19",
"    </a>",
"    ]. The analogous major isoform for the binding protein for FK506 has been termed FK binding protein (FKBP). Both cyclophilin and FKBP are highly basic and very abundant in the cytoplasm. Although these two proteins do not have sequence homology, they both function as the enzyme prolyl cis-trans isomerase (or rotamase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/20\">",
"     20",
"    </a>",
"    ]. Rotamase accelerates the conversion of cis- and trans-rotamers of proline-containing peptides or proteins. This conversion step is thought to be the rate-limiting step during normal protein folding.",
"   </p>",
"   <p>",
"    Both CSP and FK506 are potent inhibitors of rotamase activity. Their binding to these rotamases suggests that inhibition of this enzyme may be an important step leading to immunosuppression. The complex of drug and binding protein interrupts the activation cascade at the level of NF-AT dephosphorylation, and therefore, NF-AT is not able to enter the nuclear domain and activate IL-2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152830134\">",
"    <span class=\"h3\">",
"     Toxicities and clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    (CSP) is a highly lipophilic drug which is extensively metabolized with subsequent biliary, and to a lesser extent, urinary secretion. Over 15 metabolites have been isolated and identified. Some metabolites have immunosuppressive activity while others are nephrotoxic. Thus, the clinical efficacy and interactions between CSP and other drugs may be confounded by its metabolites. However, the most commonly reported inhibition or induction of CSP metabolism is by cytochrome p450 enzymes, specifically, HLp and PCN1 enzymes that are members of the cytochrome P450 IIIA gene family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/21\">",
"     21",
"    </a>",
"    ]. This interaction is important to keep in mind especially when patients are treated with antifungal medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , which may significantly increase CSP levels. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/26/420?source=see_link\">",
"     \"Isosulfan blue: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major clinical toxicities that need to be monitored with CSP administration are renal insufficiency and elevation of bilirubin levels (",
"    <a class=\"graphic graphic_table graphicRef79917 \" href=\"mobipreview.htm?24/26/25004\">",
"     table 2",
"    </a>",
"    ). Both complications appear to be dose-related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/22\">",
"     22",
"    </a>",
"    ]. The acute nephrotoxicity is due to vasoconstriction and ischemia of the afferent arterioles in the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/23\">",
"     23",
"    </a>",
"    ]. These acute changes are reversible but if continued for too long can lead to an irreversible interstitial injury with glomerular thrombosis, resulting in permanent azotemia. A major difficulty clinically is to differentiate specific side effects of the CSP from those of other drugs, such as amphotericin, MTX, aminoglycoside, or from an underlying disease process, such as GVHD itself. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other side effects that are commonly encountered are hypertension, hyperglycemia, headaches, and hirsutism. Rarer events that have been described include gum hypertrophy, brittle nails, acne, nausea and vomiting. One specific clinical concern is neurotoxicity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , which can be more prominent with hypomagnesemia and hypocholesterolemia. Potential mechanisms include vascular damage based on cyclosporine's effect on endothelial cell synthesis of prostaglandin, and release and uptake of endothelin. Reported adverse events involved all levels of the neuraxis including cortical blindness. Associated abnormalities include elevated cerebrospinal fluid protein and pleocytosis, various electroencephalographic abnormalities, and characteristic neuroimaging findings (central and extrapontine myelinolysis). In most patients these events were reversible with dosage reduction or withdrawal of therapy",
"   </p>",
"   <p>",
"    Hypertension alone can occasionally become a significant problem. Calcium channel blockers are the drugs of choice for such hypertension, since they are effective in this setting. However, their use may be associated with changes in CSP levels (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef50343 \" href=\"mobipreview.htm?3/10/3245\">",
"     table 3",
"    </a>",
"    ), which may require CSP dosing change. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link&amp;anchor=H19#H19\">",
"     \"Hypertension after renal transplantation\", section on 'Calcium channel blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSP can be administered either intravenously or orally. It is initially administered intravenously, since in the early phase following transplantation many patients develop mucositis and GI damage from the preparatory transplantation regimen, as well as from MTX given for GVHD prophylaxis. Once the patient is eating and drinking without significant difficulties, CSP may be switched to an oral preparation.",
"   </p>",
"   <p>",
"    CSP is available in solution, as well as in soft gelatin capsules. It is erratically and incompletely absorbed after oral administration, with many factors reported to influence oral CSP bioavailability. For example, food intake may have an impact in its absorption, especially if the meal is high in fat content. Absorption kinetics of CSP have been described as either zero order or a series of first order processes. CSP dosage usually is governed by research protocols, beginning the drug at a higher dose as a \"loading dose\", with a gradual taper over time. However there are several variations of dosing schedules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link&amp;anchor=H10#H10\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Absorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been several studies attempting to correlate the efficacy of prophylactic CSP with its level in either whole blood, plasma or serum. The only assay that is completely specific for the parent compound is high-pressure liquid chromatography (HPLC). All the other assays including polyclonal, monoclonal antibodies, and immunoassays, measure varying amounts of CSP metabolites. Therefore, the target level that one uses will vary, depending on which assay the diagnostic laboratory utilizes for measuring CSP levels. While the specific analytic methods are clearly more precise and preferable to the non-specific methods for therapeutic drug monitoring, the technical difficulties in current HPLC methods make it less practical to utilize HPLC widely.",
"   </p>",
"   <p>",
"    Moreover, there are limited data to suggest that there is a correlation between CSP levels and clinical outcome. Results from these studies suggest that there may be a complex relationship between dose, blood level, and occurrence of GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. These studies failed to demonstrate a clear direct correlation between drug level and occurrence of GVHD, and confirmed the intricate interactions and balance of the immune responses in the host.",
"   </p>",
"   <p>",
"    From a practical standpoint, CSP is administered to achieve a therapeutic level, but beyond that, it is important to deliver the planned dose as per protocol. It is also important to be certain that the level drawn is a trough level and is obtained under steady state conditions, otherwise the values will not be interpretable. CSP levels are used to increase the dose if they are below the therapeutic threshold, but the dose is not decreased for elevated levels if no toxicity is present. However, if the level is above two times the upper limit of the therapeutic range, then it is reasonable to decrease the dose to avoid potential neurotoxicity (ie, seizures). Therefore, there is a range where CSP levels do not result in any change in clinical management. There are also concerns about the possible interactions between CSP and other medications. Many different drugs have been implicated in increasing or decreasing CSP levels in patients (",
"    <a class=\"graphic graphic_table graphicRef50343 \" href=\"mobipreview.htm?3/10/3245\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/26/420?source=see_link\">",
"     \"Isosulfan blue: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) is a macrolide antibiotic extracted from the soil fungus streptomyces tsukubaensis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/27\">",
"     27",
"    </a>",
"    ]. It is completely different from the cyclic peptide CSP, but it does exhibit a very similar selective immunosuppressive activity. Its mechanism of action is also through the inhibition of signaling through the T cell receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165959725\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;FK506 is highly lipophilic, and its method of administration is similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSP). Its mechanism of action has been reviewed in the section immediately above describing CSP. It is generally given intravenously in the early phases following allogeneic transplantation and then switched to the oral formulation. There is rapid distribution of the drug to the extracellular space after a short intravenous infusion. (See",
"    <a class=\"local\" href=\"#H152830127\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165959732\">",
"    <span class=\"h3\">",
"     Clinical use and toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following oral administration, FK506 is erratically and incompletely absorbed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The major difference from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (CSP) is that the absorption of FK506 does not seem to depend on the presence of bile salts. FK506 undergoes extensive distribution, with the highest levels found in the lung, kidney, heart, and spleen, while in the blood, it is distributed into red blood cells. Less than 1 percent of the intravenous or oral dose appears unchanged in the urine, indicating that the drug is almost completely metabolized in the liver prior to its elimination. It is metabolized primarily through monodemethylation, demethylation, and hydroxylation. The half-life of FK506 is approximately nine hours, and is longer in those patients who have hepatic dysfunction. FK506 is monitored in a similar fashion to CSP. Appropriate doses and levels of FK506 have not yet been well defined in patients undergoing allogeneic HCT.",
"   </p>",
"   <p>",
"    FK506 is moderately well tolerated in humans. Most of the data on adverse events can be categorized as neurotoxicity, renal toxicity, and hyperglycemia and generally have been reported in solid organ transplantation recipients. FK506 can cause an increase in serum creatinine concentration similar to that of CSP, probably secondary to decrease in glomerular filtration. Hypertension in previously normotensive patients has also been described. Occasionally hypertension can be quite refractory to antihypertensive medication. The most commonly utilized anti-hypertensives, as with CSP, have included the calcium channel blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central nervous system (CNS) effects have also been found, including headaches, tremors, paresthesias, photophobia, mental status changes, and coma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/30\">",
"     30",
"    </a>",
"    ]. Other findings include pulmonary symptoms such as dyspnea, musculoskeletal pain, itching, gastrointestinal complaints (including anorexia, nausea, vomiting, abdominal pains), and fatigue. While the adverse effects of CSP and FK506 appear to be similar, there may be some advantage of FK506 in hypertensive patients. Hyperkalemia has also been observed following FK506 administration. The use of both CSP and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    has been associated with thrombotic thrombocytopenic purpura. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link&amp;anchor=H112795998#H112795998\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Immunosuppressive agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical use of FK506 has been studied. Several phase II trials have been conducted using FK506 along with MTX for the prevention of acute GVHD, with encouraging results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. A large phase III study in patients with matched related donor transplantation has suggested that the use of FK506 results in a lower incidence of acute GVHD, although there was no impact on overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/34\">",
"     34",
"    </a>",
"    ]. There are no comparisons of CSP to FK506 in the allogeneic HCT literature, while comparisons in the solid organ literature suggest that the efficacy and toxicity profiles of FK506 are similar to CSP, with perhaps less hypertension with FK506 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are reports in the solid organ literature suggesting that FK506 is an effective salvage drug for patients who have failed CSP prophylaxis of organ rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Similar anecdotal observations have been made for allogeneic HCT, but the experience is still limited.",
"   </p>",
"   <p>",
"    The method of administration and dose schedules for FK506 follow those developed for CSP. The doses used in GVHD prophylaxis trials begin at 0.03-0.04",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as a continuous infusion. When patients are able to sustain near normal oral food and fluid intake, the drug is given orally at a dose of 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day administered in two divided doses. The target trough range for FK506 has been 10-30",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (rapamycin) is a lipophilic macrolide that was identified more than 20 years ago during an antibiotic screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/38\">",
"     38",
"    </a>",
"    ]. This molecule is produced by a strain of streptomyces hygroscopicus isolated from a soil sample from Easter Island (Rapa Nui). Although lacking antibacterial activity, it inhibited yeast growth and growth of filamentous fungi.",
"   </p>",
"   <p>",
"    The first demonstration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ' immunosuppressive activity was obtained from studies demonstrating the inhibition of IgE production as well as its efficacy in experimental allergic encephalomyelitis and adjuvant arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/39\">",
"     39",
"    </a>",
"    ]. Interest in sirolimus as an immunosuppressive agent coincided with discovery of the immunosuppressive activity of FK 506, since the structure of both of these molecules contained a distinctive hemiketal-masked a,b-diketopipecolic acid amidic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    for GVHD prophylaxis improved overall survival and decreased the risk of disease progression in lymphoma patients undergoing reduced-intensity transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/41\">",
"     41",
"    </a>",
"    ]. Prospective studies employing this intriguing observation are underway.",
"   </p>",
"   <p>",
"    This agent is not currently approved by the FDA for use against GVHD, but is approved for prophylaxis of organ rejection in renal transplant patients in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    binds to the same family of intracellular receptors as FK506, termed FK506 binding proteins (FKBPs). Similar to FK506, sirolimus has two domains, a domain bound by FKBP and an effector domain forming a composite surface that interacts with the mammalian target of sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/42\">",
"     42",
"    </a>",
"    ]. The intracellular target of sirolimus or FK506 has been termed the mammalian target of sirolimus (mTOR), which is ubiquitously expressed in human tissue, with the highest levels found in the testes and skeletal muscle.",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and FK506 bind to the same family of intracellular binding proteins, their mechanisms of immunosuppression are clearly distinct. Sirolimus inhibits the growth of hematopoietic and lymphoid cells in vitro. The most striking observation is that it suppresses cytokine-driven growth of these cells. The data demonstrate a significant increase in the proportion of G1 phase cells when sirolimus is added [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/43\">",
"     43",
"    </a>",
"    ]. The mechanism of action of sirolimus is to inhibit specifically the progression of cells from G1 into the S phase, suggesting that it may interfere with the signaling that is critical for the cyclin-cdk complex required for cellular proliferation (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"mobipreview.htm?17/21/17746\">",
"     figure 1",
"    </a>",
"    ). Data using human peripheral blood T cells demonstrate that the block of G1 may be related to an increase in a species of titratable inhibitor of G1 cyclin-cdk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to regulation of the cell cycle,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may also exert an effect on signal transduction pathways which mediate specific cytokine responses. For example, sirolimus has been shown to inhibit IL-1 driven gamma-interferon production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/45\">",
"     45",
"    </a>",
"    ]. Moreover, the secondary signals required for T cell activation and proliferation are dependent on ligation of the B7 family with CD28. Lack of the secondary signal has been shown to result in anergy in the responding T cell. While the signaling through the T cell receptor is not affected by sirolimus, the signaling through CD28 is inhibited by sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/46\">",
"     46",
"    </a>",
"    ]. These data suggest that the major effect of sirolimus is via the CD28 signaling pathway, distinct from either CSP or FK506.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from animal observations and solid organ transplantation suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    is toxic to the GI system, including elevation of liver function tests and diarrhea. In contrast to the renal side effects which are common with CSP and FK506, nephrotoxicity is rarely encountered with sirolimus. Other problems include hypertriglyceridemia, a decrease in platelets and leukocytes, epistaxis, blood pressure changes, headaches, nausea, mucous membrane irritation, and infections. Adverse reactions previously observed with other macrolide antibiotics are also of concern. Testicular atrophy has been observed in both mice and non-human primates. These early observations suggest that liver function abnormalities, thrombocytopenia, and neutropenia may be its dose limiting toxicity.",
"   </p>",
"   <p>",
"    A pilot trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as second-line therapy was conducted in 21 patients who had failed treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for acute GVHD following allogeneic hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/47\">",
"     47",
"    </a>",
"    ]. There were five complete and seven partial remissions. Toxicity included increased triglycerides and cholesterol, thrombocytopenia, and neutropenia. Five patients had evidence of hemolytic uremic syndrome concurrent with or after use of this agent.",
"   </p>",
"   <p>",
"    A more definitive study assessed the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    after myeloablative allogeneic HCT from 53 matched related donors (MRDs) and 30 unrelated donors (URDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/48\">",
"     48",
"    </a>",
"    ]. This combination is of great interest in that it avoids the use of methotrexate and its inherent toxicity. The incidences of grade II-IV and III-IV acute GVHD were 20.5 and 4.8 percent, respectively, with a cumulative incidence of chronic GVHD of 59 percent. There were no differences in the incidences of acute or chronic GVHD between MRD and URD cohorts.",
"   </p>",
"   <p>",
"    The omission of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was associated with low transplant-related toxicity, with 30-day and 100-day treatment-related mortality rates of zero and 4.8 percent, respectively, although there was some concern regarding possible veno-occlusive disease of the liver. Relapse-free survivals at one and two years were 72 and 68 percent, respectively, with overall survival at one and two years of 77 and 72 percent, respectively. There were no differences in relapse-free or overall survival between MRD and URD cohorts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    Mofetil (MMF, CellCept&reg;) is a morpholinoethyl ester of mycophenolic acid (MPA). The sodium salt of mycophenolate is also available (Myfortic&reg;). Mycophenolate is produced by several species of Penicillium molds and possesses antibacterial, antifungal, antiviral, antitumor and immunosuppressive properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. MMF's immunosuppressive activity occurs after hydrolysis to MPA. Although MPA is the active moiety, it is formulated as MMF to enhance its bioavailability. Its use in preventing rejection following renal transplantation is discussed separately as is its use in the rheumatic diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link&amp;anchor=H18#H18\">",
"     \"Acute renal allograft rejection: Treatment\", section on 'Mycophenolate mofetil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of MMF following HCT remains to be defined, although this drug appears to be uniquely synergistic with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in its ability to enhance engraftment following nonmyeloablative preparatory regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/51\">",
"     51",
"    </a>",
"    ]. In the solid organ transplantation literature, MMF has been used as a steroid-sparing agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purines are essential for the growth and survival of cells. Cells have two pathways to produce purines, a de novo and a salvage pathway. Lymphocytes are highly dependent on de novo synthesis, while other cells can utilize both pathways. The therapeutic index of MMF depends on the lymphocyte's reliance on de novo synthesis of purines, allowing for greater immunosuppressive activity with less toxicity.",
"   </p>",
"   <p>",
"    In the de novo pathway, the ribose phosphate portion of the purine nucleotide is derived from 5-phosphoribosyl-1-pyrophosphate. This 5-phosphoribosyl-1-pyrophosphate is formed from adenosine triphosphate and the sugar ribose-5-phosphate. Therefore, 5-phosphoribosyl-1-pyrophosphate is an essential intermediary in the synthesis of purines. Following lymphocyte stimulation, there is a brisk and sustained increase in 5-phosphoribosyl-1-pyrophosphate and guanosines and deoxyguanosines, which activate 5-phosphoribosyl-1-pyrophosphate synthetase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depletion of guanosines would lead to a decrease in 5-phosphoribosyl-1-pyrophosphate synthetase and inhibition of the purine synthesis which is required for T cell activation. MPA's action is through the inhibition of inosine monophosphate dehydrogenase (IMPDH). This enzyme catalyzes oxidation of inosine monophosphate to xanthine monophosphate, a required intermediate in the synthesis of guanosine triphosphate. The enzyme IMPDH is a critical enzyme for the de novo biosynthesis of purine nucleotides, specifically guanosine monophosphate (GMP). Blockade of GMP synthesis leads to a negative feedback inhibition of 5-phosphoribosyl-1-pyrophosphate and prevention of T cell activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of note, MMF does not seem to deplete GTP in neutrophils in contrast to lymphocytes and monocytes. Its selective action on lymphocytes seems to spare the higher risk of acute infections. MMF has been administered in the allograft setting using 1 gram orally twice daily and can be increased up to 1.5 gram twice daily.",
"   </p>",
"   <p>",
"    The major side effect of MMF has been suppression of the hematopoietic system with neutropenia. Gastrointestinal side effects have also been reported occasionally. Doses up to 1.5 gram twice daily had no nephrotoxicity, myelosuppression, or other serious side effects in patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/53\">",
"     53",
"    </a>",
"    ]. MMF is listed as a category D drug (positive evidence of risk) for use in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H18#H18\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of MMF has also been associated with progressive multifocal leukoencephalopathy (PML), and a \"black box\"",
"    <a class=\"external\" href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm\">",
"     warning",
"    </a>",
"    to this effect has been issued by the United States FDA&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methods for monitoring drug levels of MMF are available, although it is not yet clear as to how these tests should be utilized. One study demonstrated that the median bioavailability of MMF was 72 percent, with eightfold variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/55\">",
"     55",
"    </a>",
"    ]. There is also the suggestion from this study that three times daily dosing may be more advantageous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many antibodies have been used for the prevention and treatment of GVHD. Most of the promising data have come from studies using selected monoclonal antibodies directed at specific epitopes. However, these antibodies are generally not available and most of the studies have involved small groups of patients. The following antibodies will be discussed here: OKT3, antithymocyte globulin (ATG), intravenous immunoglobulin (IGIV, IVIG),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Muromonab-CD3 (OKT3)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muromonab-CD3 (OKT3, Orthoclone&reg; OKT3) is a monoclonal mouse antibody licensed for the therapy of allograft rejection. This antibody has been used to treat GVHD, but because it is a T cell mitogen, the results have not been uniformly successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. However, OKT3 has been used as an adjunct to the preparatory regimen given before HCT as a method to enhance engraftment, as well a supplementary agent to be used after HCT for the prevention of GVHD.",
"   </p>",
"   <p>",
"    The long-term efficacy of OKT3 in the treatment of acute GVHD has not been established. Furthermore, the dose-limiting side effects resulting from T cell activation and the high incidence of infection have discouraged further use of this antibody. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'OKT3 and anti-CD3 antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A \"humanized\" OKT3 is available, which does not activate T cells and which retains significant immunosuppressive properties. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44135?source=see_link&amp;anchor=H14#H14\">",
"     \"Investigational immunosuppressive drugs and approaches in clinical kidney transplantation\", section on 'Humanized OKT3'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antithymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithymocyte globulin (ATG) is a polyclonal immunoglobulin prepared by injecting various cellular preparations into animals. One product uses thymocytes injected into horses, while a second uses rabbits. A third product uses Jurkat cells (a T cell line) as the antigen. The antibodies thus produced are capable of destroying human leukocytes to varying degrees. Since the antigens employed are quite varied, the list of antibodies against all the antigens present on thymocytes is quite broad and the immune effects can be extensive.",
"   </p>",
"   <p>",
"    For the horse antibody the process of generating this product is inconsistent (ie, different horses, different pooled lymphocytes, different dominant responses). Accordingly, it is difficult to determine pharmacokinetics and efficacy, because of significant lot-to-lot and animal-to-animal variabilities. The rabbit product appears to suffer less from lot-to-lot variations. While the measurable half-life of the antibody is approximately nine hours, the functional half-life is not known.",
"   </p>",
"   <p>",
"    ATG has been used as part of the preparatory regimen prior to infusion of the donor cells to decrease the incidence of graft rejection, or following HCT to prevent or ameliorate GVHD. The addition of ATG to other GVHD prophylaxis regimens decreases the rate of acute GVHD, but has not demonstrated a survival benefit. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42041?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Antithymocyte globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Doses of horse ATG have varied widely, but are generally in the range of 10-30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, while the rabbit ATG dose is about one-half of the horse ATG dose. Since ATG is both a foreign xenogeneic protein and an antibody, serum sickness can occur after its use. Corticosteroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , H1 and H2 blockers are frequently used to prevent or treat the symptoms associated with the infusion of ATG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Antithymocyte globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are known to be allergic to horse proteins, ATG derived from a different animal may be used (eg, rabbits). The use of ATG after HCT has been associated with an increase in post-transplant lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31738?source=see_link&amp;anchor=H16930159#H16930159\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyclonal human immunoglobulins purified and sterilized from pooled serum have been used to manipulate the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/60\">",
"     60",
"    </a>",
"    ]. There are many preparations of intravenous immunoglobulin (IGIV) with different titers of anti-cytomegalovirus activity (eg, Cytogam&reg;). To date there are no known clinical differences with the use of any of these commercial preparations. Occasionally, one preparation may be preferable to another based on the need to conserve the total volume that a patient receives.",
"   </p>",
"   <p>",
"    Initial studies focused on the use of IGIV to prevent infectious complications following HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, in a large randomized trial of IGIV, this product was also associated with a decrease in the incidence of GVHD, especially in HCT recipients under the age of 20 years. Moreover, there was a decrease in the overall mortality in favor of those who had received IGIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/62\">",
"     62",
"    </a>",
"    ]. While this agent is effective in the early phase following HCT, its prolonged use, in the absence of hypogammaglobulinemia after day +100, does not reduce late complications or chronic GVHD and may be associated with impairment of humoral immune recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42041?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy\", section on 'Intravenous immune globulin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link&amp;anchor=H7#H7\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Antibacterial prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=see_link&amp;anchor=H598240#H598240\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Prevention of infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14398623\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H) is a humanized anti-CD52 monoclonal antibody that is approved for treatment of chronic lymphocytic leukemia. Alemtuzumab results in depletion of both B and T cells. As such, it has been studied as a method of in vivo T cell depletion in an attempt to decrease GVHD. Most studies of alemtuzumab in this setting have been performed in children.",
"   </p>",
"   <p>",
"    As an example, a retrospective study analyzed the effect of in vivo T cell depletion in children with acute lymphoblastic leukemia who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (132 patients), ATG (191 patients), or no in vivo T cell depletion (392 patients) prior to allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/64\">",
"     64",
"    </a>",
"    ]. When compared with those who did not receive T cell depletion, patients treated with alemtuzumab had lower rates of grade 2 to 4 acute GVHD (Hazard Ratio [HR] 0.24; 95% CI 0.16-0.36) and chronic GVHD (HR 0.21; 95% CI 0.13-0.34). Patients treated with ATG also had lower rates of GVHD. All three groups had similar estimated rates of relapse, non-relapse mortality, overall survival, and leukemia-free survival at three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8565127\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies are investigating the use of the anti-CD20 monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , in an attempt to decrease allogeneic donor B cell immunity and, potentially, associated chronic GVHD. While initial results demonstrate decreased B cell immunity and low rates of chronic GVHD, this approach remains experimental. Randomized trials are needed to determine the efficacy and toxicity of rituximab in this setting, including the effect on long-term B cell function.",
"   </p>",
"   <p>",
"    As an example, in a single center prospective study, 22 patients with high-risk chronic lymphocytic leukemia and 13 patients with mantle cell lymphoma were treated with total lymphoid irradiation (80 cGy for 10 days) and antithymocyte globulin (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for five days) followed by allogeneic HCT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on days 56, 63, 70, and 77 post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/65\">",
"     65",
"    </a>",
"    ]. Studies on a subset of patients demonstrated reduced B cell allogeneic immunity. The cumulative incidences of acute GVHD, chronic GVHD, and non-relapse mortality were 6, 20, and 3 percent, respectively.",
"   </p>",
"   <p>",
"    Further studies are needed to evaluate the efficacy of this approach in patients with B-cell lymphoproliferative disorders and other disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THALIDOMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    was first synthesized in 1954. The antihistaminic properties for which it was initially synthesized were weak, but it produced significant sedation in animals leading to its clinical use as a sedative. Its use was widespread until the observation of increased limb malformations was reported in Germany and neighboring countries, which led to the withdrawal of the drug because of the well known features of phycomelia.",
"   </p>",
"   <p>",
"    The first indication for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    following HCT came from animal studies done in 1966 in which allogeneic HCT recipients treated with thalidomide had a splenic weight that was lower than those who received placebo, and demonstrating that GVHD activity was decreased by the addition of thalidomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/66\">",
"     66",
"    </a>",
"    ]. Thalidomide should be considered more as an immunomodulator, since it lacks a global inhibitory effect upon lymphocyte proliferation and does not impair delayed type hypersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is a racemic mixture in which both enantiomers undergo racemization with a relatively fast velocity under physiologic conditions. There are data to suggest that the S-form may be the major enantiomer associated with the immune effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/67\">",
"     67",
"    </a>",
"    ]. Thalidomide is poorly water-soluble and is not well absorbed when given orally. About 40 percent of the oral dose is renally excreted as hydrolysis products.",
"   </p>",
"   <p>",
"    The intracellular activities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    are not well understood. The observation of its teratogenic effect led to the suggestion that inhibition of angiogenesis led to the defect of limb bud formation. There has been keen interest to understand thalidomide&rsquo;s interaction with angiogenesis as well as its interaction with vascular or endothelial adhesion molecules. For example, upregulation of the adhesion molecules E-Selectin and VCAM is inhibited by high concentrations of thalidomide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/68\">",
"     68",
"    </a>",
"    ]. Effects on these molecules may be one mechanism of action by which thalidomide leads to immunosuppression. For example, interference with adhesion of T cells to antigen presenting cells or proper T cell migration and trafficking may result in a delay or prevention of T cell responses. Thalidomide analogs may bind with high avidity to macrophages as well as CD4 and CD8 cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    is not known, its effects are clearly distinct from those of steroids, CSP, and the macrolide immunosuppressants. They also differ from phosphodiesterase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , inhibitors of arachidonic acid synthesis, nucleotide analogs, or natural products, such as mycophenolic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in its use following HCT are dose related and include sedation and constipation. Many of these side effects improve with continued use of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/69\">",
"     69",
"    </a>",
"    ]. In a study of 80 patients with steroid-resistant chronic GVHD at Stanford University and City of Hope National Medical Center, the toxicities of thalidomide included: sedation (40 percent),",
"    <span class=\"nowrap\">",
"     constipation/nausea",
"    </span>",
"    (30 percent), neutropenia or thrombocytopenia (18 percent), new skin rash (16 percent), and neuritis (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/70\">",
"     70",
"    </a>",
"    ]. The primary reasons for discontinuation of the drug were neuropathy and neutropenia, although occasionally sedation and GI symptoms were severe enough to warrant discontinuation. Infectious complications were not a common finding in this group of patients, suggesting that there was not clinically relevant immunosuppression resulting from administration of this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has primarily been used for the treatment of chronic GVHD, with a response rate ranging from 20 to 60 percent, depending on the timing and the patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Because the drug is available only as an oral formulation, it has not been tried systematically in the therapy of acute GVHD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of chronic graft-versus-host disease\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of the drug has not been well defined. Correlative studies have suggested that up to 1.6 grams of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in divided doses is necessary to achieve the equivalent serum levels found in the rodent system to obtain an effect on GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/71\">",
"     71",
"    </a>",
"    ]. Thalidomide is usually started at a dose of 100 mg twice daily and escalated gradually by doubling the dose every four to seven days to achieve a daily dose of 800 to 1600 mg, based on patient tolerability and acceptance. In the treatment study, the median dose of thalidomide was 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses. If the patient responded and improved, the drug was maintained for 6 to 12 months and then gradually tapered. If a patient's GVHD flared, the drug was increased back to the prior level. Use of a laxative is helpful, and often one dose of thalidomide can be taken prior to bedtime to take advantage of its sedative effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has also been tested for",
"    <strong>",
"     prevention",
"    </strong>",
"    of chronic GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/72\">",
"     72",
"    </a>",
"    ]. The rationale was that perhaps a lower dose of a drug that was effective in the treatment of chronic GVHD would be effective in preventing the occurrence of chronic GVHD. In one study, patients were randomized to receive either placebo or thalidomide (200 mg PO twice daily) beginning 80 days following allogeneic HCT. Fifty-three evaluable patients were analyzed, 26 patients received placebo and 27 patients received thalidomide. Following the first interim analysis using intent to treat parameters, patients receiving thalidomide developed more chronic GVHD compared with patients receiving placebo (p = 0.05). Moreover, there was an advantage of overall survival for patients receiving placebo compared with those receiving thalidomide (p = 0.005). Thalidomide treatment appeared to effect a shift in the balance between GVHD and induction of tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HYDROXYCHLOROQUINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is a 4-amino-quinoline that is trophic for the lysosome. It is well tolerated and has been used for decades as a treatment for malaria. It has also been used to treat autoimmune diseases, specifically for decreasing the use of glucocorticoids.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    , which differs from hydroxychloroquine by a single hydroxyl group, had previously been demonstrated in preclinical studies to be effective in the prevention of GVHD.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has been used for the treatment of chronic GVHD. In a phase II trial of 40 patients with steroid-resistant or steroid-dependent chronic GVHD, three complete responses and 14 partial responses were seen in 32 evaluable patients (53 percent response rate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/73\">",
"     73",
"    </a>",
"    ]. All responders tolerated at least a 50 percent reduction of their steroid dose. There was no hematologic, hepatic, renal, or retinal toxicity.",
"   </p>",
"   <p>",
"    However, in a subsequent phase III trial, 95 recipients of allogeneic peripheral blood stem cell transplantation, all of whom received prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A (CSA), were randomly assigned to also receive either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or placebo starting 21 days pretransplant and continued until day +365 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/74\">",
"     74",
"    </a>",
"    ]. While the drug was well tolerated, addition of hydroxychloroquine to single-agent CSA had no effect on acute GVHD, chronic GVHD, or survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is a weak base that raises the lysosomal and endosomal pH and interferes with antigen processing and antigen presentation through the major histocompatibility complex (MHC) class II molecules. Under this mechanism, exogenous proteins are taken up and processed through the lysosomal and endosomal compartments before peptides are placed onto the MHC groove. By interfering with this process, antigen presentation is affected. Moreover, there appears to be synergy with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in in vitro studies of T cell responses to endogenous antigens. Hydroxychloroquine also reduces the production of inflammatory cytokines such as IL-1, IL-6 and TNF-alpha. The drug is rapidly and completely absorbed, and approximately 55 percent of the drug is protein-bound. It is metabolized by the liver and excreted through the urine, with an elimination half-life of 32 to 50 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects are visual disturbances with difficulty of accommodation, blurred vision, photophobia, and retinopathy. Other central nervous system changes such as nervousness and ataxia may also be experienced. Another toxicity is a neuromyopathy, leading to progressive weakness and atrophy of proximal muscle groups. It is important to separate the side effects of the drug from the symptoms of GVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NOVEL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anti-cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the major factors implicated in the evolution of GVHD have been TNF-alpha, IL-1 and gamma-interferon. Use of a polyclonal neutralizing antibody against TNF-alpha resulted in a 70 percent reduction in GVHD-associated mortality and also in diminished lesions in the skin and the intestines in an experimental model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/75\">",
"     75",
"    </a>",
"    ]. Similar findings were observed using a neutralizing antibody against murine TNF with reduction of splenomegaly in GVHD models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/76\">",
"     76",
"    </a>",
"    ]. Higher TNF levels have also been described in patients who develop GVHD, although this finding has not been universally observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results using the TNF alpha inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    suggest that this agent, when combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , was effective as initial therapy for acute GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Induction of anergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data generated from studies of T cell activation have clearly demonstrated that there is a critical need for a second costimulatory signal for a positive immune response. Lack of secondary signals results in specific T cell anergy. CTLA4-Ig (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ) is a fusion protein designed in an attempt to prevent the costimulation signals. Variable results have been observed using the abatacept to block GVHD across major histocompatibility barriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/79\">",
"     79",
"    </a>",
"    ]. These results may be variable according to the model of GVHD selected (ie, major histocompatibility differences) or the activation state of T cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=see_link&amp;anchor=H12#H12\">",
"     \"Transplantation immunobiology\", section on 'T-cell costimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Methods to block costimulation hold significant promise in achieving antigen specific unresponsiveness or anergy and therefore a state of tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Such new approaches may circumvent the need for prolonged immunosuppression after HCT and may be clinically beneficial for patients who require an allogeneic HCT. Initial clinical studies utilizing this approach appear promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because GVHD and solid organ rejection remain such a difficult clinical problem, there is a need for continued efforts to develop novel immunosuppressive or immunomodulatory agents. Other drugs or non-pharmacological treatment options that appear to be promising include clofazimine, psoralen and ultraviolet light A (PUVA), photopheresis, radiation therapy, and novel molecules such as a fusion immunotoxin directed against CD3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/1/34842/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of acute graft-versus-host disease: Clinical trials\", section on 'Anti-CD3 and anti-CD5 immunotoxins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152829970\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. The pathogenesis of GVHD is a complex, multistep process, but is primarily a T cell mediated process. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=see_link\">",
"       \"Pathogenesis of graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic agents used for the prevention and treatment of GVHD include non-specific immunosuppressive drugs, such as corticosteroids and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , as well as more specific T cell immunosuppressive drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      GVHD prophylaxis is typically administered as a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and a calcineurin inhibitor (",
"      <a class=\"graphic graphic_table graphicRef60951 \" href=\"mobipreview.htm?8/19/8509\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=see_link\">",
"       \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Four doses of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) are commonly used for the prevention of GVHD. Prior to each dose, patients should be very well hydrated, and have their urine alkalinized with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      ; MTX should not be administered until the urine pH is &ge;8.0. Dose attenuation should be considered for elevations of creatinine or bilirubin or the presence of grade III-IV mucositis (",
"      <a class=\"graphic graphic_table graphicRef79917 \" href=\"mobipreview.htm?24/26/25004\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is initially administered intravenously, followed by an oral formulation when patients are able to eat sufficiently. Cyclosporine trough levels are used to increase the dose if they are below the therapeutic threshold, but the dose is not decreased for elevated levels if no toxicity is present unless the level is above two times the upper limit of the therapeutic range. Many different drugs have been implicated in increasing or decreasing cyclosporine levels in patients (",
"      <a class=\"graphic graphic_table graphicRef50343 \" href=\"mobipreview.htm?3/10/3245\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids are the most widely used \"front-line\" therapy for the treatment of clinical GVHD, commonly administered in combination with therapeutic doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (FK506). Like cyclosporine, dosing of FK506 is adjusted based upon trough levels. Patients with chronic GVHD who fail to improve with these agents may benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Tacrolimus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Thalidomide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of chronic graft-versus-host disease\", section on 'Treatment approaches'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/1\">",
"      Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/2\">",
"      Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/3\">",
"      Oosterhuis B, ten Berge IJ, Schellekens PT, et al. Prednisolone concentration-effect relations in humans and the influence of plasma hydrocortisone. J Pharmacol Exp Ther 1986; 239:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/4\">",
"      Almawi WY, Lipman ML, Stevens AC, et al. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991; 146:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/5\">",
"      Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD--TNF-antibodies and related antagonists. Bone Marrow Transplant 1993; 12 Suppl 3:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/6\">",
"      Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/7\">",
"      Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000; 6:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/8\">",
"      Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/9\">",
"      Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/10\">",
"      Zaharko DS, Fung WP, Yang KH. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 1977; 37:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/11\">",
"      Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/12\">",
"      Schilsky RL, Bailey BD, Chabner BA. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A 1980; 77:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/13\">",
"      Fabre G, Goldman ID. Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro. Cancer Res 1985; 45:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/14\">",
"      Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/15\">",
"      Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/16\">",
"      Nevill TJ, Tirgan MH, Deeg HJ, et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     Borel JF. The history of cyclosporin A and its significance. In: Cyclosporin A, White DG (Ed), Elsevier, New York 1982. p.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/18\">",
"      Bierer BE. Advances in therapeutic immunosuppression: Biology, molecular actions and clinical implications. Curr Opin Hematol 1993; 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/19\">",
"      Bram RJ, Hung DT, Martin PK, et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993; 13:4760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/20\">",
"      Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992; 355:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/21\">",
"      Nebert DW, Nelson DR, Adesnik M, et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/22\">",
"      Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med 1983; 99:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/23\">",
"      Petric R, Freeman D, Wallace C, et al. Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 1988; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/24\">",
"      Gluckman E, Lokeic F, Devergie A. Pharmacokinetic monitoring of cyclosporine in allogeneic bone marrow transplants. Transplant Proc 1980; 20:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/25\">",
"      Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/26\">",
"      Yee GC, Self SG, McGuire TR, et al. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. N Engl J Med 1988; 319:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/27\">",
"      Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/28\">",
"      Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     Mekki Q, Lee C, Aweeka F, et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients. Clin Pharmacol Ther 1993; 53:238.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/30\">",
"      Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/31\">",
"      Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88:4383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/32\">",
"      Fay JW, Wingard JR, Antin JH, et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87:3514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/33\">",
"      Nash RA, Etzioni R, Storb R, et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85:3746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/34\">",
"      Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/35\">",
"      Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991; 23:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/36\">",
"      Lewis WD, Jenkins RL, Burke PA, et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc 1991; 23:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/37\">",
"      Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/38\">",
"      Sehgal SN, Baker H, V&eacute;zina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/39\">",
"      Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/40\">",
"      Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/41\">",
"      Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/42\">",
"      Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995; 82:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/43\">",
"      Morice WG, Brunn GJ, Wiederrecht G, et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993; 268:3734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/44\">",
"      Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/45\">",
"      Altmeyer A, Dumont FJ. Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. Cytokine 1993; 5:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/46\">",
"      Lai JH, Tan TH. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994; 269:30077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/47\">",
"      Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/48\">",
"      Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/49\">",
"      Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/50\">",
"      Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/51\">",
"      Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89:3048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/52\">",
"      Hovi T, Allison AC, Allsop J. Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes. FEBS Lett 1975; 55:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/53\">",
"      Schiff MH, Goldblum R, Rees MMC. 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid arthritis. Arthritis Rheum 1990; 33:s1.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm (Accessed on June 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/55\">",
"      Jacobson P, Green K, Rogosheske J, et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 2007; 47:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/56\">",
"      Gratama JW, Jansen J, Lipovich RA, et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 1984; 38:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/57\">",
"      Gleixner B, Kolb HJ, Holler E, et al. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplant 1991; 8:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/58\">",
"      Martin PJ, Hansen JA, Anasetti C, et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis 1988; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/59\">",
"      Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/60\">",
"      Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/61\">",
"      Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/62\">",
"      Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/63\">",
"      Sullivan KM, Storek J, Kopecky KJ, et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 1996; 2:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/64\">",
"      Veys P, Wynn RF, Ahn KW, et al. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood 2012; 119:6155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/65\">",
"      Arai S, Sahaf B, Narasimhan B, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 2012; 119:6145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/66\">",
"      Field EO, Gibbs JE, Tucker DF, Hellmann K. Effect of thalidomide on the graft versus host reaction. Nature 1966; 211:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/67\">",
"      Zwingenberger K, Wendt S. Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. J Inflam 1996; 46:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/68\">",
"      Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/69\">",
"      Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/70\">",
"      Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/71\">",
"      Vogelsang GB, Hess AD, Friedman KJ, Santos GW. Therapy of chronic graft-v-host disease in a rat model. Blood 1989; 74:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/72\">",
"      Chao NJ, Parker PM, Niland JC, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996; 2:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/73\">",
"      Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/74\">",
"      Fong T, Trinkaus K, Adkins D, et al. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/75\">",
"      Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/76\">",
"      Shalaby MR, Fendly B, Sheehan KC, et al. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation 1989; 47:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/77\">",
"      Holler E, Kolb HJ, M&ouml;ller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/78\">",
"      Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/79\">",
"      Wallace PM, Johnson JS, MacMaster JF, et al. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/80\">",
"      Gribben JG, Guinan EC, Boussiotis VA, et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 1996; 87:4887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/81\">",
"      Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 1995; 85:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/82\">",
"      Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/1/34842/abstract/83\">",
"      Vallera DA, Panoskaltsis-Mortari A, Jost C, et al. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood 1996; 88:2342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3553 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34842=[""].join("\n");
var outline_f34_1_34842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H152829970\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NON-SPECIFIC IMMUNOSUPPRESSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164641633\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164641640\">",
"      - Clinical use and toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164641602\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H164641609\">",
"      - Toxicities and clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SPECIFIC T CELL IMMUNOSUPPRESSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H152830127\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H152830134\">",
"      - Toxicities and clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165959725\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165959732\">",
"      - Clinical use and toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Muromonab-CD3 (OKT3)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antithymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14398623\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8565127\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THALIDOMIDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HYDROXYCHLOROQUINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NOVEL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anti-cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Induction of anergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152829970\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/3553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3553|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/21/17746\" title=\"figure 1\">",
"      Signal transduction in T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/3553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/19/8509\" title=\"table 1\">",
"      CYE MTX regimen prevent GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/26/25004\" title=\"table 2\">",
"      Dose adj prevention GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/10/3245\" title=\"table 3\">",
"      Drugs affecting cyclosporine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/6/44135?source=related_link\">",
"      Investigational immunosuppressive drugs and approaches in clinical kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/26/420?source=related_link\">",
"      Isosulfan blue: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42041?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6666?source=related_link\">",
"      Treatment of acute graft-versus-host disease: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_1_34843="Medications that may cause depression";
var content_f34_1_34843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F87554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F87554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications that may cause depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        ACTH (Corticotropin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acutane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha-methyldopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anabolic steroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baclofen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetadine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycloserine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guanethidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L-dopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metaclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenothiazines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudoephedrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reserpine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varenicline",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Agency for Health Care Policy and Research. Depression Associated with Medications. In: Depression in Primary Care: Detection and Diagnosis. AHCPR Publication No. 93-0550. US Department of Health and Human Services, Washington, DC, 1993. Vol 1, p.67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34843=[""].join("\n");
var outline_f34_1_34843=null;
var title_f34_1_34844="Antimicrobial prophylaxis for vascular surgery";
var content_f34_1_34844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for vascular surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nature of operation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Arterial surgery involving a prosthesis, the abdominal aorta, or a groin incision",
"       </td>",
"       <td rowspan=\"2\">",
"        S. aureus, S. epidermidis, enteric gram-negative bacilli",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        vancomycin&bull;",
"       </td>",
"       <td>",
"        1 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lower extremity amputation for ischemia",
"       </td>",
"       <td rowspan=\"2\">",
"        S. aureus, S. epidermidis, enteric gram-negative bacilli, clostridia",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        vancomycin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1 g IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Vancomycin can be used in hospitals in which methicillin-resistant S. aureus and S. epidermidis are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. Some experts would give 15 mg/kg of vancomycin to patients weighing more than 75 kg, up to a maximum of 1.5 g, with a slower infusion rate (90 minutes for 1.5 g). For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin, tobramycin, or amikacin), aztreonam, or a fluoroquinolone.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34844=[""].join("\n");
var outline_f34_1_34844=null;
var title_f34_1_34845="Diabetes increases coronary mortality";
var content_f34_1_34845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Diabetes increases coronary mortality with and without a prior MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a seven-year follow-up of 1059 subjects with type 2 diabetes and 1378 nondiabetics, diabetics with or without a prior myocardial infarction (MI) had a greater mortality from coronary disease compared to nondiabetics (42 versus 16 percent for those with a prior MI and 15 versus 2 percent for those without a prior MI). The rate of coronary death and fatal and nonfatal MI in diabetics without a prior MI was the same as in nondiabetics with a prior MI, providing part of the rationale for considering type 2 diabetes a coronary equivalent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Haffner SM, Lehto S, Ronnemaa T, et al. N Engl J Med 1998; 339:229.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34845=[""].join("\n");
var outline_f34_1_34845=null;
var title_f34_1_34846="Maximum dimensions of abdominal wall defect for CST";
var content_f34_1_34846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maximum dimensions of abdominal wall defect for CST",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The maximum size of an abdominal wall defect or hernia that can be reconstructed in the upper, middle, and lower abdominal wall using the component separation technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Nguyen VT and Shestak KC. \"Separation of anatomic components\" Method of abdominal wall reconstruction. Clin Plast Surg 2006; 33:247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34846=[""].join("\n");
var outline_f34_1_34846=null;
var title_f34_1_34847="Tetralogy Fallot PA angio I";
var content_f34_1_34847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Main pulmonary artery angiogram in tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angled angiogram performed in the main pulmonary artery demonstrates severe proximal left pulmonary artery (LPA) stenosis (*). There is discrepancy in size between the proximal right pulmonary artery (RPA) and the proximal LPA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_1_34847=[""].join("\n");
var outline_f34_1_34847=null;
   